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General introduction 
-D· 'ementia--is--·a ·-common --and---disabling -disorder---in--the--elderly-.- -Because---of---the---
worldwide increase of the proportion of elderly in the population, dementia is of 
growing public health relevance, 
Alzheimer's disease, the most common dementia subtype, is characterized by pro-
gressive loss of memOlY and cognitive function and affects an estimated 15 million 
people worldwide, The incidence increases sharply from 0.5% per year at the age 
of 65 to nearly 8 percent per year at the age of 85 (1). As people with Alzheimer's 
disease usually survive for approximately a decade, prevalence increases from 3% at 
65 years of age to almost 50% at age 85 (1), With increasing longevity of the popUla-
tion and decreasing bilth rates, the prevalence will continue to rise. In Alzheimer's 
disease several deficiencies of neurotl'ansmitier systems, such as the cholinergic 
neurotransmission, have been found (2), Cerebral extracellular ~-amyloid deposition 
as senile plaques and intraneuronal neurofibrillmy tangles appear to represent criti-
cal processes in the development of these deficiencies (3). 
Early treatment of Alzheimer's disease would be important as it might reduce cog-
nitive and behavioural symptoms of this disease and it might slow disease progres-
sion, thereby alleviating some of the social and economic costs, However, currentiy 
available treatments for patients with Alzheimer's disease mainly focus on the cho-
linergic pathway. Because of 01e limited efficacy of these tl'eatment modalities they 
must be viewed as palliative (4). 
Knowledge on potential alternative therapeutic strategies for the prevention of 
Alzheimer's disease is mainly based on observational studies in subjects \vith preva-
lent dementia. As these studies often have methodological shortcomings valid risk 
estimates are scarce. 
This thesis concerns the role of certain chronically used drugs in the development 
of Alzheimer's disease. The aim was to assess the contribution of different types of 
dlUgS in the prevention of Alzheimer's disease, and to determine candidate drugs 
for future investigation or preventive use. Hereto, the literature on Alzheimer's dis-
ease and potentially protective drug effects was reviewed (chapter 2). In chapter 3 
the results of a study on the association between NSAlD and Iisk of dementia are 
described, with a focus on duration of use (3.2 and 3.3) and misclassification of expo-
sure (3.1 and 3.3), In chapter 4 the effccts of antihypertensive drugs on dementia 
and its subtypes m"e discussed, Subsequently, in chapter 5, we report on the risk of 
Alzheimer's disease in women repOlung plior use of hormone replacement therapy. 
All studies presented in chapters 3 to 5 were conducted in The Rotterdam Study, 
which is a prospective population-based cohort study of neurological, cardiovasculm", 
locomotor, endocrinological and ophthalmological diseases in the elderly. The focus 
in chapter 6 is on the association between psychotropic drugs and cognitive func-
tion as examined in The Rotterdam Scan Study, a non-demented elderly sub-sample 
of two population-based studies. In chapter seven, after summarizing the main find-
ings, we will discuss quantitative and qualitative problems, which m'e typical for 
3 
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care aspects, and potential dIrections for future research. 
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EVIEW 

Pharmacological prevention of 
Alzheimer's disease 
A review oj the epidemiological eVidence 
ABSTRACT 
In this chapter, we describe the current state of epidemiological studies on potentially effi-
cacious drugs, not specifically designed or prescribed for the prevention or treatment of 
Alzheimer's disease. The focus is on the potential methodological pitfalls related to validity 
and precision of the various studies. 
NSAID and to a lesser extent hormone replacement therapy (HRT) are the drugs which 
have most frequently been studied in relation to Alzheimer's disease. A protective effect was 
most consistently demonstrated for the long-term use of HRT. However, only two-third of the 
15 studies have been positive and secondary prevention trials are inconsistent. If proven 
efficacious a further growth of its use seems likely. Although optimistic reviews, mainly based 
on studies in prevalent Alzheimer's disease, have been published on the potentially protec-
tive role of NSAID in Alzheimer's disease, not all prospective studies support this. Even 
when these drugs appear to be protective, large-scale preventive use in their current form 
is unlikely given their toxicity. However, these studies may boost the development of safer 
NSAtD. 
Studies on antihypertensive therapy and Alzheimer's disease are scanty but promising. 
As these drugs are of proven efficacy in cerebro- and cardiovascular disease, placebo 
controlled primary prevention trials are unethical and additional observational studies are 
needed to quantify their effecl. 
Free radical scavengers comprise a variety of substances. The most promising, next to 
HRT, are Ginkgo biloba, selegiline and vitamin CIE. EvIdence is promising but too limited 
and too diverse to draw conclusions. However, given the good safety profile of a number of 
these agents, if proven efficacious, a further increase in their use is likely. 
Epidemiological studies on glucocorticoids, other anti-inflammatory drugs, H2-antago-
nists, and benzodiazepines are Inconsistent and insufficient to judge their potential contri-
bution. As glucocorticoids are toxic and benzodiazepines addictive on long-term use, it is 
unlikely that these drugs will be of major value in the primary prevention of Alzheimer's dis-
ease, even when effective, 
In conclusion, we are only just in the begllming of making vatid and useful assessments 
of protective drug effects in Alzheimer's disease. Currently available studies are often vulner-
able to a number of obvious and less obvious biases. Given this fact, for no agent preventive 
use is currently justified. For the future, placebo-controlled trials are needed but they may 
prove to be cumbersome. In the meantime there are a number of niches that will remain in 
which observational studies will be able to contribute. However, in order to further untangle 
these often difficult issues more uniform and more valid approaches are needed. 
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. INTRODUCTION 
Dementia is a neurodegenerative disorder characterized by changes in cognitive 
function and behavior. According to current diagnostic criteria, Alzheimer's disease 
is the nlOst common subtype of dementia diagnosed in approximately two thirds of 
all cases of dementia (1). Other well lrnown but less common forms are vascular 
dementia and Parkinson's dementia. Alzheimer's disease is characterized by a grad-
ual and progressive decline of long-term episodic memory and of other cognitive 
domains of mental functioning (2). A diagnosis of Alzheimer's disease is considered 
probable when alternative causes of dementia are excluded (3, 4). Many cases of 
Alzheimer's disease may have important co-morbidity of clinical-, or magnetic reso-
nance imaging detected cerebrovasculm' disease that could conb'ibute to the demen-
tia. 
Age, depression, low educational level, atherosclerosis, vascular factors (5-7) mld 
smoking (8) are associated with an increased lisle of Alzheimer's disease. There are 
also a growing number of genetic factors that have been implicated in Alzheimer's 
disease. including dominant mutations (amyloid precursor protein. presenilins 1 
and 2) and susceptibility genes (ApoHpoprotein-E and others under investigation 
such as- <x,-macroglobulin) (9, 10). 
Because a deficit of acetylcholine is an Important characteristic of Alzheimer's 
disease, drug development and treatment of Alzheimer's disease has U1US far primm'-
ily involved cholinesterase inhibitors, although drugs with a different mode of action 
m'e under investigation. The Food and Drug Administration approved the drugs 
tacrine, donepezil and rivastigmine (11), Other drugs such as selective muscruinic 
agonlsts m'e sometimes prescrIbed as supplements to these drugs. 
In this review, we focus on medications not developed specifically for Alzheim-
er's disease but which have been reported in observational studies and trials to 
have a protective effect in Alzheimer's disease, \Ve focus on plimmy prevention 
of Alzheimer's disease, not on related outcomes such as cognitive impairment. or 
other dementia such as vascular dementia, The drugs we examine are estrogens, in 
the form of hormonal replacement therapy (HRT); non-steroidal anti-inflanlmatOlY 
drugs (NSAlD) and aspirin. steroids and other "anti-inflammatOly agents"; antihy-
pertensive agents; histamine-2-receptor (H2) antagonists; benzodJazepines; and free 
radical scavengers. 
First. we discuss the methodological issues related to the interpretation of obser-
vational studies of drugs and the risk of Alzheimer's disease. Then, we discuss the 
putative biological mechanisms by which different drugs m'e thought to modulate 
Alzheimer's disease expression. and ilie relevant prevalence and incidence studies 
and trials for each class of drugs. Finally. we summarize the overall evidence and 
discuss possible implications for future development of pharmacological interven-
tion against Alzheimer's disease, 
8 
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METHODOLOGICAL CONSIDERATIONS 
Validity 
A number of biases have been described for epidemiological studies (12), There are, 
several bIases that are particularly important to the Interpretation of studies on 
dnlg exposure and Alzheimer'S disease (13). Roughly they can be categorized as 
selection bias related to survival and to inclusion into the study: information bias 
by (mis)classffication of exposure; and confounding by factors related to whether 
or not someone receives a medication (confounding by indication, severity or co-
morbidity), 
Selection bias 
Selection bias may occur when the use of a drug leads to a difference in survIval 
between cases and non-cases. For example, a drug may slow progression of disease 
that is differentially distributed between cases and conb'ols. Or, inappropriate drug 
intalce as a consequence of cognitive problems in Ule pre-clinical phase of Alzheim-
er's disease could lead to severe adverse effects and a lower survival. In a study 
based on prevalent cases this may lead to the conclusion Ulat the drug protects 
against Alzheimer's disease. Selection bias may also occur if cases and controls are 
drawn from different source popUlations (14, 15). For example, studies based on 
cases referred to health services may be subject to selection bias jf cases and con-
b'ols differentially use one type of health service over another (16). Subjects taking 
a certain drug for other reasons may have other health-care-seeking behavior than 
Alzheimer's disease patients who do not have problems that require the drug. 
Diagnostic bias is a special case of biased selection into a study population. In 
studies of Alzheimer's disease, persons taldng drugs against cardio- or cerebrovas-
cular disease may be excluded from a diagnosiS of Alzheimer's disease a priorI. 
Information bias 
A major concern is the potential for misclassification of exposure of drugs. Exposure 
includes drug compounds, frequency and duration of use, and route of adminislra-
tion. These are all elements involved in studying dose-response effects of medica-
tions. Another source of misclassification is a wrong definition of the biologically 
relevant e;.".'posure window relative lo the onset of the disease. Alzheimer's disease is 
probably preceded by a long sub-clinical period, and it is velY difficult to get reliable 
estimates of when clinical symploms began. As a result it is difficult to delermine 
whether the exposure preceded disease onset. One important potential source of mis-
classification is information from proxy iniormants differentially collected between 
cases and controls. Furthermore, ever/never drug use reported in a baseline inter-
view is often used as an approximation of chronic use. As chronic use generally 
increases with age and age is the most important risk factor for Alzheimer's disease, 
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misc1assification by such approximation may be differential. An additional source 
of exposure misc1assification may be differences in compliance between Alzheimer's 
disease cases and non-cases. 
Confounding by indication, severity or co~morbidity 
These are of particular importance in studies of persons with compromised cogni-
tive function. It is possible that doctors differentially prescribe drugs, depending 
on the patients' cognitive status. For example, cognitively intact patients may more 
assertively demand drugs with a putative beneficial effecl against cognitive impair-
ment. This may lead to a differential prescription of these drugs. Or, doctors may 
be reluctant to presclibe drugs with a high frequency of adverse reactions to cogni-
tively impaired Alzheimer's disease patients. On the other hand, one could argue 
that diagnosis of cognitive impairment leads to more diagnostlc tests and increased 
responsiveness from the patient and family members to get any preliminaty promis-
ing drugs. 
Bias in prevalence studies 
Cross-sectional studies use existing cases and this may lead to biased estimates. 
Validity may be compromised by selective survival, an unclear temporal relationship, 
and because information is obtained from pro},.)' informants. 
Bias in incidence studies 
Because of the absence of the so-called "prevalent -case bias", studies relying on 
incident cases of Alzheimer's disease are Ul0ught to be more valid ,vith respecl to 
sl:rengUl and direction of the association. However, one problem that typically aJises 
in incidence studies, is the competing risk for deaUl. This may be an important 
alternative explanation for the finding that some drugs are inversely associated ,vith 
onset of Alzheimer's disease. Users of certain drugs may have more co-morbidity and 
consequently a higher mortality rate than subjects who do not use the drugs. Users 
are then less frequently able to reach Ule endpOint of Alzheimer's disease aJld seem 
to be protected by the drug. 
Precision 
Sampling error is a potential problem that may arise in epidemiological studies on 
Alzheimer's disease, but is often not addressed. As most population-based epidemiO-
logical studies aJ'e mUlti-purpose and not specifically designed to sludy drug effects 
in Alzheimer's disease, sample size is often a limiting factol' fol' studying drugs \Vitil 
low exposure. This Is in particular a problem when dose-response is under investiga-
tion, as inability to show dose-response effects in Alzheimer's disease weakens con-
clusions regarding a beneficial effect. 
10 
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EPIDEMIOLOGY OF DRUGS IN THE ONSET OF ALZHEIMER'S DISEASE 
Hormone replacement therapy 
Biological mechanism 
HRT in the form of estrogen (in combination with progesUns), is generally prescribed 
for estrogen dependent post-menopausal complaints and for the prevention and 
treatment of osteoporosis. 
The assumption Ulat estrogen may alter a person's risk of Alzheimer's disease is 
based on evidence that it direcUy affects neuronal function, growth and repair mech-
anisnls (l7-24). Estrogens may down-regulate p-adrenergic and serotonin 5-HT2 
receptors (25, 26), increase the release of endogenous catecholamines ii'om the 
hypothalamus (27), inhibit monoamine oxidase (28) as well as enhance Ule amyloid 
precursor protein metabolism (28). Estrogen may also have antioxidant- (29) and 
anti-inflammatOlY properties (30). In addition, estrogen may alter brain activation 
patterns in posbnenopausal women duting the performance of verbal memOlY func-
tion (3I). Finally, estrogen may be involved in the pathogenesis of Alzheimer's dis-
ease through its role in vascular disease (32). 
Prevalence studies 
There is evidence that the reduced production of estrogen lllay be linked to the onset 
of Alzheimer's disease. Several studies suggest that proxy measures of higher levels 
of exposure to estrogen -- a higher body mass index (33, 34), late age at menopause 
(35) and early age at menarche -- are inversely associated with the risk of Alzheimer's 
disease. Studies relating HRT to the risk of Alzheinler's disease have yielded incon-
sistent results {table I}. Initial case-control studies did show that estrogen use was 
inversely associated with Alzheimer's disease (36-39). However, Ulese studies had 
limited measures of exposure {ever/recenO, investigated the association in prevalent 
cases, and were designed to examine multiple risk factors. Furthermore, these ear-
lier studies did not adequately control for potential conJounders such as education 
and age at menopause. In later case-control studies (40-45) exposure was measured 
with relatively unbiased methods, for example by abstracting medical records {42}. 
Only two studies {40, 46} were population based. These latter studies all suggested 
a risk reduction of apprOximately 50%, 
Incidence studies (table 1) 
In the Leisure \\'orid Cohort, an upper-middle-class elderly population, information 
on hormone Use of non-demented women was collected during a baseline interview. 
Alzheimer's disease, dementia or senility were diagnosed on the basis of death cer-
tificates. Estrogen users had a Significantly lower risk of Alzheimer's disease and 
associated disorders. The risk was lowest for those women that used HRT for the 
longest peliod in U,e highest dose (47). An important limitatlon of this study is that 
II 
" 
TABLE 1 Q 
Studies on hormone replacement therapy (HRT). .§ 
,-
RRIOR (95% el) ~ Author! year Exposure Exposure source Design Case source (nO) Control source 
'" or probability 
Studies in prevalent Alzheimers disease 
Heyman 1984(38) Ever last 3 months Interview Matched case- Epidemiologic study Community 2.32 NS 
control 9rouP (n = 28) 
Amaducci 1986(37) EverHRT Interview next-of-kin Matched case- Seven centers (n = Hospital/population Hospital 0.71 NS 
control 116) Population 1.67 
NS 
Graves 1990(39) Ever HRT Telephone interviews Matched case- Clinic based (n = 60) Friends and non- 1.15 (0.50-2.64) 
with patients and control blood relatives. 
controls surrogates 
Broe 1990(36) Ever HRT Interview Matched case- Clinic based (n = General practice of 0.78 (0.39-1.56) 
control 106) corresponding case 
Henderson 1994(43) Ever HRT Interview in non~ Case-control Volunteer sample of Volunteer sample of 0.33 (0.15-0.74) 
demented and primary consecutively consecutively 
caregivers in AD enrolled women (n = enrolled women 
143) 
Birge 1994(41) Current use and Interview Matched case- Clinic (n = 158) Clinic 0.07 (p<0.01) 
duration of HRT control 
MorteI1995(42) Ever HRT medical record! proxy Case-control 306 subjects refer- Friend/relative 0.53 (0.27-0.94) 
informant red to clinic (n = 93) 
Lemer 1997(44) Ever HRT Interview in non- Case~contro! UK (n = 88) UK 0.58 (0.25-0.91) 
demented and primary 
caregivers in AD 
Balderischi 1998(40) Ever HRT Interview Population 8 municipal popula~ 8 municipal 0.28 (0.08-0.9S) 
based cohort tion registers (n = population registers 
92) 
Sloo!er 1999(46) EverHRT Interview next-of~kin Matched case· All patients with Municipal population 0.44 (0.21-0.96) 
control early onset AD in register 
two regions of the 
Netherlands (n = 
109) 
Studies in incident Alzheimer's disease 
Brenner 1994(45) All HRT before Computerized pharm- Case-control Alzheimer's disease Stratified random 1.1 (0.6-1.8) ~ onset acy data for maximum registry from health sample of health 0.7 (OA-1.5) 
Oral HRT before of 15 years plan population (n = plan population , 3 
onset 107) 0 0 
Paganini-HiI! 1996(62) HRT~3yrs Interview (repetitive) Nested matched Retirement Retirement 0.83 (0.56-1.22) 0 :2 HRT 4-14 yrs case-control community (n = 248) community 0.50 (0.31-0.81) 
" HRT ~ 15 yrs 0.44 (0.26-0.75) a 
Tang 1996(49) HRT:s; 1 yr Interview Prospective Medicare recipients, Medicare recipients, 0.47 (0.2-1.10) 
" ~ HRT> 1 cohort senior centers and senior centers and 0.13 (0.02-0.92) c 
• elder-Iy housing elder-Jy housing ~ 
sites (n = 167) sites g. 
~ 
Kawas 1997(50) HRT > 0-5 yr Repetitive interviews Cohort Community Community 0.44 (0.12-1.51) ~ HRT 5-10 yr volunteers (n = 34) volunteers 0.34 (0.05-2.52) » 
HRT >10 yr 0.50 NS ;;-
Waring 1999 (155) HRT < 6 mos Review of medical Matched case- Mayo clinic residents Sample from 0.85 (0.44-1.62) ii 
HRT~6mos records control of Rochester (n = Rochester 0.42 (0.18-0.96) §. 
• 222) population. , 
"-
Trials "-~. 
Schneider 1996 (56) HRT/tacrine NA Randomized Multi-center (n = NA Enhancement of • 0 placebo-control- 318) tacrine effect by 
" 0 Jed secondary estrogens I 
prevention trial » 
Mulnard 2000 (57) Randomization to NA Randomized Multi-center (n = NA Clinical Global ~ c 
placebo or estro- placebo-control- 120) Impression Scale ~. 
gen Replacement led secondary (p=OA3) 
Therapy prevention trial ~ 
(0.625/1.25 mg) ·In hysterectomi- SO 
for 1 year zed women 0 
.g 
Henderson 2000 (52) Randomization to NA Randomized Multi-center (n = 42) NA Alzheimer's 0: placebo or estro- placebo-control- Disease 0 
gen Replacement led secondary Assessment Scale 3 0-Therapy (1.25 mg) prevention trial NS g for 16 weeks ;s. 
a 
P = probability, NA = not applicable, NS = non-significant, UK = unknown, RR = relative risk. OR = odds ratio, CI = confidence interval. 0 
c 
0: 
8 
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Alzhe-liiiel'-'s--clfsease cases were kfenHfiecr-on the bases o( death certificates, which 
underestimate dementia (48). 
Other prospective studies are based on clinically assessed Alzheimer's disease. In 
the Manhattan cohort, the relative risk of developing Alzheimer's disease for users 
of oral and transdermal estrogen was significantly lower after acljustment for educa-
tion, ethnic group, sample source but not for other behavioral and medical risk: fac-
tors. \Vomen who had used estrogen for longer than a year had a greater reduction 
in risk, although confidence intervals overlapped with women who had used HRT 
for a shorter period of time (49). In this study, participants were sampled from Medi-
care recipients, senior centers and elderly housing sites. This may lead to biased 
estimates if a group with a different risk of Alzhehner's disease also had a different 
chance of getting HRT. In a sample of 472 peri- and postmenopausal women of the 
Baltimore Longitudinal Study of Aging, followed for up to 16 years, HRT use (45%) 
was prospectively documented during each visit. AlUlOugh the number of cases was 
small (n :::: 34), the risk of Alzheimer's disease in users of HRT was significantly 
reduced: there was no effect of duration of therapy (50). In a study based on the 
Mayo clinic cohort iliere was a significantly inverse association between long-term 
(> 6 months) estrogen tllerapy and Alzheimer's disease adjusting for education and 
age at menopause. There was a significant trend of decreasing risk: with increasing 
duration of use. 
Trials 
There are no published primaty prevention data available on HRT and Alzheimer's 
disease. There are, however, ongoing primmy prevention trials. The \Vomen's Health 
Initiative MemOlY Study (51) is a multi-center trial designed to test the hypothesis 
that HRT reduces all-cause-dementia in women aged 65 years and older. This lIial 
is designed to show a 40% risk reduction and it is anticipated that over 7500 
women will be randomized. Other ongoing investigations are tlle \Vomen's Interna-
tional Study of Long Duration Estrogen for Menopause and the Preventing Postnleno-
pausal memOlY Loss and Alzheimer's with Replacement Estrogens study (52). 
In several small secondmy prevention trials there is some evidence that estro-
gen may he heneficial in improving specific cognitive domains (53-55), and that It 
modifies the effect of cholinesterase-inhibitors (56). These beneficial results were not 
confirmed in a Im'ger more recent trial, in which a sixteen-week treatment did not 
improve symptoms. Moreover, in an even longer and larger trial, estrogen replace-
ment therapy for 1 yem' did not slow disease progression nor did it improve global, 
cognitive or functional outcomes in women with mild to moderate Alzheimer's dis-
ease (57). 
AlLhough iliere is relatively consistent evidence of a protective effect of HRT one 
needs to consider the possibility of selection bias in observational studies using HRT 
as an e"''Posure. Women taking HRT may be healthier in general (58-60) and subse-
quently have a reduced risk: of Alzheimer's disease. Furiliermore, a higher education 
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and socioeconomic status are associated- with th __ e use of HR't. both or which an~ 
associated with a reduced lisk of Alzheimer's disease (61). Selection bias pertaining 
to HRT -users might arise from increased estrogen-related mortality due to breast 
cancer or trombotic complications. On the other hand if HRT has a positive prognos-
tic effect on survival after onset of Alzheimer's disease, as suggested by some (47, 62), 
a prevalent series of Alzheimer's disease cases may over-represent women who 
use HRT. This would mal{e it more difficult to find an association if one existed. The 
need for caution in interpreting results is highlighted in a large-scale secondary pre-
vention trial on HRT-use and coronaty heart disease (63). This study did not confirm 
a protective effect earlier found in a large number of observational studies. This 
suggests the possibility that undetected selection and observation biases could be 
responsible for the previously found lowered Iisk. On the other hanet, the pathologi-
cal substrate and therefore intervention strategies may be different once there is 
clinical disease. 
Other problems not frequently addressed are the changing prescription habits 
and contents of HRT products over time. Today's HRT preparations contain more 
progestins (if any) than those prescribed in the last 20 years and are based on differ-
ent types of estrogen. Il is possible lhallhese changes affect the efficacy of the drug. 
Non-steroidal anti-inflammatory drugs and aspirin 
Biological mechanism 
Non-steroidal anti-inflammatOlY drugs (NSAID) are prescribed for a variety of condi-
tions. The most impOliant indications for chronic use are (inflammatory) Joint dis-
eases such as rheumatoid arthritis and osteoarthritis or oUler systemic diseases 
\vith Joint manifestations. Short-term indications are sprains, headaches, dysmen-
orrhoea and dental complaints. NSAID include salicylates, phenylacetic acid deriv-
atives, propionic acid derivatives, oxtcam derivatives, pyrazol1n derivatives and a 
small group of other compounds. At present the most frequently used NSAID are 
nonspecific inhibitors of both isoforms of cycloxygenase: COX-l and COX-2. 
A strong infianlmatOlY response may be autotoxic to neurons, exacerbating the 
fundamental pathology in Alzheimer's disease (64). There are several theories on how 
NSAID (and aspirin) could aller this inflammatory course: the first is inhibition of 
inflammation perse Ulrough either a COX or a non-COX-dependent mechanism by 
directly activating the peroxisome proliferator gamma (PPAR-y) nuclear transcription 
factor (65-67). This factor acts to suppress Ule expression of certain pro-inf1amma-
tDly genes (66, 68). Another theDlY is that NSAID interfere in a process involving 
post-synaptic signaling events that use the arachidonic pathway (69). 
Alzheimer's disease may also be a consequence of impaired vascular d~livelY of 
nullients 10 lhe brain (70). Drugs like NSAID ancl aspirin exhibit anti-clolting proper-
ties and could thereby potentially improve disease course. 
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-Pi~eval(dice studies 
The association of anti-inflammatory Ulerapy and Alzheimer's disease has been stud-
ied in a number of ways (table 2). Initial case-control studies exanlined the associa-
tion indirectly by using proxies of anti-inflammatOly drug llse as exposure measure 
such as rheumatoid arthritis (36, 38, 39, 71-75). These studies have been reviewed 
extensively elsewhere (13, 76). Results from these studies were conflicting but also 
largely incomparable. 
In other studies, the association between a histOly of anti-inflammatory drug 
therapy and Alzheimer's disease was studied. Several older case-control studies in 
which the use of analgesics (including acetaminophen) was examined were also 
inconclusive (37, 77). l\vo studies on subjects WiUl a shared genetic background 
(twins and siblings) provided support for a protective role of NSAID in Alzheimer's 
disease (78, 79), In bOUl studies there was e\1dence that (long-term) use of NSAID 
significantly reduced the risk of Alzheimer's disease. 
A number of population-based studies on the cross-sectional association between 
NSAID and prevalent Alzheimer's disease show an inverse association (80-82) with 
an effect size ranging from 0.4 to 0.6. 
Incidence studies (table 2) 
Several incidence studies on the association between NSAID and Alzheimer's disease 
have been published (82-89). Some studies showed no association between NSAID 
use and llie risk of Alzheimer's disease (82-84, 86, 89). Other studies showed a non-
significant trend towards a reduced risk in persons with a history of NSAID use 
(87, 88). TIle relative risk of Alzheimer's disease was assessed among reported users 
of aspirin or oUler NSAlD over a 16-year follow-up in the Baltimore Longitudinal 
Study of Aging. The risk of Alzheimer's disease decreased Witil increasing duration 
of NSAID use. Among tilOse with two or more years of reported NSAID use. the rela-
tive risk was lower Ulrul for those WiUl less than 2 years of NSAID use. Overall use of 
aspirin and acetaminophen was not associated Witil Alzheimer's disease (85). 
StudIes on NSAID ruoe particularly vulnerable to misclassificaUon of exposure. 
Because NSAID are often used periodically. ruld to a different extent in dIfferent age 
groups it is difficult to obtain reliable information on exposure. Reliable and valid 
data might be pru°ticularly dUlicult to obtain from proxy interviews. 
Over the counter sales may decrease the validity of medical and phruomacy 
records as sources of drug exposure. In general. measurement of exposure has been 
a problem to some extent in all follow-up studies on NSAID. In some studies. dura-
lion was not taken Into account at all (82-84, 86, 87, 89), In other studies, the 
methodology used to measure duration of exposure may have introduced misclas-
sification bias. Repeated cross-sectional measurements could have led to an overes-
timation of drug use (85). In earlier analyses in The Rotterdam Study. the missing 
duration of individual prescliptions was imputed; Ulis might have led to systematic 
or random misclassificaUon (88). A problem in an these studies was that it was 
16 
Plwrmacological prevention oj AI.tlwimer's disease - A review oj the epidemiological evidence 
unclear whidi parficulai;--NSAIb \vas used- by- the slibjects:-Flirthermore, oIlly two 
studies (85, 88) took into account the timing of intake in relation to the time of onset; 
this may be important given the unknown duration of the pre-clinical period. 
Finally, confounding by contraindication may be important. Due to the higher 
chance of adverse events in cognilively impaired subjects, doctors may be less likely 
to prescrIbe NSAID in the pre-clinical and clinical phase of Alzheimer's disease. 
Trials 
To our lrnowledge, there are no prinlaIY prevention trials published on anti-inflam-
matOlY drugs and Alzheimer's disease. A 6-month secondaty prevention uial on 
indomethacin in Alzheimer's disease showed that patients performed significaIltly 
better after six months of therapy compared to placebo on a battely of cognitive tests 
(90). There were, however, a large number of pat"ticipatltS with adverse effects and 
consequently there was a high dropout rate. 
The efficacy and safety of diclofenac in combination with misoprostol was evalu-
ated in 41 patients wiUl mild-moderate Alzheimer's disease in a prospective 25-week, 
randomized, double-blind placebo-controlled Ilial (91). This small pilot study did 
not demonstrate a significant eflecl of NSAID b·eatment in Alzheimer's disease. but 
the trends observed jusUly further investigations with a larger number of prutici-
pants. The combination of diclofenac and misoprostol seems safe in Alzheimer's dis-
ease patients, but its tolerability is not optimal. Before more definite conclusions 
CaIl be drawn, results of studies on COX2-inhibitors (cel1coxib/rofecoxib) have to be 
awaited (92, 93). It is, however, questionable whether it is valid to extrapolate find-
ings of these trials to primmy prevention. Therefore we have to await the resulls Ii·om 
a primalY prevention lIial cmrently pending (94). 
Studies on aspirin have mainly focussed on stroke, showing a protective effect 
in secondary prevention of stroke (95). 'Vhether and to what extent this protective 
effect can be exb-apolated to non-vasculaI' dementia and in particular to Alzheimer's 
disease remains to be elucidated. 
Glucocorticoids and other anti-inflammatory drugs 
Biological mechanism 
Glucocorticoids are mainly used for the treatment of non-infectious inflammalOlY 
diseases aIld in Ule b·eatment of chronic ObSU"llctive pulmonaIY disease. These are 
potent anti-inflammatory/immunosuppressive dnlgs, which are also used to sup-
press inflammatOlY processes in the brain. They suppress the acute phase response 
neutrophil adherence and monocyte accumulation as well as inhibit prostaglandin 
production (30). However, doses commonly used to suppress secondaty brain inflam-
mation in other diseases are toxic on long-term b·eatment and lead to a high inci-
dence of severe adverse effects like osteoporosis, behavioral disturbances and other 
problems (96, 97). II has been suggested thal glucocortlcoids may be toxic to the hlp-
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Studies on anti-inflammatory drugs. .§ 
;,-
~ 
Author! year Exposure Exposure source Design Case source (n° ) Control source RRiOR (95% GI) '" or probability 
Studies of prevalent Alzheimer's disease 
Heyman 1984(38) Arthritis Interview Matched case- Epidemiologic study Community 1.19 NS 
Ever use of control group (n = 40) 1.23 NS 
analgesics 
French 1985(72) Arthritis Interview with random Matched case- Veterans Hospital- and non- 0.62 (0.29-1.29) 
Hayfever reconfirmation control Administration hospital controls (He) 
Medical Center (n = 2.75 (0.81-10.22) 
78) 
Amaduee; 1986(37) Analgesics ever Next-of-kin Matched case- Consecutive AD Hospital 1.21 NS 
control patients of 7 Friend 1.0 NS 
neurology centers (n 
= 116) 
Jenkinson 1989(73) Rheumatoid Presence of RA Case-control Consecutive Consecutive 0.17 (P < 0.005) 
arthritis according to accepted patients of geriatric patients of geriatric 
criteria. unit (n=96) unit 
Broe 1990(36) Arthritis Interview Matched case- Clinic based (n = GP practice of 0.56 (0.36-0.87) 
Allergies control 170) corresponding case 0.97 (0.60-1.58) 
Graves 1990(39) History of steroid Telephone interviews Matched case- Clinic based (n = Friends and non- 0.73 (0.38-1.38) 
use with patients and control 130) blood relatives. 1.18 (0.35-3.91) 
Rheumatoid controls surrogates 
arthritis 
Hay fever 
McGeer 1990(74) Rheumatoid Presence of RA Incidence study Clinic based (n = 4) None but referenced 2.7% vs. 5.1% 
arthritis to Canadian Study 
of Health and Aging 
Beard 1991 (75) Rheumatoid Presence of RA Incidence study Clinic based (n = 23) Reference to other 4.4% vs. 2.7% 
arthritis clinical population 
MeGeer 1992 (100) Continuous Current use Cohort Living leprosy Living leprosy 0.63 (0.43-0.92) 
dapsone use or patients Japan (n = patients Japan 
closely related 151 all dementia) 
agents 
Li 1992(71) Arthritis (before Interview of relatives Matched case- Clinic based (n = 70) Registration offices 0.2 (0.06-0.70) 
onset) control neighborhoods 1.0 (0.09-11.03) ~ 
Analgesics ( 2! 2 ~ yrs use) 
Henderson 1992(77) Analgesics (ever Interview of an Matched case- GP practice {n = 170 GP practice 1.4 (P = 0.05) S 0 
daily >6 mas) informant control ) consecutive early onset "-<2 referrals 0.5 NS late onset 
" Canadian Health Arthritis Questionnaires Nested case- Communities and Communities and 0.55 (0.37-0.82) -
Study 1994(80) NSAIO completed by proxy control institutions (n = 224) institutions 0.75 (0.39-1.46) 't , 
Steroids. respondents 0.54 (0.36-1.46) ~ 
Breitner 1994(78) Anti-inflammatory Self-reporting or if not Co-twin control Male and female Male and female 1.0 (0.21-4.73) ~ 
drugs (> 1 yr use; possible from twins from USA twins from USA (male) g 
began> 2 yrs surrogates 0.0 (0.01-0.43) ~ before onset) (female) ,. 
Breitner 1995(79) NSAID (duration) Interview of unaffected Sibship study Siblings (n=107) Siblings 0.19 (0.06-0.64) 8: 
Steroids individuals and/or 0.63 (0.12-2.63) 
" Aspirin collateral information 0.34 (0.14-0.84) ~ 
Rich 1995(156) NSAIO Interview Cohort Cohort of AD NA Better ~ .-
current/past patients performance on "-
12 mos on daily MMSE, Boston 
" basis Naming Test and 2 
" others. ~ 
I 
Andersen 1995(81) NSAID (use in Interview of subjects Population Cohort (n = 339) Cohort (total) 0.38 (0.15-0.95) ,. 
past week, dose) and/or proxy based cohort Topical medication 
" informants study users (subgroup) 0.54 (0.16-1.78) ~ li" 
Endoh 1999 (101) Dapsone, Medical files Cohort Leprosy patients of Leprosy patients of 0.79 (0.53-1.84) 5 
rifampicin, the national the national 3.37 (1.87-5.97) ~ 
clofazimine, leprosarium in Tokyo leprosarium in Tokyo <80 yrs 
" 
minomycin or (n = 35) 
ofloxacin 
"' Studies of incident Alzheimer's disease 5: ~ 
Kukull 1994(83) NSAIO (5 years Computerized Case-control AD patient registry Health Maintenance 3 2: prior) pharmacy data HMO (n = 268) Organization 0.8 (0.6-1.2) <2 Ever 1.1 (0.7-1.8) ~ > 180 daily doses 
0 
6: 
~ 
co ~ 
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TABLE 2 - continued Q 0 ~ 
'6 
Author! year Exposure Exposure source Design Case source (nO) Control source RRiOR (95% el) 0-
ar probability ~ 
'" 
Fourrier 1996(83) NSAID use (both Repetetive interviews Prospective Random sample of Random sample of 0.98 (0.23-4.16) 
at baseline and 1 population population of France population of France 
year later) based cohort (n =47) 
study 
BLSA(85) NSAID « 2yrs) Repetitive interviews Nested Case- Volunteers (n = 81) Volunteers 0.65 (0.33-1.29) 
NSAID (~2 yrs) control in BLSA 0.40 (0.19-0.84) 
Aspirin ( < 2yrs) 0.58 (0.28-1.18) 
Aspirin ( ;?: 2yrs) 0.82 (0.50-1.36) 
Henderson 1997(86) NSAID Interview Prospective Community Community NS 
Aspirin cohort study 
Beard 1998(87) NSAID, aspirin for Medical records Matched case- Clinic based (n = Clinic 0.47 (0.20-1.10) 
7 or more days in control 302) NSAID 
2 years before 0.90 (0.51-1.59) 
onset NSA!D +aspirin 
Brooks 1998(82) NSAID (current Interview Prospective Community (8.4 % = Community NS 
use) cohort study 53) 
Aspirin 
Comelius 1998(39) NSAJD regularly Interview Prospective pop- Cohort (n = 110) Cohort 0.8 (0.4-1.9) 
taken ulation based 
cohort study 
In 't Veld 1999(88) NSAID (in 10 General practitioners Nested matched Cohort (n=1 01) Cohort (population 
years before medical records case-control based) 
diagnosis) study within 
0.76 (0.37-1.57) < 2 months Rotterdam Study 
2-6 months 0.97 (0.44-2.17) 
> 6 months 0.27 (0.05-1.51) 
Tn'a/s 
Rogers 1993(90) Randomization to NA Placebo Volunteer AD cases NA Significantly better 
placebo or controlled (n = 44) performance on 
indomethacin secondary cognitive tests (P 
prevention trial < 0.003) 
" 
Scharf 1999(91) 
Aisen (104) 
Randomization to 
placebo or 
dicJofenacJ 
misoprostol 
NA 
Randomization to NA 
placebo or 
prednisone 10 mg 
for 1 year 
Placebo 
controlled 
secondary 
prevention trial 
Placebo 
controlled 
secondary 
prevention trial 
Volunteer AD cases NA Test-battery: no 
(n =41) significant 
differences in 
intention to treat 
analyses 
Volunteer AD cases NA No difference on 
(n = 138) ADAS-cog (P = 
0.16) 
Behavioral decline 
in treatment group 
P = probability, NA= not applicable. NS= non-significant, UK= unknown" RR= relative risk, OR= odds ratio, CI= confidence interval, RA:;; rheumatoid arthritis, 
ADAS-cog :;; Alzheimer's Disease Assessment cognitive subscale. He= hospital contro!. GP= general practitioner, BlSA = Baltimore Longitudinal Study of 
Aging."'exposure or exposure proxled by disease. 
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Cllapter 2 
pocampus (98, 99), a vital stTucture in memmy. 
Prevalence studies 
Thus far, there are only few epidemiological studies on the association between gluco-
corticoid use and Alzheimer's disease (table 2). In a twin study, the onset of Alzheim-
er's disease was inversely associated with prior concomitant use of corticosteroids 
or adrenocorticotropin (=ACTH) (78). In a larger study of siblings with a high risk 
of Alzheimer's disease, no significant difference in risk was found after exposure to 
glucocortlcolds (79). 1\vo other studies that were considerably larger (39, 80), one of 
which was population-based (80), did notllnd a significant association (table 2), In 
a recent review on the role of anti-infiammatOlY drugs in Alzheimer's disease, pool-
ing of data from the above studies yielded a significant inverse association (OR 0.65) 
(76). 
In a Japanese study on leprosy, the anti-inflamrnatOlY /bacteriostatic agent dap-
sone ( = diaphenylsulfone) appeared to have a protective effect on dementia (100). 
In a more recent study from Japan of prevalent Alzheimer's disease cases in which 
a variety of anti-leprosy drugs were investigated this protective effed was not con-
firmed (101). In subjects below 80 years of age there was an increased risk of 
Alzheimer's disease in users. Finally, colchicine, normally prescribed for gout. has 
been proposed as a potential beneficial agent in Alzheimer's disease (102) and sec-
ondruy prevention bials in Alzheimer's disease have been started. 
Incidence studies and trials 
No incidence studies have been published. Results from the secondruy prevention 
"Multicenter Trial of Prednisone in Alzheimer's disease" (l03) have recently become 
available (104). A total of 138 subjects were randomized either to placebo or to an 
initial dose of 20 mg prednisone tapered after four weeks to 10 mg and continued 
for a year. There were no differences in performance on the cognitive sub scale of the 
Alzheimer's disease Assessment Scale. However, prednisone tTeated subjects showed 
behavioral decline compared to the placebo group. 
Trials on other anti-inflammatOlY drugs, Hke hydro>"''Ychloroquine and colchicine 
have to be awaited. 
Histamine-2-receptor blocking agents 
Biological mechanism 
H2-antagonists are frequenUy prescribed for duodenal ulcers, reflux esophagitis or 
ulcerative lesions caused by the use of NSAID. Histamine Is a neurotransmitter In 
the brain, which has not been clearly iI'nplicated in maJor diseases. All histaminer-
gic neurons reside in the posterior hypothalamus and innervate most brain areas, 
which is compatible with the idea that histamine is involved in general central regula-
tory mechanisms. A recent post-mortem study in humans suggested that a decrease 
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in brain histamine may contribute to the cognitive decline in Alzheimer's disease 
directly or through the cholinergic system {l05}. Furthermore, iliere is evidence that 
H2-antagonists can aggravate the neuronal damage in ilie hippocampus caused by 
ischemia (l06). These latter data are In contrast to the hypothesis that H2-antago-
nists may Inhibit the cascade leading to excllotoxic cell-death (79). 
Prevalence studies 
Until now, only two observational epidemiological studies have been published; one 
showed a prolective effect of H2-anlagonlsls Independent of NSAID exposure (79), 
the other found no association (107) (lable 3). It may be dllllcult to study the indepen-
dent effect of H2-antagonists since previous NSAID and/or glucocorticoid use may 
induce the prescribing of H2-antagonists if gastrointestinal adverse effects occur. 
Antihypertensives 
Biological mechanism 
Antihypertensives are mainly prescribed for hypertension but also after myocardial 
infarction to prevent llie heart from remodeling (particularly angiotensin-convert-
ing-enzym inhibitors), and for post-menopausal complaints (clonidine). There is 
increasing evidence that hypertensIon may conb-ibute to the developlllent of cogni-
tive impairment and dementia (108-111). This logically leads to the hypothesis that 
antihypertensive drugs might protect against the development of cognitive dysfunc-
tion and dementia. It is currently unclear, whether a protective effect on the brain 
is the consequence of the lowering of the high blood pressure or that also other 
mechanisms are involved (112), Another mechanism that was suggested is that 
some antihypertensives, i.e. calcium antagonists may benefiCially influence calciulll 
homeostasis of neurons thereby preventing or delaying onset of Alzheimer's disease 
(113). 
Prevalence studies 
Prevalence studies on the association between antihypertensive drugs and Alzheim-
er's disease are not available. 
Incidence studies 
There is little evidence of a beneficial effect of antihypertensive drugs on the risk 
of Alzheimer's disease (table 4). In the populallon-based Kungsholmen study of sub-
jects aged 75 years and over, persons using antihypertensive medication or diuretic 
mono therapy at baselIne had a reduced risk of developing demenlla compared to 
non-users (l14). 
Observational studies on antihypertensives and Alzheimer's disease are seriously 
limited by confounding by indication and co-morbidity. Specific drugs are prescribed 
according to degree of severity and co-morbidity, Furthermore, this co-morbidity is 
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Author! year Exposure 
Studies of prevalent Alzheimer's disease 
Breitner 1995(79) H2-antagonists 
Launer(107) 
(duration) 
H2-antagonists 
(use in past week, 
dose) 
Exposure source Design 
Interview of unaffected Sibship study 
individuals and/or 
collateral information 
Interview Population 
based cohort 
study 
Case source (nO) Control source 
Siblings (n = 107) Siblings 
Cohort (n = 208) Cohort 
Mas = months" RR = relative risk, OR = odds ratio, CI = confidence interval, H2-antagonists = histamine-2-receptor antagonists. 
RRiOR (95% el) 
or probability 
0.2 (0.1-0.7) 1-12 
mos 
0.06(0.0-0.3) > 12 
mos 
1.24 (0.52-2.98) 
Q 
~ , 
~ 
'" 
'" 
'" 
TABLE 4 
Studies on antihypertensives. 
Author! year Exposure 
Studies of incident Alzheimer's disease 
Guo 1999(114) Antihypertensive 
use in two weeks 
before interview 
Primary prevention trial 
Forette 1998(113) Randomization to 
placebo or 
nitrendipine 
(+enaJapril and/or 
hydrochlorothiazide 
if necessary) 
Exposure source 
InteNiew 
Dispensed in trial 
Design 
Prospective 
population 
based cohort 
study 
Randomized 
placebo 
controlled trial 
Case source (no) Control source 
Community cohort (n Community cohort 
= 204 all dementia) 
People with systolic NA 
hypertension 
(n = 23) 
P :: probability, NA= not applicable. RR= relative risk, OR= odds ratio, CI= confidence interval. 
RRiOR (95% el) 
or probability 
0.7(0.6-1.0).11 
antihypertensives 
0.6 (0.4-0.9) 
diuretics 
0.6 (0.3-1.2) 
betablockers or 
calcium 
antagonists 
p = 0.05 50% 
lower risk 
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sometimes in itself associated witil tile occurrence of Alzheimer's disease (e.g. car-
diac problems, diabetes mellitus and stroke) or death as competing risk. Another 
potential problem is that hypertension may lead to cognitive impairment, which 
appears to be associated with less compliant behavIor and exposure misclassifica-
lion (115). II may Lhen be hard Lo deLermine whallhc aclual effect of antihyperten-
sive drugs is. 
Trials 
CurrenUy, the only primary prevention lrial on the association belween antihyper-
tensives use and the risk of dementia is tile Systolic Hypertension in Europe Trial. 
In this trial of isolated systolic hypertension (160-219 mm Hgl subjects were lreated 
with nitrendipine and, if blood pressure was not lowered sufficiently, enalapril 
and/or hydrochlorothiazide were added. They found that the incidence of dementia 
was 50% lower in the trcatment group (113). It is, however, unclear whether this pro-
tective effect, if real, was a consequence of the lower blood pressure or of a specific 
neuroprotectlve effect of calcium channel-blockade (112). This was a small study, 
which needs to be replicated. 
In a trial on stroke prevention by thiazide treatment (=diuretic) in older persons 
with isolated systolic hypertension, treatment significantly reduced the risk of stroke 
but not of cognitive impairment (116). In a secondary prevention trIal sabeluzole, a 
new benzothiazole derivative (calcium channel-blocker), appeared to exert beneficial 
effects on memOl), in Alzheimer's disease paUents (117). 
It is now clear that both diastolic and systolic hypertension are associated with 
an increased risk of cardio- and cerebrovascular morbidity and mortality. Because 
of ethical problems, it is unlikely that future placebo controlled primm)' prevention 
trials will be initiated in subjects who fulfill the established criteria for treatment. 
Trials can only compare different antihypcrtensive agents, and not the overall effect 
of antihypertensive lreatment. Large observational prospective population based 
studies will be needed to study the overall effect of antihypertensive drugs on 
Alzheimer's disease. 
Benzodiazepines 
Biological mechanism 
Benzodiazepines are among tile most frequently prescribed drugs in tile elderly. 
Their clinical applications include adminisb'ation as sedatives-hypnotics, anticon-
vulsants and anxiolytics. In animal models of cerebral ischemia, the inhibitOl), 
neurotransmitter y-amlnobutyrlc acId (GABA) illU\ GABA-mimetlc drugs (benzodiaze-
pines) were reported to protect against neuronal damage (118-122). BenzodiazepJnes 
may proted neurons by reducing cerebral oxygen demand through reduction of syn-
aptic transmission (123). A large number of experimental studies are available on 
the potential (short-term) reversible adverse effects of benzodiazepines on memOl), 
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performance (124-129). However, velY little is known about the long-term cognitive 
effects of chronic benzodiazepine exposure. 
There are no prevalence studies on Ule association ofbenzodiazepines and Alzheim-
er's disease. This may reflect the fact that benzodiazepines are often prescribed for 
behavioral and sleeping problems in Alzheimer's disease, making it impossible to 
study associations. 
Incidence studies 
The relation between ilie chronic use of benzodiazepines and incident dementia was 
examined In tile Kungshohnen Study (130) (lable 5). Users of benzodlazeplncs bolh 
at baseline and follow-up had a lower incidence of Alzheimer's disease compared to 
non-users, after adjusting for age, sex, education and use of NSAlD and estrogen. As 
this is the first study on the association other studies are needed before any conclu-
sion can be drawn. A potential threat to the validity in studies relating benzodia-
zepines to Alzheimer's disease is that pre-clinical symptoms in Alzheimer's disease 
such as sleeping problems may be treated with benzodiazepines, although such a 
bias would tend to overestimate the risk. 
Free radical scavengers 
Biological mechanism 
Oxidative stress may play an important etiologic role in Alzheimer's disease (131, 
132). Free radical scavengers are agents that sequester free radicals so that they do 
not initiate oxidative reactions that can lead to cellular damage. These free radical 
scavengers can be naturally occurring substances (Beta-carotene, vitanlin C and E, 
estrogen (133. 134) and Ginkgo blloba) or synthetically prepared subslances (sele-
giline, a monoamine-oxidase (l'vlAO)-B inhibitor established in the therapy of Parldn-
son's disease, lazabemide another more selective MAO-B inhibitor (135, 136) and 
tenllsetam, which is believed to be an advanced glycaUon end products-inhibitor 
(137)). 
Prevalence studies 
Observational data on free radical scavengers and the rIsk of Alzheimer's disease are 
limited (table 6). 
Incidence studies 
In an analysis on data of the Rotterdam Sludy timt included 58 subjects with Incl-
dent dementia, dietmy jntake of anti-oxidants was not associated with a reduced 
incidence of dementia (133). Obselvational data on use of vitamin E and vitamin C 
supplements and incident Alzheimer's disease is reported in one study (134). In this 
prospective study of 633 persons of 65 years and older, a stratified random sample 
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Studies on benzodiazepines. 
Author! year Exposure Exposure source 
Studies of incident Alzheimer's disease 
Fastbom 1998(130) benzodiazepines Interview 
(regular) 
P = probability, RR:;; relative risk, OR= odds ratio, CI= confidence interval. 
Design 
Prospective 
population 
based cohort 
study 
Case source (nO) Control source 
Cohort (n = 33) Cohort 
RRiOR (95% el) 
or probability 
P = 0.012 (aU 
benzodiazepines) 
P = 0.013 
(hypnotics) 
~ 
'" if 
~ 
" 
" 
'" 
TABLES 
Studies on radical scavengers and antioxidants. 
Authori year Exposure Exposure source 
Studies of prevalent Alzheimer's disease 
Brae 1990(36) Vitamin E by proxy Interview 
informants 
Studies of inCident Alzheimer's disease 
Morris 1998(134) Vitamin C and E Interview with direct 
Kalmijn(1S7) 
Trials 
Haase 1996 (141) 
Sano 1997(142) 
Le Bars 2000 (140) 
taken in previous inspection 
two weeks 
Anti-oxidants Food questionnaire 
interview 
EGb 761 LV.4 NA 
days per week for 
4 weeks 
Selegiline (10 mg) NA 
and/or 
(X-tocopherol 
(2000IU) 
Egb 761t.i.d. 40 NA 
mg 
Design 
Case-control 
study 
Prospective 
cohort study 
Prospective 
population 
based cohort 
study 
Randomized 
double blind 
secondary 
prevention trial 
Randomized 
double blind 
secondary 
prevention trial 
Randomized 
double blind 
secondary 
prevention trial 
Case source (no) Control source 
General practice (n General practice 
= 170) 
Stratified sample of Stratified sample of 
cohort of disease cohort of disease 
free subjects (n = free subjects 
91) 
Cohort (n = 58) Cohort 
(Alzheimer, NA 
vascular, or mixed 
type) 
23 centers (n = 341) NA 
Multicenter (n=309) NA 
(Alzheimer, vascular 
dementia) 
RRiOR (95% Cil 
or probability 
1.3 (0.6-1.65) 
vitamin E 
1.17 (0.5-2.5) iron 
P = 0.10 Vitamin C 
P = 0.04 Vitamin A 
No reduction 
NAB P=0.05 
CGI P=0.05 
IADL 
Significant delay 
until institution-
alization for treat-
ment group 
ADAS-cog P=0.04 
GERRI P=0.007 
CGI 
P = probability, NA= not applicable, RR= relative risk, OR= odds ratio, C!= confidence interval. ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive 
Subscale, GERRI=Geriatric Evaluation by Relative's Rating Instrument. CGI= Clinical Global Impression of Change, NAB=Numberger-Alters-Beobachtungs-
skala. lADL=lnstrumental Activities of Daily Living. 
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was selected from a disease-li'ee population, At baseline, all vitamin supplements 
taken In the previous 2 weeks were identified by direct inspection. After an average 
follow-up period of 4.3 years, 91 of the sample participants with vHamin infonna-
tion met accepted criteria for the clinical diagnosis of Alzheimer's disease. This study 
data suggest an inverse association between high vitamin E and vitamin C intake 
and Alzheimer's disease. However, further exploration is needed as this is the first 
longitudinal study and results were only significant for Vitamin C. 
One of the reasons for the scarcity of observational studies may be the compli-
cated assessment of cA1Josure: some are in the form of over-the-counter supple-
ments, herbs or food. High over-the-counter sales mean that medical or pharmacy 
records do not provide a valid measure of intake. In addition, similar to the use of 
HRT, the healthy user effect may hamper valid assessments. 
Trials 
Ginkgo biloba (138-141) and selegillne or a-tocopherol (vitamin E) have been studied 
as secondary protective agents against Alzheimer's disease (142). The largest Ginkgo 
bHoba trial published thus far, in which primmy outcome measures included the 
ADAS-Cog, the GeriatTic Evaluation by Relative's Rating Instrument and the Clinical 
Global Impression of Change showed superiority of Ginkgo blloba extracl over pla-
cebo. In compmison to the baseline values, the placebo group worsened statistically 
Significantly on all domains of assessment, while the group receiving Ginl<go biloba 
extract was considered slightly improved on cognitive assessment mld daily living 
and social behaviour. Regarding safety. no differences were observed. The recently 
stm'ted Ginkgo Evaluation of Memory Study may resolve the question whether or not 
these findings can be e~irapolated to primmy prevention, 
The selegiline/a-tocopherol trial showed that in patients with moderately severe 
impairment from Alzheimer's disease, treatment \vith selegiline or a-tocopherol 
slowed the progression of disease. A potential limitation of this trial is that progres-
sion was defined as a non-specHic outcome timt included time until institutional 
placement, or loss of activity to perform basic activities of daily living, or severe 
dementia or death. There were no significant differences in any of the cognitive test 
scores. Furthermore, selegiline may act as an m1ti-depressant, which could lead to 
improved cognition. The results of bials \vith lazabemide have to be awaited (l36). 
DISCUSSION AND CONCLUSION 
In recent years, some progress has been made in unraveling presumed protective 
effects of drugs in Alzheimer's disease. There are several methodological problems 
that are encountered in epidemiological research on drug effects and Alzheimer's 
disease. The exposure definition of drug use is often imprecise and lacks unU'or-
mity over studies. When studying drug effects, an adequate definition of drug expo-
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sure is needed that encompasses when the drug was used relative to the onset of 
Ule disease. at what dose, and for how long. Standardization of research criteria 
used to define Alzheimer's disease would also increase the comparability of studies, 
Although NINCDS-ADRDA criteria are li'equently used, the use of diiJerent diagnos-
tic cIiteria may lead to very different case populations (143) and potentially to non-
comparable and different risk estimates. The time of first clinical syl1lptoms should 
be well documented. as, for obvious reasons, exposure can only be preventive if it 
occurs before diagnosis of the disease. However, it is recognized that these are dif-
ficult data to obtain reliably, An additional problem in studies of Alzheimer's disease 
is the sub-clinical period ofunknowI1 duration, in which a drug mayor may not influ-
ence progression. Since drug use or non-use could be associated willl factors that 
are in itself associated with the risk of a disease, these factors should be equally wen 
defined as the drug under study and correctly controlled for in tile analysis (144). 
NSAID and to a lesser extent HRT are the drugs which have been most frequenUy 
studied in relation to Alzheimer's diseas~, For other drugs that have been studied, 
evidence is yet too scanty to evaluate their effect on the risk. A protective effect 
was most consistently demonstrated for the long-term use of HRT, although only 10 
of 15 studies have been positive and secondruy prevention trials are inconsistent. 
Because of beneficial effects on post-menopausal complaInts, osteoporosis (145. 
146) ruld atherosclerosis (147, 148), use of HRT is currently increasing in western 
society. In case a beneficial effect of HRT in Alzheimer's disease is demonstrated 
in (ongoing) clinical t.rials, the benefits may be considered so large that in spite of 
Ule increased risk of venous thrombo embolism (63) and breast crulcer (l49), a fur-
ther increase of its use seems likely, This development will be further strengthened 
if selective estrogen receptor modulators, a new class of synUletic estrogens, really 
turn out to retain beneficial estrogenic effects in the brain without exhibiting men-
tioned adverse effects (150, 151), 
Although optimist Ic reviews, mainly based on studies in prevalent Alzheimer's dis-
ease, have been published on the potentially proteclive role of NSAID in Alzheimer's 
disease, most prospeelive studies do not support 011s. In addition, currently avail-
able secondaty prevenlion trials are inconclusive. These differences across studies 
may be the result of differences In study design, measurement of exposure, drug 
composition, ascertainment of cases (em'Iy /late onset, familial/sporadic). Given the 
high percentage of severe adverse-effects of the use of NSAID {90. 152}, their poten-
tial role in the pIimaIY prevention of Alzheimer's disease is far less clear-cut (a 
disadvantage that also holds for the use of oOler anti-inflammatOly drugs). It is ques-
tionable whether future developments of selective COX2-inhibJtors and/or nitric 
Oxide-releasing NSAID may change 1his (153, 154), 
Although studies of antihypertensive Ulerapy and Alzheimer's disease are scanty. 
the first results ru'e promising. Reseru'ch all the role of antihypertensives in Alzheinl-
er's disease should probably locus on the potential mechanism and thus on Ule ques-
tion whether a protective efiect, if present, is solely explained by lowering of blood 
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pressure. Because of beneficial effects in cardio- and cerebrovascular disease in gen-
eral. when proven effective in Alzheimer's disease, it is likely that treatment with 
antihypertensive drugs will be further intensified. 
Given the low frequency of adverse effects of naturally occuning free radical scav-
engers their use will probably increase when proven beneficial. It will, however, be 
difficult to monitor their use because they are mainly obtained over the counter. 
Because of the high risk of addiction, short-term memory problems and higher 
!isk of fractures and accidents it is unlikely that benzodiazepines will ever be intro-
duced as primary preventive agents in Alzheimer's disease. 
In conclusion, we are only just in the beginning of making valid and useful assess-
ments of protective drug effects in Alzheimer's disease and there is a long way to go. 
For the future, placebo-controlled trials for plimruy prevention may be velY cumber-
some. However, in the light of the developing lru'ge scale efforts (HRT. NSAID and 
Ginl{go) it may prove possible to study most of the suggested hypotheses. In order to 
be of help, how should observational studies contribute? Given the publicity regard-
ing some of the drugs, and use of drugs for related co-morbidity. it nlay become 
more difficult to do observational studies. There ru'e nevertheless a number of issues 
like the temporal relationship, the optimal dose level and the identification of pru'-
ticular risk groups tlmt can and should be addressed in observational studies. How-
ever, in order to further untangle these difficull issues more uniform approaches are 
needed. 
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Chapter 3 
NSAID AND DEMENTIA 

3.1 
Risk estimation based on cross-sectional 
drug assessment at baseline in cohort 
studies may be biased by differential 
misclassification of exposure 
ABSTRACT 
Exposure 10 drugs is difficullio measure, In Ihis sludy, we explored Ihe effecls of exposure 
misclassification on Ihe association belween reporled and chronic use of NSAID and 
Alzheimer's disease, We included participanls who were inlerviewed aller January 1", 1992, 
who were regislered with one of Ihe pharmacies Ihal provided dala 10 Ihe Rollerdam Siudy 
and who provided baseline inlerview dala on drug use (n=4402), Sensitivily, specificity, 
negative and positive predictive value of inlerview dala as a measure of NSAID exposure 
compared to pharmacy data were used as outcome measures, In conclusion, baseline cross-
sectional NSAID exposure is nol a valid melhod for Ihe assessmenl of chronic use of NSAID 
in Ihe elderfy. The validily of cross-sectional inlerview NSAID exposure dala varies highly 
wilh age, sex and cognitive function. In our sludy, Ihe misclassification resulled in a bias 
lowards Ihe null regarding Ihe association belween chronic use of NSAID and Alzheimer's 
disease. However, cross-sectional exposure assessment of NSAID use at baseline in a 
cohorl sludy among elderfy may yield risk estimales for Alzheimer's disease Ihal can be 
biased in any direction since Ihe degree of miscfassification depends on age, gender and 
cognitive function al baseline, In order 10 prevenllhis we recommend Ihe use of longiludinal 
pharmacy data for drug exposure assessment in epidemiological cohort studies, 
INTRODUCTION 
In epidemiological studies, specific and sensitive information on the type, close and 
duration of exposure is essential (1), \\Then compared to the usuaUy rigorous valida-
tion and standardization of clinical measurements, the extent to which drug expo-
sure is assessed in epidemiological studies is often poor. There are many examples 
of population-based cohort studies that have used cross-sedionalinterview data to 
assess drug exposure. Among those are controversial studies associating calcium 
channel blockers with cancer, myocardia1infarction and gastro-intestinal bleeding 
(2-4), NSAID and aspirin \ViU, cancer (5), but also studies relating benzodiazeplnes 
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to hip fractures (6). Cross-sectional assessment of current drug exposure by means 
of interview may provide little insight into the duration of past or current drug expo-
sure given the dynamic character of pharmacological treatment. Using such data 
as a measure of exposure may introduce serious exposure misclassilication. Several 
authors who base their conclusions on this type of exposure measurement have 
acknowledged the potential for misclassificatlon. However, it is often assumed that 
this nlisclassification will be non-differential and leads to a more conservative risk 
estinlate, and lilat an observed Significant observation therefore is a true one. 
Triggered by some contradict011' studies regarding tile association between use 
of NSAID and the occurrence of Alzheimer's disease (7-1 O) we conducted a study 
to quantifY the degree of misc1assitlcation introduced by using cross-sectional data, 
and to estimate the effects of exposure misc1assHication on the estimated risk of 
Alzheimer's disease associated with NSAID use. 
METHODS 
Study population 
The Rotterdam Study is a prospective population-based cohort study of neurological, 
cardiovasculm', locomotor and ophthalmological diseases in the elderly and has been 
described extensively elsewhere (11). In brief, all inhabitants of Ommoord, a suburb 
of the city of Rotterdam in the Netherlands, aged 55 years or older and living in the 
disLIict for at least one year were invited in 1990-1993 to participate in the study. Of 
lhe 10,275 eligible subjects, 7,983 (78%) parllclpated and were Interviewed. During 
the interview, a questionnaire was administered covering, among other topics, socio-
economic background, medical hist011' and medication use. During subsequent 
visits to the research center, subjects underwent additional interviewing and clinical 
examinations, including screening for and diagnostic work-up of dementia (12, 13). 
In Ommoord, seven computerized pharmacies that are all linked to one network 
serve the total population. These records were linked to the database of the Rotter-
dam Study. Over a 7-yem' period more than 95% of the study population had filled 
at least one prescription in these pharmacies. 
All dispensed drugs have been filed since \JanumT pt, 1991 and m"e available 
in computerized format. The population for the current study comprised all cohort 
members who were interviewed after JanuatT PI, 1992 (to ensure at least 1 yem" of 
potential drug hist011') and who were labeled as clients of one of the pharmacies. 
Automated pharmacy records containing all preserlplion medication histories of 
7814 oul of 7983 subjects (97.9%) were available. \Ve excluded 4 subjects since they 
had no baseline interview data and 3408 subjects because the interview was con-
dueled before Janum1' 1'" 1992. The study population Ulerelore comprised 4402 
subjects. 
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Drug exposure assessment 
Interview data 
At base1ine, all participants were interviewed by a t.Tained research assistant and 
were asked to show all vials of medications (either prescription or over-the-counter) 
tilat were used during the preceding week. Names or brands of drugs were recorded 
and classified according to their corresponding Anatomical-Therapeutical-Chemical-
code (ATe-code) (14). For this study we used all information that was recorded per-
taining to the use of NSAID (ATe: MOl), 
Pharmacy data 
Medication histOlies included information on all filled prescriptions characterized by 
the name, ATC codes, amount dispensed and Ole dosage regimen. The legend dura-
tion of use of each NSAID prescription was calculated as the ratio of the dispensed 
number of tablets or capsules and the prescribed daily number. 
\Ve created several categories of NSAID exposure depending on the time and dura-
tion of use. Exposure to NSAID in the year prior to tile baseline interview was char-
acleIized as non-use (no prescription). occasional use and chronIc use. Persons were 
classified as chronic users of NSAID if the cumulative legend duration of NSAID 
amounted to at least 180 days in the 12 months before the baseline intenriew date 
{I5}. Use for less Ulall 180 days in the 12 months before tile baseline interview date 
was defined as occasional use 
Analysis 
\Ve were interested in chronic NSAID use, because this type of exposure has been 
reported to protect against Alzheimer's disease (9), To quantity the validity of NSAID 
exposure as measured by means of cross-sectional interview data we calculated the 
sensitivity, specificity, positive alld negative predictive value of tile NSAID exposure 
classification between interview and pharmacy data. As atllie time of measurement 
no NSAlD were available without prescription, we considered the pharmacy data 
as the gold standard. \Ve calculated these pal'ameters for chronic use durIng the 
I-year period preceding the baseline interview. \Ve furthermore examined whether 
age, gender or low cogniUve function, defined as a Mini Mental State ExaminaUon 
(MMSE) (16) of beiow 26, were associated with the validity of NSAID exposure assess-
ment as a proxy of chronic use. 
In addition, we performed a logistic regression analysis to determine whether 
these factors independently affected the validity while controlling for tile otller fac-
tors. 
Finally, to explore the effects of potential misclassification on the association 
behveen use of NSAlD and the occurrence of Alzheimer's disease, we examined 
the effect of exposure misclassification introduced by interview data on the asso-
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ciation between NSAID use and Alzheimer's disease. To this purpose we compared 
the hazards between persons who developed Alzheimer's disease in the Rotterdam 
Study (17) and persons who remained free of Alzheimer's disease during follow-up, 
based on eUher interview data or pharmacy eA1Josure data in persons who were non-
demented at baseline. Age and gender acUusted hazard ratios were calculated by 
means of Cox' proportional hazards regression analyses. 
RESULTS 
Of the 4402 subjects in our study population. 336 (7.6%) subjects reported NSAID 
use during the baseline interview. According to the pharmacy database, 994 (22.60/0) 
of the study subjects used NSAID in Ule one year prior to the interview, of whom 
131(3%) were chronic user to 180 days in plioI' 12 months) and 863 (19.6%) suhJects 
were occasional user (1-179 days in prior 12 months). 
Table 1 shows the exposure c1assjfication of subjects according to interview and 
pharmacy data. Although tlle sensitivity and specificity were high for chronic use, 
the table shows also that only 31 % of those reporting NSAID use at baseline were 
actual chronic users (positive predictive value). 
Table 2 shows the validity for interview data according to age, gender and low 
cognUive function. The validity of assessment of NSAID use at interview as a proxy 
of chronic use by interview differed per age class. Despite a lower sensitivity and 
specificity in older age, the proportion of people that reported NSAID use at baseline 
and who were real chronic users increased significantly with age from 25% below 
65 years to approximately 41 % above 80 years of age (positive predictive value). Men 
and women did not significantly differ with respect to any of the validity measures. 
In subjects with low cognitive performance (MMSE < 26) sensitivity (57% ) was sig-
nificantly lower Ulan in subjects with a normal cognitive function (88%). Additional 
analyses showed that higher age and llie presence of cognitive impairment, but not 
TABLE 1 
Validity of a single interview~based exposure measurement for the assessment of 
chronic NSAID exposure in the year prior to the interview. 
User status Pharmacy 
User status Chronic Occasional Non-
Validity status for 
Total Chronic use (n=131) Interview user user use 
Sensitivity 80.2% 
User 105 184 47 336 Specificity 94.6% 
Non~user 26 679 3361 4066 PPV 31.3% NPV 99.4% Total 131 863 3408 4402 
PPV =positlve predictive value, NPV =negaUve predictive value. 
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TABLE 2 
Validity of a single interview based exposure measurement forthe assessment of chronic NSAID exposure in the year preceding the 
interview, stratified by age, sex and cognitive function. 
VALIDITY PARAMETERS 
Sensitivity Specificity PPV NPV 
AGE 55-64 yrs 100% 95.0% (93.9-96.1) 25.2% (17.7-32.7) 100% 
65-79 yrs 77.8% (66.7-88.9) 95.0% (94.0-96.0) 30.9% (23.1-38.7) 99.3% (98.9-99.7) 
~80 yrs 70.2% (57.1-83.3) 92.5% (90.5-94.5) 40.7% (28.5-47.5) 97.7% (96.3-99.1) 
SEX Male 79.4% (71.8-87.0) 93.6% (92.6-94.6) 33.9% (27.8-40.0) 99.1 % (98.7-99.5) 
Female 82.7% (68.7-96.7) 96.0% (95.1-96.9) 24.7% (15.9-33.5) 99.7% (99.4-100.0) 
COGNITION MMSE <26 66.7% (48.3-83.6) 93.3% (91.3-95.3) 31.6% (19.6-43.6) 98.4% (97.4-99.4) 
MMSE~6 92.5% (85.9-98.8) 94.5% (93.8-95.2) 25.4% (19.9-29.9) 99.8% (99.6-100.0) 
PPV :;;positive predictive value, NPV =negative predictive value. 
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sex, independently and sIgnificantly modified the association between the baseline 
interview and chronic use according to the pharmacy data (data not shown). 
To examine the potentJal consequences of the misclassiIication, we compared 
the risks of exposure to reported and chronic NSAID use between 117 incident 
Alzheimer patients and 3750 non-Alzheimer's disease patients. The age and sex 
adjusted hazard ratio for exposure to NSAID according to cross-sectional interview 
data was 0.81. According to pharmacy data the hazard ratio was 0.51 for subjects 
chronically exposed in the year prior to the interview. 
DISCUSSION 
\Ve found that cross-sectional assessment of NSAID cx'posure with baseline interview 
data is not a valid method for the estimation of preceding chronic NSAID use in ti1e 
elderly. The amount of misclassification was inversely associated with age, which 
itself is a strong risk factor for AlzheImer's disease. This differential misclassification 
means that the effect on the relative risk can go into any direction. In our study a pro-
tective point estimate of 0.81 for NSAID use in Alzheimer's disease changed to 0.51 
after making use of a chronic exposure estimate. Although the current study is by 
design not suitable to adequately address the true association between NSAID and 
Alzheimer's disease, these findings are important because in several epidemiological 
studies regarding Alzheimer's disease, drug exposure is measured cross-sectionally 
on ti1e basis or current use (7, 8,10,18.19). Interviews on current NSAID use lead 
to a high number of false positives when used as a proxy of chronic use. Because 
exposure will be overestimated in all subjects, but especially in younger subjects 
as their prevalence of chronic use is lower, Moreover, subjects with cognitive impair-
ment Significantly less often showed their NSAID vials, when in fact tlley had been 
chronic users in the past year. Since cognitive impairment may be a symptom of 
Alzheimer's disease this is one of the reasons why such a design should not be used 
in prevalent demented subjects. 
In this study we have shown that misclassification of exposure is substantial 
when medication use in the past week is used as a proxy for "long-term" use. This 
is not new, since many authors have acknowledged iliis issue when outlining the 
limitations of their study, However, we quantified ti1e effect and more importantly we 
have shown that the degree of misclassification changes with cognitive status and 
within strata of age. 
In interpreting our results. we need to discuss the potential limitations of this 
study. Selection bias is not likeiy to be an issue as our study is population based 
and the exclusion of subjects was only dependent on the baseline interview date that 
was aSSigned randomly. \Ve used drug exposure as recorded in pharmacy data as 
the gold standard in this study. In the Netherlands, because of the high insurance 
coverage of approximately 99.4% (20) there is no economic incentive for switching 
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among pharmacies, Pharmacy records are therefore considered virtually complete 
resources for drug exposure, and are often used to assess completeness of medical 
records or interview data (21, 22). On the basis of the pharmacy records we may 
have misclassified chronic exposure as a consequence of people not finishing their 
prescIiptions, However, as it is highly improbable that people regularly fill prescIip-
tions that they do not use we think that it is unlikely that this influenced Ule results, 
Moreover, as the mean duration of the cumulative prescriptions was 308 days in the 
year preceding and encompassing the interview date, subjects may have Inissed on 
average 1 in evelY three prescriptions and still be accurately classified as a chronic 
user. Even though the pharmacy data are a reliable source in determining chronic 
use, a limitation to our study is the simplification of Ule definition of this chronic use, 
By changing the definition, estimates of validity change, However, when chronic use 
was defined as use during 365 days per year, misclassification was similar and tile 
effect on the risk estimate for prevalent Alzheimer's disease was comparable, 
It is unclear to what extent our findings can be extrapolated to other populations, 
Although prescription patterns and patterns of use may be different, it is Hkely that 
age is a determinant of chronic drug use as it is the most important determinant 
of chronic disease in western society, Finally, it is important to note Ulat the often 
intermittent pattern of use of NSAID is probably dllJerent from, for example, the pat-
tern of use of antihypertensives, which are normally used chronically, 
\Vhat are the implications of these findings on judging the existing studies of demen-
tia and on the design of future studies? If misclassificaUon of a dichotomous expo-
sure is independent of disease status, e,g, non-differential, the risk estimate is 
biased towards the null, However, in studies on dementia, but also in other diseases, 
errors in exposure and disease may be associated and lead to differential misclassi-
fication, To what exient this mlsclassification may have happened in previous stud-
ies is unclear, It may be considerable but depends among oUler things on age and 
gender distribution, degree of co-morbidity and paUerns of NSAID lIse, Because the 
potential effects of misclassification of exposure on the relative risk are complex 
and not easily generalized, each study should be evaluated individually (23), This 
potential for misclassHlcation may be one of the contTibuting causes of the conflict-
ing results that have been found in studies on NSAID and Alzheimer's disease, In 
conclusion, we think that in view of these results, cross-sectional exposure assess-
ment at baseline in a cohort study may yield biased risk estimates of diseases, which 
are related to chronic drug exposure, As misclassilication of exposure can not be 
dealt with by the methods used for control of confounding (24). we strongly recom-
mend the use of continuously gathered dnlg exposure data in pharmaco-epidemio-
logical studies instead of cross-sectional drug exposure information. 
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NSAID and incident Alzheimer's disease 
The Rotterdam Study 
ABSTRACT 
Recent studies suggest that the use of non-steroidal anti-inflammatory drugs (NSAID) may 
reduce the risk for Alzheimer's disease. We investigated the retation of NSAID use over a ten-
year period and the risk for incident Alzheimer's disease using a nested case-control design 
in the population based Rotterdam Study. The study was performed in 306 subjects; 74 
Alzheimer patients diagnosed according to NINCDS-ARDRA criteria and 232 age and sex 
matched controls. NSAID use was abstracted from general practitioners medical records 
and expressed as cumulative prescription days. The relative risk of Alzheimer's disease 
associated with long-term use (?: 2 months) was 0.95 (95% CI: 0.46-1.99) as compared to 
non-users, after controlling for possible confounders. tn a separate examination, subjects 
who had more than 6 months of prescription days had a reduced relative risk of Alzheimer's 
disease; O. 74 (95% CI: 0.20-2. 72). In an age-stratified analysis the effect in long-term users 
was evident in those aged 85 and under; 0.53 (95% Ct: 0.15-1.77). All risk estimates were 
lower when the last two years of exposure were excluded from the analyses. Our point 
estimates in subjects younger than 85 years and in subjects using NSAtD for 6 months or 
more are consistent with the hypothesis that long-term use of NSAID reduces the risk of 
Alzheimer's disease. However, overall there was no association between NSAID use and the 
risk of incident Alzheimer's disease. 
INTRODUCTION 
Alzheimer's disease is a progressive age related dementing disorder, that increases 
in incidence from about 1 per 1000 person-years at age 65 to 80 per 1000 persol1-
years in people aged 85 and over (1), Due to aging and the increased life exped;;llicy 
in many populations an increase in the number of cases of Alzheimer's disease is 
expected, Ulai has enormous medical and social consequences. Therefore, studies of 
determinants of Alzheimer's disease that could eventually lead to the development 
of preventive strategies are a priOIiiy. There aTe indicators of immune-mediated 
auto-destructive processes in brain Lissue in Alzheimer's disease patients (2-5), sug-
53 
Chapler :3.2 
gesting that inflammatOlY processes may playa role in Alzheimer's disease. It has 
been hypothesized that anti-inflammatory drugs, such as non-steroidal anti-inflam-
matOlY drugs (NSAID), might slow the onset or progression of Alzheimer's disease. 
Studies of the association of NSAID with the risk for Alzheimer's disease have 
been inconclusive. Some showed a reduced lisk (6,7) or a lower than expected li<e-
quency of Alzheimer's disease, in groups Ulought to be chronically exposed to NSAID 
{S-121; whereas other studies showed no association (13,14). Recently, a study, 
in the volunteer cohort of the Baltimore Longitudinal Study of Aging, showed an 
inverse relation between the duration of exposure to NSAID and the development 
of Alzheimer's disease over a 15 year peliod (15). \Ve have previously reported an 
inverse association of recent NSAID use and Alzheimer's disease on prevalent cases 
detected in tlle population based Rotterdam Study (12). However. in that cross-sec-
tional study information on duration of NSAID use was not available. Furthermore, 
that study was based on prevalent cases, and is therefore subject to stnvival bias. 
To address some of these wealmesses. we examined the association between incident 
Alzheimer's disease and NSAID use up to ten years plioI' to the onset using a nested 
case-control design based on the Rotterdam Study cohort. 
METHODS 
Study population 
The Rotterdam Study is a prospective population-based cohort study of neurological. 
cardiovascular. locomotor and ophthalmologic diseases in the elderly. All inhabit-
ants of Ommoord, a suburb of Rotterdam in tlle Netherlands. aged 55 years or more 
and living in the district for alleast one year were invited in 1990-1993 to participate 
in [he study. or lhe 10,275 eligible subJecls, 7,983 (78%) participated and were 
interviewed at home; 7,129 (S9%) of them made two follow-up visits to the research 
center. In the home interview, trained interviewers administered a questionnaire cov-
ering. among other topics, socia-economic background, medical histOlY and medica-
tion use. DUling the center visits, subjects underwent additional interviewing and 
clinical examinations, including screening and diagnosis of dementia. 
Case finding for dementia 
At baseline, subjects were screened for dementia in a two step procedure. All sub-
Jects were screened on cognitive function using ti1e Mini-Mental State Examination 
(MMSE)(16) and the Geriatric Menial Stale schedule (GMS) (17). Those scoring 25 
or below on the MMSE or sCOling 1 or more on the OMS were selected for furUler 
diagnostic evaluation. This included more detailed neuropsychologic testing and an 
informant interview based on the Cambridge Examination for Mental Disorders of 
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the Elderly (IB), as well as neurologic exanlination. Some parlicipants underwent 
brain imaging. A clinical diagnosis of dementia was made according to the DSM-
lII-R criteria for dementia (19) and possible and probable Alzheimer's disease was 
diagnosed according to NINCDS-ADRDA criteria (20). 
Case and control selection 
The 7046 subjects who were WiUlOut demenlia at baseline were eligible for the pres-
ent study. Over a lliree-year period after baseline examination all new cases of 
dementia were assembled. New cases were identified in weekly computerized reports 
of relevant morbidity sent by the general practitioner, through the regional institute 
for outpalient mental Health care, or were detected in a second round of investiga-
tion three years after Ule initial one, according to the same schedule of investigations 
followed to identify prevalent cases. As of Janumy 1995, 101 incident Alzheimer 
patients had been detected. These subjects form the case-group. The date of diag-
nosis was defined as the index date. For each case, three age- l±2 years) and sex-
matched controls were drawn from Ule remainder of the cohort lhat did not have 
a diagnosis of dementia before Janual1' 1995. Prior to Ule stmt of Ule study, we 
calculated that this number of su~jects was sufficient to detect a 50% reduction in 
risk (a.=0.05, P=0.20), an estimate which was close to our earlier and to other studies 
(12,15). 
Definition of NSAID use 
In a 40-day period two medically trained students visited the general practitioners of 
all cases and controls and abstracted prescription data from medical records. In so 
far as was possible, the abstractors were blinded to case status. For each case, data 
on medication use were collected, from ten yem"s till six monUls plior to the date 
of diagnosis (index-date), The six-month cut-off was used to reduce the possibility 
that prescription patterns were associated with the clinical expression of Alzheimer's 
disease. For each NSAID prescription, the drug was classified according to the cor-
responding Anatomical Therapeutical Chemical (ATC) code (21), generic name, pre-
scription date, (calculated) end date, and dosage. Each new NSAlD prescription was 
entered separately and directly into a computerized database. A new prescIiplion 
was defined when a change in generIc name or dosage was recorded or when the 
interval between start dates was longer thml Ulree months. For each prescription, 
the duration of exposure was calculated on the basis of the total number of capsules 
(tablets or suppositories) prescribed, divided by the number of units per day, 
If the start date was present and stop date or prescription duration missing, Ulen 
the prescription was regm"ded as incomplete. To nlinimize loss ofinformation we sup-
plemented general practitioner data with pharmacy filling information Ii'om the com-
puterized database of the three Onulloord pharmacies. These data were available 
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on the Rollerdam Study cohort as of Januaty 1991. Using approximately 25,000 
compleLe NSAJD prescriptions we calculated a mean prescription duration for each 
specific ATe-code. Subsequently these were used to replace missing durations for 
tile prescriptions that had a starL date. 
To obtain the number of cumulative days exposed we added all prescription dura-
tions during the study period for each subject. This variable was then further catego-
lized into, never users (35.2%). short term users (less then 2 months: 34.9%) and 
long term users {2 months or more: 29.7%}. This two-month perIod waS the median 
exposure duration of subjects who used NSAID. 
Confounding variables 
The folloWing data were entered into tile statistical models as to controllar putative 
confounding: education (low, middle and high). smoking (never, fornler, current), 
alcohol use (none, ~13.2 g/day, >13.2 g/day), living situation (independent, sup-
ported, nursing-home), self reported stroke (no/yes). These data were collected 
during tile home interview prior to the onset of demenHa. Alcohol intake was avail-
able only on community dwellers; a dummy variable indicating missing for this vari-
able was incorporated into the model. 
\Ve also included salicylates (categorized in none, short-term and long-term use 
based on the median of ten months in users) and benzodiazepines (I point for at 
least one prescription in evelY two years; 5 pOints when at least once in evelY hvo 
year a benzodiazepine was prescribed; categorical range 0-5) in Lhe regression model. 
Data on the latter two were collected at the same Ume as the NSAID data. 
Analytical sample 
Of the initial 388 subjects, medIcal records could not be retrieved for 16 cases (mean 
age 88.5 yrs, 43% nursing home reSidents) and 35 controls (mean age 88.8 yrs. 48 
% nursing-home residents). Furthermore, 11 cases and 20 conb'ols had less than 
10 years of medical histOly available. The analytical sample therefore comprised 306 
subjects out of 388 eligible subjects, of whom 74 were cases and 232 controls. As 
some cases lost a control and vice versa we reallocated conb'ols to different age and 
sex matched cases. This resulted in 14% male and 23% female cases respectively 
with 2 controls, and 33% male and 40% female cases WiUl 4 controls. 
Statistical analyses 
Univariate comparisons between cases and conb'ols were tested with the chi-square 
statisUc, a linear test for trend and conditional logistic regression analysis. The rela-
tive risk for Alzheimer's disease associated with NSAlD use was estimated by calcula-
tion of the odds ratios (95% confidence interval), using conditional logistic regreSSion 
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analysis, 
The main analysis was supplemented with three sub-analyses. \Ve restricted the 
exposure window to 10-2 yeal's prior to the index datc. This was done to examine 
the possibility that the sub-clinical disease process already affected drug utilization 
patterns in an early phase alld because the diseasc process may already have pro-
gressed to a stage at which NSAID are no longer protective (15). Secondly, an expo-
sure of 2 monUls may be too short to see an efIect. Therefore wc split the group 
of long-term users into a group exposed 2-6 months and a group e},.'})osed for more 
than 6 monUls, which is approximately the upper 10% of use. Finally, we stratified 
NSAID exposure into two age classes, according to t he median age of the cases: 85 
years or younger (n=144) and those aged over 85 yeal's (n=162). Multivariate con-
ditional logistic regression was performed to adjust for the confounding variables. 
All analyses were done on a microcomputer using SPSSjPC 7.0 for \Vindows and 
EGRET. 
RESULTS 
As a result of matching the mean age in both groups was almost equal: 85.3 years 
in cases and 84.7 yeal's in controls (Table 1). There were significantly more female 
than male sets. Conll'ols had a longer mean exposure than cases. The proportion of 
incomplete prescriptions was high, but similar in cases and controls. A significantly 
higher proportion of cases compared to controls were residents of a nursing home 
(35.1% vs. 19.3%, p=O.Ol) and cases were significantly more often current smokers. 
then controls (23% vs. 9%, p=0.008). Controls more frequently reported a stroke 
then cases (6% vs. 4%). Benzodiazepine and salicylate use was equally distributed 
between cases and controls over a 10 year period. 
TABLE 1 
Description of sample and prescription behavior for incident cases of Alzheimer's 
disease and matched controls: The Rotterdam Study 
Mean age (SEM) 
Male (%) 
Number of prescriptions 
Incident cases of 
Alzheimer's disease 
(n=74) 
85.3 (0.8) 
27 
158 
Controls 
(n=232) 
84.7 (0.4) 
27 
490 
Mean number of prescription days (SE) 
Subjects with all original prescriptions (%) 
Prescriptions that were complete (% of all 
prescription) 
62.1 (11.7) 104.9 (19.8) 
36 34 
26 25 
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TABLE 2 
Risk of Incident Alzheimer's disease and NSAID use over a ten year period: The 
Rotterdam Study 
Prescription days Incident AD Controls Crude odds Adjusted odds 
for NSAID n=74 n=232 ratio (95% CI) ratiol (95% CI) 
10-0.5 years before 
diagnosis 
None 24 (32.4%) 84 (36.2%) 1.0 1.0 
< 2 monlhs 27 (36.5%) 80 (34.5%) 1.17 (0.62-2.19) 1.08 (0.50-2.33) 
2-6 months 19 (25,7%) 44 (19.0%) 1.36 (0.68-2.70) 1.03 (0.46-2.31) 
;, 6 months 4 (5.4%) 24 (10.3%) 0.68 (0.21-2.14) 0.74 (0.20-2.72) 
10-2 years before 
diagnosls* 
None 32 (43.3%) 93 (40.0%) 1.0 1.0 
< 2 months 24 (32.4%) 82 (35.3%) 0.83 (0.45-1.54) 0.76 (0.37-1.57) 
2-6 months 16 (21.6%) 38 (16.4%) 1.19 (0.60-2.35) 0.97 (0.44-2.17) 
;, 6 months 2 (2.7%) 19 (8.2%) 0.32 (0.07-1.43) 0.27 (0.05-1.51) 
2-0.5 years before 
diagnosis 
None 53 (71.7%) 185 (79.7%) 1.0 1.0 
Users 21 (28.3%) 47 (20.3%) 1.53 (0.82-2.85) 1.41 (0.65-3.05) 
* the last 2 years of NSA1D exposure before diagnosis of Alzheimer's disease are excluded. 
t adjusted for smoking, alcohol, living situation, education, benzodiazepine and aspirin use by means of 
multivariate conditional logistic regression analysis. 
After controlling [or smoldng, alcohol use, residence, education, benzodlazepine 
and aspirin use no statistically significant difference bet ween cases with Alzheimer's 
disease and controls was observed when short-term and long-term (mean use 273 
days) NSAID users were compared to never users. Odds ratios in both comparisons 
hovered near 1. After excluding prescription data from 2 years to 6 months prior to 
diagnosis, the odds ratios in bOUl short-and long-term users were lower allhollgh 
the confidence interval sUll included 1 (Table 2). Separate examination [or the period 
from two yem's to 6 months suggested that compared to controls, cases had rela-
tively more NSAlD prescription days (36.5 days for conb'ols and 59.5 [or cases). In 
the additional analyses, in which we compared subjects WiUl more than 6 months of 
NSAID use (mean use 720 days) to none users we found lower risk estimates, for the 
10-0.5 year period: odds ratio 0.74 (95% CI: 0.20-2.72) as well as for the 10-2 year 
restricted exposure window: odds ratio 0.27 (95% CI: 0.05-1.51) (Table 2). 
Stratification [or age showed a non-significant reduced risk for long term lIsers 
aged 85 years or under, lor both the 10-0.5 year period: odds raUo 0.53 (95% CI: 
0.15-1.77) as well as [or the 10-2 year resb-icled exposure Window: odds ratio 0.40 
(95% CI: 0.11-1.44). Long-term users aged over 85 had odds ratios close to 1 (Table 
3). 
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TABLE 3 
Risk of incident Alzheimer's disease and NSAID use over a ten year period by age: 
The Rotterdam Study 
Prescription days for Incident AD Controls Crude odds Adjusted odds NSAID cases ratio (95% CI) ratio' (95% CI) 
AGE :0 85 YEARS n = 33 n = 111 
10-0_5 years before 
diagnosis 
None 12 (36.4%) 40 (36.0%) 1.0 1.0 
Short « 2 months) 13 (39.4%) 38 (39.4%) 1.23 (0.50-3.04) 1.29 (0.48-3.46) 
Long (;:: 2 months) 8 (24.2%) 33 (29.7%) 0.60 (0.20-1.75) 0.53 (0.11-1.43) 
10-2 years before 
dlagnosisi< 
None 17 (51.5%) 45 (40.5%) 1.0 1.0 
Short-term «2 months) 9 (27.3%) 38 (34.2%) 0.77 (0.31-1.95) 0.69 (0.25-1.91) 
Long-term (;::2 months) 7 (21.2%) 28 (25.2%) 0.38 (0.11-1.24) 0.40 (0.11-1.44) 
AGE> 85 YEARS n = 41 n = 121 
10-0.5 years before 
diagnosis 
None 12 (29.3%) 44 (36.4%) 1.0 1.0 
Short « 2 months) 14 (34.1%) 42 (34.7%) 1.43 (0.58-3.07) 1.86 (0.67-5.18) 
Long (;:: 2 months) 15 (36.6%) 35 (28.9%) 1.33 (0.58-3.07) 1.32 (0.51-3.37) 
10-2 years before 
dlagnosisi< 
None 15 (36.6%) 48 (39.7%) 1.0 1.0 
Short-term «2 months) 15 (36.6%) 44 (36.4%) 1.28 (0.56-2.94) 1.81 (0.72-4.54) 
Long-term (;::2 months) 11 (26.8%) 29 (24.0%) 1.02 (0.43-2.42) 0.93 (0.35-2.47) 
* the last 2 years of NSAID exposure before diagnosis of Alzheimer'S disease were excluded. 
t adjusted for smoking, alcohol, living situation, education, benzodiazepine and aspirin use by means of 
multivariate conditional logistic regression analysis. 
DISCUSSION 
In this population based nested case-control study. overall Ulere was no significant 
association of NSAID use with the risk for incident Alzheimer's disease, However, 
there was a non-Significant tendency towards a risk reduction for subjects with at 
least six months of exposure. Furthermore, there was some evidence that a protec-
tive effect may be detectable in subjects younger UlaIl 85 years. 
Several Issues of validity need to be discussed when Interpreting these results, 
i.e. potential selection bias, information bias and confounding. As the Rotterdanl 
Study is popUlation based with complete ascertainment of incident dementia, selec-
tion bias of cases is unlikely. 
Misclassification of exposure may have affected our results. One major concern 
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in earlier cross-sectional and case-conb"ol designs was the potential for bias by 
misclassification due to underreporting by proxy informants of drug use among 
cases. To avoid this problem we used general practitioner records as an independent 
assessment of exposure. In the Netherlands, general practitioners, are the gatekeep-
ers of health care, and presctibe the majority of NSAID. There are no published fig-
ures of over the counter NSAID use in relation to prescription use. However, it is 
likely that over-the-counter use in the elderly is minimal because all healUl insur-
ance packages in the Netherlands reimburse for iliese drugs. Moreover, for the study 
petiod only ibuprofen could be obtained without prescription, but these had to be 
bought at a pharmacy" Salicylates were available duting the study period for over-
Ule-counter use. However, they only exhibit anti-inflammatOlY properties in high 
doses, which are normally obtained through prescriptions only. Medical specialists 
also prescribe NSAID. However, iliese specialists are required to report b"eahnent to 
the general practitioners. As we are not aware of diseases that require chronic NSAID 
therapy that are etiologically associated with Alzheimer's disease, missing reports 
from specIalists should not be different between cases and controls. 
Despite the notable advantages to using medical records in the Netherlands, gen-
eral practitioner records were not complete with regard to NSAID use. In a validation 
study we found that medical record data under-reported NSAID and aspirin prescrip-
tions compared to pharmacy filling data (22). However, the number of incomplete 
prescriptions in our study was equally distributed over cases and controls, suggest-
ing that systematic under-reporting by case status was minimaL 
Another potential source of exposure misclassification may have been introduced 
by the meUlOd we used to impute exposure in incomplete prescriptions. \Ve imputed 
exposure on a compound basis (I.e., by ATC code) using a large number of records. 
This large saruple size should give us stable mean estimates. However, by applying a 
mear1 exposure to all incomplete prescrIptions, we may have overestimated expo-
sure in subjects using NSAID for an acute problem, and underestimated exposure 
among chronic users. The distribution of incomplete prescriptions was equal among 
cases and conb"ols. \Vithout knowing the proportion of chronic users in the case and 
control groups, it is not possible to determine the direction of the bias that might 
have been inb-oduced by the imputation procedure. Examining phar"macy data from 
1991-1996, thereby only partially overlapping the study period, we found that the 
fraction of subjects with longer-term prescriptJons, ranging from 60 to 90 days (dura-
tions usually prescribed in chronic users), was similar in cases and controls. There-
fore, we think that it is less likely that the applicatJon of an overall mean duration 
for a prescription with a missing duration can explain the results. However, we can 
not exclude the possibility that in this pedoct ihe physician's prescription behavlolll' 
was influenced by the diagnosis of Alzheimer's disease. 
Confounding by indication is an important issue in this type of study. Previously 
we hypothesized that sub-clinically demented individuals may not receive NSAID 
prescriptions because they would have an impaired ability to express complaints or 
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because doctors may be less eager to prescrIbe NSAID in case of an adverse event. 
In this study there is some evidence to the contrmy, Comparisons of results in table 
2 show a more frequent exposure to NSAID in cases within the 24-6 month period 
prior to diagnosis, This suggests that in the period preceding ti1e presumptive diag-
nosis of Alzheimer's disease there may already be chm1ges in behavior, that are sub-
sequently related to whether or not the individual receives NSAID, This confounding 
would make it more dHlicuH to detect an effect if one existed, 
In conclusion in this population based nested case-control study, overall there was 
no significant association of NSAID use with the risk for incident Alzheimer's dis-
ease, However, there was a non-significant tendency towm-ds a risk reduction for 
subjects with at a longer exposure which was more prominent subjects younger than 
85 yem·s. These inverse associations were stronger when the exposure-window was 
restricted to 10-2 years prior to ti1e onset of Alzheimer's disease. 
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NSAID and the risk of Alzheimer's disease 
and vascular dementia 
The Rotterdam Study 
ABSTRACT 
A large number of observational sludies on the association between NSAID and Alzheimer's 
disease have been published, but Ihe resulls have been inconsislent. Almost all previous 
sludies have obtained information on exposure to NSAID using methods vulnerable to mis-
classification. To examine the association between NSAID and aspirin use, and the long-
term risk of incidenl Alzheimer's disease and vascular dementia we conducled a prospective 
cohort sludy using dala from Ihe population-based Rollerdam Siudy. The sludy population 
comprised all subjects (n=6989) who were non-demenled al baseline and had dala on drug 
use during Ihe sludy period provided by Ihe 7 pharmacies serving Ihis population. Dementia 
screening look place in 1990-93, 1993-1994 and 1997-1999. In addition, Ihe cohort was con-
tinuously monitored for incidenl cases of dementia. Proportional hazards regression analy-
sis was used to estimale Ihe risk of Alzheimer's disease in relation 10 Ihe use of NSAID. 
NSAID use was defined as four mUlually exclusive time varying exposure calegories: no 
exposure, less Ihan 1 monlh (incidenla/), 1-23 monlhs (inlermediale) and 24 monlhs or 
more (Iong-Ierm). Adjuslmenls were made for age, gender, education and use of aspirin, 
H2-anlagonisls or anti-diabetic drugs. During 47498 person-years of follow-up, 394 subjecls 
developed dementia, of whom 294 had Alzheimer's disease, 55 vascular dementia and 45 
olher Iypes of dementia. Average follow-up was 6.8 years. Compared 10 non-use Ihe relative 
risk of Alzheimer's disease was 0.95 (95% CI 0.70-1.29) in incidenlal users, 0.83 (95% CI 
0.62-1.11) in inlermediale users and 0.21 (95% CI 0.05-0.83) in Ihose subjecls Ihalused 
NSAID for 2 years or more. The use and duration of NSAID use were nol associaled with 
Ihe risk of vascular dementia. This sludy suggesls Ihal prolonged NSAID use may reduce 
Ihe risk of Alzheimer's disease. 
INTRODUCTION 
InflanlmatOlY processes playa role in the pathogenesis of Alzheimer's disease. The 
accumulation of microglia around plaques, the cytokine-mediated cerebral acute 
phase response and aclivaUon of the complement. cascade, all contribute to the 
tissue destruction in Alzheimer's disease (1, 2), This inOammatOlY response may 
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be auto toxic to neurons, exacerbating the fundamental pathology in Alzheimer's 
disease (3). Non-steroidal anti-inflammatOlY drugs (NSAID) have been proposed 
as agents that could alter this inflammatory course. Suggested mechanisms are 
through Inhibition of cyclo-oxygenase (COX) 1 and 2 and through activation of the 
peroxisome proliferator gamma (PPAR-y) nuclear transcription factor (4-6), leading to 
inhibition of Inflammation and Inhibition of platelet aggregation. 
Evidence from obsenrational studies with regard to the association of NSAJD use 
and Alzheimer's disease is inconsistent. Some studies suggested a protective effect 
whereas others dId not {7, 8}. However, almost all previous studies obtained infor-
mation on NSAID exposure by either retrospective recall, surrogate interviews, re-
peated cross-sectional interviews or -as we did in an earlier study- by using medical 
records as exposure measure (9). These exposure measures are all vulnerable to 
misciassification. In The Netherlands, pharmacy records m'e considered virt ually 
complete resources of drug exposure on a daily basis. These prospectively gathered 
automated data comprise quantitative and qualitative information on all filled pre-
sCliption drugs and are extensively used for drug utilization and other types (IO) of 
pharmaeo-epldemiologtcal studtes (11-15). Linkage of tI,ese pharmacy data to the 
research database of tile Rotterdam Study, provided us with the possibility to exam-
ine wheUler the use of NSAID and aspirin, was associated with a decreased risk of 
Alzheimer's disease or vascular dementia. 
METHODS 
Setting 
The Rotterdam Study is a prospective population-based cohort study of neurologi-
cal, cardiovascular, locomotor, and ophthalmological diseases in the elderly that 
has been described extensively elsewhere (16). In brief. all inhabitants of Ommoord 
aged 55 yem's or older who were living in this suburb of Rotterdam were invited to 
particlpale in the study (1990-1993). Of the 10,275 eligible subjects, 7983 (78%) 
participated mld were interviewed at home. During this visit, trained interviewers 
administered an eAiensive questionnaire covering, among other topics, socio-eco-
nomic background, food intal{e, medical histOly and medication use. During sub-
sequent visits to the resem'ch center, subjects underwent additional interviewing 
and clinical examinations, including screening and diagnosis of dementia. In addi-
tion, apolipoprotein E (APOE) genotyping was performed on coded DNA samples 
without Imowledge of tile diagnosis for subJecls who developed dernenlia (17). The 
large majority of the participmlts (99.7%) were registered at one or more of the seven 
pharmacies serving the Ommoord area. These pharmaCies are fully automated and 
currently comprise data as of Januruy 1 1991 until Janumy 1 1999. During the 
study period approximately 98% of tile study population obtained at least one pre-
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scription through one of these pharmacies, 
Study population 
In this cohort study, the potential study period consisted of the 8-year period 
between JanUlli)T 1 1991 and January 1 1999, \Ve included all subjects who were 
free of dementia at baseline (n=7046). From this group, we excluded all subjects 
(n= 17) who were not registered at one of the pharmacies, and all persons with a 
follow-up of less than 6 months medication histOlY (n=40). During follow-up partici-
pants were screened for dementia in a second [1993-1995) and third [1997-1999) 
exalllination as described below, EvelY member of the study population (n=6989) 
was followed unLil death, dementia or the end of the study period whichever came 
first. The end of the study period was set at the date of the last examination unless 
this date fell in 1999 In which case the endpoint was set at December 31 1998, 
Exposure definition 
All prescriptions are available in automated form and include the product name, 
international non-proprletaty name, the Anatomical Therapeutical Chemical {ATC} 
code (IS), number of filled tablets/capsules or other dosage forms, the date of deliv-
ely, the prescribed daily number, the dosage, and Ule legend duration {prescription 
length}. For dosage comparisons. we used the cumulative meatl prescribed daily 
dosage expressed as defined daily dosage [DOD). The DOD is defined by the Worid 
Health Organization as the average dosage of a drug used byatl adult for Ule main 
indication (I9). NSAID were our primaty interest and included all prescriptions for 
oral NSAID [ATC-code MOIA; prescriptions for MOIB were not filled). All prescrip-
tions filled during follow-up were used to construct time-varying covariates. Sepa-
rate variables were constructed for oral salicylate analgeSiCS (ATe-code N02BA) and 
for the platelet-inhibiting salicylates acetylsalicylic acid [ATC-code BOIAC06) and 
carbasalate calcium [ATC-code BO IAC08). 
Case ascertainment of dementia 
BOUl at baseline and at the follow-up examinations, subjects were screened for 
dementia jn a stepwise procedure. Subjects were screened for dementia with a com-
bined Mini Mental State Examination [MMSE) [20) and the Geriatric Mental State 
schedule [GMS-A, organic level) [21). Those scoring 25 or below on the MMSE 01' 
scoring one or more on tile OMS were selected for further diagnostic evaluation and 
were subsequently examined by a physician with the CAMDEX diagnostic interview, 
which includes an informant interview (22). Finally, subjects who were suspected of 
dementia were examined by a neurologist, a neuropsychologist and had a brain MR!. 
In addition to the dementia screening. the cohort is continuously monitored for inter-
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val cases of dementia (23). A clinical diagnosis of dementia was made according to 
the DSM~III-R criteria for dementia by a panel that reviewed all existing informa-
tion. A sub-diagnosis of Alzheimer's disease was made according to the NINCDS-
ADRDA criteria (24). A sub-dJagnosis of vascular dementia was made according to 
the NINDS-AlREN criteria (25). The date of dementia onset was defined, as midway 
the latest date a person was known to be non-demented and the first known date a 
person was diagnosed WiUl dementia. 
Analysis 
For evelY cohort member we calculated duration of follow-up. Since drug exposure 
may vary over time, we calculated relative risks for demenlia with a Cox proportional 
hazards model (26) with tile exposure to drugs represented by time-vruying covari-
ates. In the Cox model age in days was used as the time axis, to ensure optimal con-
trolling for age (27). The model compares each case of dementia with all subjects in 
the study who are alive and free of dementia at the age when the dementia case was 
diagnosed. For the Cox regreSSions, SAS Proc PHREG v6.12 was used to estimate 
the age specific incidence of Alzheimer's disease and vascular dementia in relation 
to the use of NSAID and aspirin. Next to a time-dependent comparison in which ever 
use was compared to never use, we also used a time-dependent categorical variable 
in four mutually exclusive categories for the duration of use (no use, less than 1 
month, 1-23 months and 24 months or more). Cut-points were chosen to ensure an 
adequate number of subjects in each group; in addition, a 2-year exposure period 
has previously been reported as a cutoff of interest (28). The time-dependent cat-
egorical exposure variable was represented in the models by use of 3 dummy vari-
ables, with no use as reference categOlY. 
Potential confounders that were examined included gender, baseline age, educa-
tional status. and time valying lise of anti-diabetics {as proxy for diabetes}, anti-
hypertensives, histamine-2 (H2)-antagonists and either aspirin or NSAID. All lisk 
estimates were also adjusted for these factors. 
As the strength of the antHnflammatOlY effect of NSAID increases with an 
increasing dose, we stratified according to the use of low or high mean use, defined 
as either a DDD ~ 1 or a DDD>l. 
In an eadier study, we found that a risk reduction was particularly present in 
subjects aged less than 85 years (9). In addilional analyses, we therefore examined 
wheUler baseline age modified tile effect of NSAID on Alzheimer's disease. Finally, 
to investigate the possibility of pharmacogenetic interaction we examined whether 
effects of NSAID were different over strata of sex and APOE, comparing the effect of 
NSAID in subjects with a APOE2E4. APOE3E4 or APOE4E4 genotype with that of 
those with an APOE3E3 genotype. 
Modeling the relationship between drug exposure and dementia using a small 
nunlber of exposure categOIies has some shortcomings (29, 30). First, the probably 
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smooth dose response relation is approximated with an unrealistic step function 
with sudden jumps. Second, no use is made of the within category information. 
Third, results can be sensitive for the choice of the categOlY cut-points. Taking a 
larger number of categOlies makes the estimates velY unstable. Therefore, as an 
alternative way of representing exposure in the model, we modeled the duration rela-
tionship using restricted quadratic spline regression with four knots (29, 30). This 
al10ws a smooth continuous estimate of tile duration response relationship, while 
no within categOlY information is lost. in this analysis we also examined whether 
excluding either the last one or last two years of follow-up was suggestive for the 
presence ofa latency time (28, 31-33). In addition we did a trend test for each of the 
three splines. 
RESULTS 
During 47498 person-years of follow-up a total of 394 subjects were diagnosed with 
dementia (mean follow-up 6.8 years). Of these patients 294 had Alzheimer's disease, 
of whom 264 without and 30 witi) cerebrovascular disease, 55 had vascular demen-
tia and 45 other types of dementia. Of the 6989 particIpants, 60% were women, and 
87% of the suqjects had a follow-up of 5 years or more. Thirty-four percent had more 
TABLE 1 
General profile of Rotterdam Study cohort members foilowed between January 1991 
and January 1999. 
Number of Number of Person- Dementia 
Variable Category subjects (n=6989) years (n=47498) cases (n=394) 
Number % Number % Number 
Gender Male 2795 40.0 19014 40.2 125 
Female 4194 60.0 28484 59.8 269 
Education < 6 yr. 4407 63.1 29635 62.3 271 
~ 6 yr. 2379 34.0 16834 35.6 82 
Missing 203 2.9 1029 2.1 41 
Baseline age S 65 yr. 3162 45.2 23485 50.0 25 
66-75 yr. 2323 33.2 15776 33.4 127 
76-85 yr. 1504 21.5 8237 17.3 242 
Follow-up < 3 yr. 461 6.6 920 1.9 155 
3-4 yr. 478 6.8 1930 4.1 102 
5-6 yr. 1651 23.6 10604 22.3 131 
~ 7 yr. 4399 62.9 34044 71.7 6 
APOE genotype 33 3780 54.1 26027 54.8 166 
24/34/44 1793 25.6 12240 25.8 137 
Missing 536 7.7 3086 6.5 49 
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than 6 years of education and 23.1% had eithcr an APOE3E4 or APOE4E4 genotype 
(Table 1). 
Diclofenac, ibuprofen and naproxen together accounted for approximately eighty 
percent of the total number of prescriptions and seventy percent of the total number 
of NSAID prescription days (table 2). Relatively more women than men had used 
NSAlD at any lime dming follow-up (68.5 vs. 56.9%). Of subjects who used NSAlD. 
women had a higher exposure fraction UIaII men (7.0% vs. 4.0% of the total number 
of person-days). Those with a lower education more frequently used NSAID at any 
time during follow-up than those with higher education (66 vs. 60%), The rate at 
which NSAID were obtained ii'om the pharmacy was remarkably constant over time 
and varied between 37 aIId 40 days of exposure per 1000 person days over the 
8 years of follow-up (table 3). Aspirin was predominantly prescribed as a platelet 
aggregation-inhibiting drug (± 83% of total). However, even when registered as all 
oral aIIalgesic, apprOximately 95% of the remaining 17 % prescriptions were in fact 
prescribed in platelet aggregation inhibiting doses. \Ve therefore decided to pool both 
types of exposure. In total. 2340 (33.4%) subjects had used aspirin, 616 (8.8%) sub-
jects had used anti-diabelic medica lion, 4012 (57.4%) anllhyper!ensives and 1778 
(25.4%) subjects had used H2-antagonlsts at any time during follow-up 
Ever versus never use of NSAID, defmed as a binaIY time dependent variable, was 
associatcd with a non-significaIlt lower risk of Alzheimer's disease (RR 0.86; 95% 
CI 0.66-l.09). In examining duration of use, compared to non-use, the relative risk 
of Alzheimer's disease was 0.95 (95% CI 0.70- 1.29) In incidental users, 0.83 (95% 
CI 0.62- I. Il) In Intermediate users and 0.21 (95% CI 0.05-0.83) for those subjects 
that used NSAID for 2 ycars or more. There were no substantial differences in type 
of NSAID use between cases and reference subjects. No relation was found between 
NSAID use and risk of vascular dementia (Table 4), For aspirin users, we found no 
relation with risk of Alzheimer's disease and an increased risk of vas cuI aI' dementia 
that increased with the duration of usc (Table 4), 
In the stratified analyses, long-term NSAID users with a high average prescribed 
daily dose had relative risks comparable to users with a low average dose. For tile 
incidental aIId intermediate users risks were lower in the high-dose group (table 
5). Men seemed to have somewhat lower relative risks than females, although con-
fidence intervals overlapped. The stratified analysis for age revealed a significantly 
lower risk in the intermediate duration stratum in younger subjects. Stratification 
for APOE genotype showed lila! subjects wllh an APOE2E4, APOE3E4 or APOE4E4 
genotype had relative risks comparable to the reference group with an APOE3E3 
genotype. 
The restricted qlladrallc spline regression in figure 1 shows lhat our results as 
obtained from the categorical analyses with the sudden Jump at 2 yeaI's of exposure 
slightly exaggerates the protective effect. In addition the figure shows UIat there is 
indeed a trend towards a lower risk with longer exposure. This trend becomes more 
prolllinent and significant after lagging eUher the last one or two years of follow-up 
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TABLE 2 
Type and numbers of NSAID used in years 1991·1998 in the Rotterdam Study cohort. 
Prescriptions Percentage Cumulative Percentage Drug type duration (number) of total (days) of total 
Diclofenac 9723 40.71 225813 33.86 
Ibuprofen 5114 22.25 140608 21.08 
Naproxen 4177 17.49 109760 16.46 
Piroxicam 1579 6.61 65564 9.83 
Indomethacin 1099 4.60 47409 7.11 
Ketoprofen 592 2.48 27385 4.11 
Diclofenac combination 512 2.14 13597 2.04 
Nabumetone 309 1.29 12736 1.91 
Azapropazone 222 0.93 6060 0.91 
Sulindac 127 0.53 5896 0.88 
Meloxicam 75 0.31 2420 0.36 
Tiaprofenic acid 64 0.27 3299 0.50 
Flurbiprofen 55 0.23 4711 0.71 
Tolfenamic acid 16 0.07 1039 0.16 
Phenylbutazon 11 0.05 353 0.05 
Tenoxicam 8 0.03 225 0.03 
8enzydamine 2 0.01 28 0.004 
TABLE 3 
NSAID use according to calendar year of prescription from 1991 ·1998 in the 
Rotterdam Study cohort. 
No of person Exposure Mean Total number Calendar days Total no of rate prescription of year 
exposed person days (exposedl duration prescriptions totat) (days) 
1991 101083 2548517 0.040 31.4 3224 
1992 101058 2509431 0.040 29.5 3430 
1993 94643 2431136 0.039 28.1 3366 
1994 87544 2342662 0.037 27.2 3215 
1995 82795 2258329 0.037 26.5 3127 
1996 83801 2159938 0.039 26.5 3160 
1997 72117 1911849 0.038 26.3 2745 
1998 43862 1186759 0.037 27.1 1618 
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TABLE 4 
Relative risk of Alzheimer's disease and vascular dementia according to duration of 
NSAID or aspirin referenced to no exposure (95% confidence interval). 
Type of dementia and RR (95% CI)' of AD RR (95% CI)' of VaD cumulative duration 
of NSAID or aspirin use (n=294) dementia (n=55) 
NSAID 
No exposure 1 (reference) 1 (reference) 
$1 month 0.95 (0.70-1.29) 1.25 (0.63-2.53) 
> 1 -23 months 0.83 (0.62-1.11) 1.36 (0.70-2.64) 
;" 24 months 0.21 (0.05-0.83) 0.99 (0.13-7.58) 
Aspirin 
No exposure 1 (reference) 1 (reference) 
$ 1 month 0.76 (0.31-1.84) 
> 1 -23 months 1.30 (0.97-1.74) 2.99 (1.57-5.71) 
;" 24 months 0.76 (0.49-1.19) 4.88 (2.38-10.0) 
"Adjusted for age, gender, education and use of H2-antagonists, antihypertensives, anti-diabetic 
medication and either aspirin or NSAtD as time varying exposure. AD=Alzheimer's disease; 
VaD=vascular dementia. 
200 400 600 800 1000 1200 ]400 
Duration of NSAID use in days 
FIGURE 1 
Duration of NSAID use and risk of Alzheimer's disease. 
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TABLES 
Risk. of Alzheimer's disease stratified for defined daily dose (DOD), baseline age, gender and APOE genotype according to duration 
of NSAID use (referenced to no exposure). 
Strata (AD cases) 
Average Daily Dose 
:: 1 DOD 
> 1 DOD 
Baseline age 
< 80 years (n=152) 
::: 80 years (n=142) 
Gender 
Male (n=81) 
Female (n=213) 
APOE Genotype** 
24/34/44 (n=111) 
33 (0=127) 
RR (95% Cll' of AD for < 1 month 
use 
1.18 (95% CI 0.82-1.70) 
0.77 (95% CI 0.50-1.19) 
0.97 (95% CI 0.66-1.53) 
0.85 (95% CI 0.52-1.39) 
0.80 (95% CI 0.46-1.80) 
0.99 (95% CI 0.69-1.33) 
0.85 (95% CI 0.52-1.39) 
1.07 (95% CI 0.71-1.63) 
RR (95% CI)* of AD for 1-23 months 
of use 
1.04 (95% CI 0.73-1.49) 
0.78 (95% CI 0.54-1.14) 
0.57 (95% CI 0.37-0.90) 
1.14 (95% CI 0.77-1.69) 
RR (95% CI)* of AD for:: 24 months 
of use 
0.17 (95% CI 0.02-1.22) 
0.25 (95% CI 0.03-1.78) 
0.23 (95% CI 0.03-1.71) 
0.18 (95% CI 0.03-1.31) 
0.44 (95% CI 0.21-0.91)' 
0.95 (95% CI 0.69-1.40) 0.23 (95% CI 0.06-0.94) 
0.73 (95% CI 0.45-1.19)' 
0.94 (95% CI 0.63-1.40) 0.41 (95% CI 0.10-1.72) 
"'Adjusted for age. gender, education and use of H2-antagonists, antihypertensives. anti-diabetic medication and either aspirin or NSAIO as time varying 
covariates. 
""Subjects with a different genotype and subjects of whom the genotype was unknown were excluded. 
t Risks for combined period as there were no demented subjects in the long-teffil exposure category. 
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before the diagnosis. 
DISCUSSION 
In this prospective population based cohort study, we found an increasing risk 
reduction of Alzheimer's disease with dura lion of NSAID use. This risk reduction was 
significant in subjects that used NSAlD for more than two years. The risk reduction 
was more prominent when excluding the last two years, suggesting that NSAJD may 
be less effective in the late pre-clinical stage. 'Ve found no relalion between aspirin 
use and Alzheimer's disease. NSAID did not reduce the risk of vascular dementia. 
In the prospective Rotterdam Study cohort, information on drug use was regis-
tered prospectively and independenUy of patient characteristics like age, sex and 
mental status. Using information gaUlered in this way avoided the limitations of 
earlier studies using information from interviews or medical records. Although the 
prospective cohort design effectively minimizes bias inherent to most cross-sectional 
and case-control st udies, several aspects of validity need to be discussed that may 
afJecl our results. 
Selcclion bias is unlikely, as our study is prospective and population-based with 
a high response rate (78%). DurIng follow-up, however, pre-clinical dementia may 
be associated with a higher fi'cquency of GP or specialist visits and therefore with a 
greater chance of finding indica lions lor NSAID. If present this phenomenon would 
have led to an undereslimalion of a protective effect, as NSAID will spuriously be 
associated with an increased risk ofAIzheimer's disease. Moreover, one would expect 
the same effect in people Witil Alzheimer's disease and in people with vascular 
dementia, which is not the case. 
The main concern in almost all earlier studies was the potential for misclassifi-
cation of exposure. In order to overcome this problem we used pharmacy records as 
exposure measure. These records provide indirect, independent and more reliable 
information regarding drug exposure, In parlieular when it comes to dose and dura-
tion. A limitation of our study is that NSAID Ulerapy may have been initiated (and 
stopped) before 1991. It is lIkely, that some subjects that were incidentally exposed 
before 1991 may not have been exposed in the years after 1991 and vice versa. It is 
also likely, that some intermediate users were in fad long-term users. In case of a 
true protective effed this may be an explanation for the rather steep decline in risk 
early in the spline curve (fig. 1). An alternative explanation for this early decline may 
be random Variation. Leaving subjects with less than 1 or 2 years of follow-up out of 
the analysis strengthened the trend towards a lisk reduetion, suggesting that this 
ldnd of mlsclassificalion may lead to an underestimation of a protective effect. 'Vith 
respect to chronic use, it is unlikely that former chronic users became non-users as 
diseases for which NSAID are prescIibed chronically, rarely subside spontaneously. 
The findings on aspirin are not straighUonvard to interpret. The validity of all 
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analyses depends on the assumption that a prescription is independent of the sub-
sequent probability of dementia. However, low dose aspirin is generally prcscrlbed 
for vascular problems that may contribute to, or precede the developmcnt of vascular 
dementia and possibly also of Alzheimer's disease (34,35). The increased risks found 
in our study in vascular dementia associated WiUl the use of mainly low dose aspirin 
are thus likely to be a consequence of protopathic bias or of confounding; by indica-
Uon. To a lesser e}..ient thc same may have occurred in Alzheimer's disease. Thcre-
fore, it is too early to state that inhibition of platelet aggregation is not important in 
the prevention of Alzheimer's disease. 
A problem in dose or duration response studies in dementia is the decision about 
biologically plausible categorizations. The arbitrruy categorization may explain the 
large difference in risk below and above 2 yeru's of NSAID exposure. To overcome this 
problem we used spline regression to describe NSAID use as a continuous variable. 
These analyses also suggested a tendency towards a risk reduction with increasing 
duration of use, 
Our results strongly suggest that NSAID use is associated with a reduced risk of 
Alzheimer's disease. Suggested mechanisms are through inhibition of COX 1 and 
2, thereby suppressing the arachidonate cascade leading to prostaglandin synUle-
sis. Accumulating evidence Indicates that COX-2 protein levels arc increased in 
Alzheimer's disease brain and may correlate with levels of Ap-pepUde (36). In addi-
tion, some NSA1D have been shown to attenuate inflammat01}' processes in a non-
COX-dependent manner by directly activating the peroxisome proli1erator gamma 
(PPAR-y) nuclear transcription factor {4-6}. This factor acts to suppress the expres-
sion of certain pro-inflammat01}, genes (5, 37). Alzheimer's disease has also been 
suggested to be a consequence ofimpaired vascular delivery of nutrients to the brain 
(38). The evidence indicates that cerebral capillary transport of vital nutrients is dis-
turbed in brains of patients with Alzheimer's disease due to abnormal hemodynamic 
flow, An additional explanation for the link between NSAID and Alzheimer's disease 
may therefore be Ulat NSAID and aspirin partly protect through Uleir anti-clotting 
properties. 
An alternative explanation is Umt either the indication for NSAlD use 01' an other 
factor related to NSAID use may be associated with the occurrence of Alzheimer's 
disease, rather than NSAlD use itself. However, we could not Ulink of any such 
factor that could explain the observed risk reduction. 
A comparison with existing data shows lilat the observed risk reduction is in 
line with evidence from immunological and histopathological studies suggesting that 
inflammatOlY mechanisms may be important in the pathophysioloRY of AJzheimer's 
disease. The results are also in line with some (28, 39) but not all longitudinal stud-
ies (g. 40-43) on the effects of NSAID in tIle prevention of Alzheimer's disease. Our 
results are closest to the Baltimore Longitudinal Study of Aging (28). In this study 
Alzheimer's disease risk was reduced in subjects using NSAID for more than 2 years 
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(RR 0.4; 95% CI 0.19-0.84). Overall use of aspirin and acetaminophen was not asso-
ciated willl Alzheimer's disease. Although, the results of this latter study are in 
accordance WiUl our findings of a prolective effect of NSAID in Alzheimer's disease, 
NSAID use was based on extrapolated cross-sectional interview data acqUired during 
biennial examinations. Exposure gathered in Ulls way is probably more vulnerable 
to (non)ditJerential misc1assification than when using pharmacy records, in particu-
lar when it comes to duration and dose of NSAID use. 
In conclusion, the evidence from our study is consistent with a beneficial effect of 
NSAlD used prior to Ule onsel of Alzheimer's disease. Although Ulere is some evi-
dence Ii'om secondary prevention trials that NSAID may be effective in slOWing cog-
nitive decline (44, 45), this evidence is inconclusive. Moreover, it is questionable 
whether secondary prevention can be compared to primaly prevention of Alzheim-
er's disease, given the huge damage, which exists once Alzheimer's disease is clini-
cally present. Therefore in order to draw more definite conclusions we have to await 
results of primmy prevention trials. 
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NTIHYPERTENSIVES 
AND DEMENTIA 

Antihypertensive drugs and incidence of 
dementia 
The Rotterdam Study 
ABSTRACT 
There is increasing evidence that hypertension may contribute to the development of demen-
tia. We investigated the relation of antihypertensive drug use and the risk of dementia in 
the cohort of the population based Rotterdam Study. The study cohort included 7046 elder/y. 
free of dementia at baseline. Dementia was diagnosed in a stepwise procedure. First, par-
ticipants were screened. Screen positives were further lested. Those suspected of dementia 
underwent a diagnostic work-up. Dementia and its subtypes were diagnosed according to 
prevailing criteria. A Cox proportional hazards regression analysis was used to estimate rela-
tive risks. After a mean follow-up of 2.2 years, subjects taking antihypertensive medication 
at baseline (n=2015) had a lower incidence of dementia (adjusted relative risk, 0.76; 95% 
confidence intervat 0.52-1.12) than subjects without antihypertensive treatment. This risk 
reduction was most pronounced for vascutar dementia, (adjusted retative risk, 0.30; 95% 
confidence interval 0.11-0.99). For Alzheimer's disease the relative risk was 0.87, but not 
significant. The risk of vascular dementia may be reduced by antihypertensive treatment. In 
order to confirm any association with Alzheimer's disease larger observational studies with 
longer follow-up are needed. 
INTRODUCTION 
There is increasing evidence that hypertension may contribute to the development 
of cognitive impairment and dementia (l-4), although there is certainly no general 
agreement on Ule mechanism (5), This logically leads to the hypothesis thai lower-
ing of the blood pressure with antihypertensive treatment might protect against tile 
development of cognitive dysfunction and dementia. 
In the Framingham Heart Study, there was no longitudinal association between 
cognitive function and blood pressure among subjects using antihypertensive drugs 
after more than 15 years of follow-up. However, in untreated subjects both higher 
systolic and diastolic blood pressure, were associated with a poor cognitive perfor-
mance later in Hfe (6). In a recently published 20-year follow-up study, it was also 
79 
Chapter 4 
shown that the association between hypertension at baseline and the development 
of cognitive dysfunction was st.rongest in untreated men (4). 
Until now, however, evidence of a beneficial effect of antihypertensive treatment 
on the development of demenlJa in epIdemIological studies is scarce. In the prospec-
tive population-based I<ungshoimen study in subjects aged 75 years and older, use 
of antihypertensive medication was studied in relation to the onset of Alzheimer's 
disease. Among the non-demented subjects, persons with antihypert.ensive medica-
tion in general and diuretic monotherapy at baseline had a significantly reduced 
risk of developing both total demenlia and Alzheimer's disease (7. 8). Other evidence 
comes from the Systolic Hypertension in Europe trial (Syst-EurJ. in which treatment 
of isolat.ed systolic hypertension with nitrendipine was associated with a borderline 
significant protective effect for total dementia. However, follow-up time was shorf.. 
(median 2 years) and numbers of demented subjects were velY small in tilis study 
(9), 
It is now clear that treatment of hypertension leads to a risk reduction of both 
cardIovascular morbidity and mortalily. A possible consequence is that ethical prob-
lems will arise in thc design and conduct of future clinical trials to assess the effect 
of blood pressure Joweling on tile risk of dementia. Therefore we invesUgated the 
association between use of antihypertensives and the incidence of dementia in tile 
Rolterdam Study, a large observational prospective population-based study. 
METHODS 
Study population 
The RoUerdanl Study is a prospective population-based cohort study of neurologi-
cal, cardiovascular, locomotor mld ophthalmological diseases in the elderly. After 
approval of the Medical Ethics Committee, all inhabitants of Ommoord, a suburb 
of Rotterdam in The Netherimlds, aged 55 years or more and living in the district 
for at least one year were invited in 1990-1993 to participate in the study. Of 
Ole 10,275 eligible subjects, 7,983 (78%) pmticipated mld signed informed consent. 
During the home interview, trained interviewers administered a questionnaire cov-
ering, among other topics, socio-economic background, medical histOlY and medi-
cation use. During subsequent visits to the research center. suqjects underwent 
additional interviewing mld clinical examinations, including screening and diagnosis 
of dementia. Complete data on dementia were available from 7,528 subjects. A diag-
nosis of dementia was made in 482 persons. The remaining 7,046 non-demented 
subjects were followed for an average of 2.2 years until the second round of exami-
nations in 1993 and 1994. At tllese examinations, 5,571 (79%) participants were 
actively screened for dementia. 01'999 (14%) subjects who were not re-examined and 
476 (7%) who died during follow-up, information on cognitive function was obtained 
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from close informants and general practitioners. 
Drug exposure and other baseline measurements 
At baseline participants were asked to report and show all medication used during 
the preceding week. Subsequently, all drugs were classified according to their cor-
responding Anatomical-Therapeutical-Chem1cal-code (ATC-code) (10). For the cur-
rent study, a classification was made according to the nature of the drug-class: 
diuretics, beta-blockers, ACE-inhibitors, calcium channel blockers and oiller anti-
hypertensives. \\fe assumed that drugs with antihypertensive properties were used 
chronically, as hypertension rarely subsides spontaneously. At the research center 
height and weight were measured. Blood pressure was measured in the sitting posi-
tion at the right upper arm with a random-zero sphygmomanometer and calculated 
as the mean of two consecutive measurements. Diabetes mellitus was deflned as tile 
use of anU-diabetic medication or at least one blood-glucose assessment higher than 
11 BUllol/l, according to \\fHO-criteria for epidemiological studies (11). A histOly of 
sb-oke was assessed during the baseline interview and verified wiill medical records 
by a neurologist. The ratio of the systolic blood pressure at the ankle to the systolic 
blood pressure at the arm was calculated for each leg. Peripheral arterial disease 
was considered present when this ankle-arm index was lower than 0.9 on at least 
one side (12). 
In addition, prescription-fllling data, provided by the 7 pharmacies in the 
Ommoord region, were available for approximately 99% of the cohort as of JanuaIY 
1991. These data comprise quantitative information on each individual prescription. 
Case ascertainment of dementia 
Both at baseline and at the follow-up examination, subjects were screened for 
dementia in a stepwise procedure. Subjects were screened on cognitive function 
using the Mini-Mental State Examination (MMSE) (13) and tile Geriatric Mental 
State schedule (GMS) (14). Those scoring 25 or below on Ihe MMSE or scoring 1 or 
more on the GMS were selected for further diagnostic evaluation. This included more 
detailed neuropsychological testing and an informant interview based on the Cam-
bridge Examination for Mental Disorders of the Elderly (15), as well as a neurologi-
cal examination. Some participants underwent magnetic resonance imaging of the 
brain. A clinical diagnosis of dementia was made according to the DSM-JIJ-R criterja 
for dementia by a panel that reviewed all existing information. A sub-diagnosis of 
Alzheimer's disease was made according to the NINCDS-ADRDA criteria (16). A sub-
diagnosis of vascular dementia was made according to the NINDS-AIREN criteria 
(17). After a mean follow-up of 2.2 years, a total of 162 demented subjects, including 
116 (73%) subjects ,vith Alzheimer's disease, of which 15 also had cerebrovascular 
disease, and 22 (140,0) subjects ,vith vascular dementia, were diagnosed. 
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Confounding variables 
The following variables were considered possible confounders and were therefore 
entered into the statistical models: age, gender, diastolic and systolic blood pressure 
(mm Hg), and history of stroke and diabetes mellitus. Additional adjustments were 
made for body mass index (BMI: kg/m2), smoking (never, fonner, current), education 
«7 years, '27 years), living situation (independent, home for the elderly), baseline 
MMSE and peripheral arterial disease. 
Statistical analyses 
Analysis of covruiance adjusted for gender and age was used to compare character-
istics of subjects with and without antihypertensives at baseline. 'Ve used Cox pro-
portional hazru'ds regression analysis to calculate relative lisks with 95% confidence 
intervals (95% CI) for total dementia, Alzheimer's disease ,vlth and without cerebro-
vascular disease and vascular dementia during use of antihypertensive drugs. For 
categorical data WiUl missing values we incorporated missing indicator vru-iables in 
the model. 
Subsequently, we excluded 622 subjects of whom 376 had a missing blood pres-
sure measurements, 243 a missing Mini Mental State Examination (MMSE) and 404 
a missing body mass index (BMI). The mean age in this excluded group was higher 
than in the remainder of the populatlon (77.6 vs. 68.6 years), they were more often 
females (71.9% vs. 58.7%) and were far more often inhabitants of homes for tile 
elderly (36.7% VS. 4.7%). 
To reduce the possibility of differential reporting of drug use because of potential 
pre-cHnleal dementia at baseline, we did an additional analysis in which we excluded 
subjects who were diagnosed with dementia within one year after baseline examina-
tion. 
The risk of dementia in subjects with hypertension and associated co-morbidity 
may be different from subjects without hypertension. In a second sub-analysis, we 
therefore excluded all untreated subjects without hypertenSion according to the 
'VHO criteria (18) and calculated relative risks of b-eatment for dementia (sub) types. 
According to the 'VHO hypertension is defined as a diastolic blood pressure of at 
least 95 mm Hg and/or a systolic blood pressure of at least] 60 mm Hg. 
Next, we studied the effect of gender. 'Ve examined whether gender modified the 
relation by calculating relative risks for men and women separately. 
To exanline confounding by indication we stratified according to monotherapy 
willi first- (diuretics/beta-blockers) ruld second-line antihypertensive treatment 
(remaining drugs and combinations of drugs). 
In order to examine whether misclassification of exposure was important in Ollr 
study, we examined a sub-population of our cohort that had a first time exaluination 
after June 30 1991 (n=5101) and were not living in a home for the elderly. 'Ve llsed 
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this cut-off, as pharmacy data were only available as of Januaty 1991. \Ve then cal-
culated Ule percentage of subjects that reported both antihypertensive drug use at 
baseline atId filled an antihypertensive prescription at the pharmacy in the 6 monUls 
before baseline examination. As the duration of a prescription is normally limited to 
3 months it is likely that most drugs were captured using a six month period. 
RESULTS 
Of the 6,416 subjects included in the present study, 118 subjects developed demen-
tia, of whom 82 had Alzheimer's disease, 18 vascular dementia and 18 other forms of 
dementia. In table 1, baseline chat'acLeristics are given for subjects with and without 
exposure to an antihypertensive drug. Meatl age, diastolic- and systolic blood pres-
sure and BMI were significatltly higher in users of antihypertensive drugs. Further-
more, relatively many women were users and lIsers more li'equenUy had diabetes 
mellitus, peripheral arterial disease and a histOlY of stroke. Finally, users were less 
often current smokers than non-users. The mean MMSE, grade of education and 
tile proportion of subjects living independently were comparable behveen groups. 
TABLE 1 
General characteristics of participants at baseline. 
Non-users Users of anti
M 
Baseline measurements N=4401 hypertensive Ancova* drugs N=2015 
Mean age (yrs) 67.4 71.4 P<0,001 
Female gender 57,0% 62,5% P=0,003 
MMSE 27,6 (17-30) 27,6 (16-30) Ns 
Body mass index 25,8 27.4 P<0,001 
Mean diastolic blood pressure (mm Hg) 73,1 75,1 P<0,001 
Mean systolic blood pressure (mm Hg) 137.7 142,5 P<0,001 
Smoking 
Current 24,6% 18,8% P<0,001 
Education of more than 6 years 36,1% 35,6% NS 
Diabetes mellilus 8,1% 14,2% P<0,001 
Housing 
Ho me for the elderly 4,5% 5.2% NS 
Markers of vascular disease 
Peripheral arterial disease 15,5% 21,1% P<0,001 
History of stroke 1,6% 3.9% P<0,001 
*Age and gender adjusted analysis of covariance. 
83 
Chnpter4 
TABLE 2 
Use of any type of antihypertensive drug at baseline and the risk of dementia 
expressed as relative risk (95% confidence Interval). 
Number of Relative rlsk* Relative rlskt Dementia type demented N=6416 N=6416 
subjects 
Total dementiatt 118 0.76 (0.52-1.12) 0.67 (0.45-1.00) 
Tolal AD 82 0.87 (0.56-1.37) 0.77 (0.49-1.24) 
AD withoul vascular pathology 68 0.94 (0.57-1.53) 0.83 (0.49-1.39) 
AD with vascular pathology 14 0.64 (0.21-1.91) 0.63 (0.20-1.93) 
Vascular Dementia 18 0.33 (0.11 -0.99) 0.30 (0.09-0.92) 
* Cox proportional hazards regression analysis adjusted for age, gender, diastolic and systolic blood 
pressure, diabetes mellitus and stroke. 
t Additional adjustment for body mass index, baseline MMSE, smoking, education, living situation and 
peripheral atherosclerotic disease. 
tt This includes 18 subjects with an other type of dementia: Parkinson's dementia (n=4), other type 
(n=13) and undetermined (n=3) 
Of the 6.416 subjects 31.3% used antihypertensive medication of which 21.1% 
used monoU1erapy, 8.5% used hvo drugs and 1.7% used three or more drugs. In 
total 14.6 % reported use of beta-blockers, 15.3 % reported use of diuretics, 5.9 % 
reported use of calcium antagonists, 5.7 % reported use of ACE-inhibitors and 1.9 
% reported use of other antihypertensives. 
Table 2 shows a non-significant risk reduction for dementia in general in users of 
antihypertensive drugs. The risk reduction was significant and most prominent for 
vascular dementia. Furthennore, it was present independent o[ adjustments made 
[or potential confounders. Risk reduction was similar when we excluded those sub-
jects (n=27) with a diagnosis o[ dementia in the first year of foHow-up or a follow-up 
of less U1811 a year (data not shown). For AI7,heimer's disease the reduction in risk 
was, although not significant, most prominent in those with vascul81< pathology. The 
exclusion of untreated subjects without hypertension revealed comp81°able risk esti-
mates (table 3). 
Stratified analysis revealed l81'gel' risk reductions [or men (RR 0.52; 95% CI 
0.22- 1.20) lhan for women (RR 0.93; 95% CI 0.59- 1.46) and for first line therapy 
than second line therapy (data not shown) for total dementia. However, in both 
instances confidence intervals overlapped largely. Stratification for individual drugs 
could not confirm the earlier suggestion that calcium-ch811nel blockers (RR 0.70; 
95% CI 0.32- 1.52) and diurellcs fRR 0.83; 95% CI 0.33-1.30) in particular are prolec-
tive against ctcmenlia. 
In those living independently at baseline the concordance between reported use 
and aclually filled prescriptions in the pharmacy was hIgh and not significantly dif-
ferent for both healthy subjects (n=4703: 94.6%) and demenled subjects al follow-up 
(11=40: 92.9%). 
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TABLE 3 
Relative risk of dementia according to drug use after exclusion of all normotensive 
subjects (diastolic blood pressure <95 mmHg andlor systolic blood pressure <160 
mmHg) without treatment. 
Dementia type 
Total dementia 
Total AD 
Vascular Dementia 
Number of 
demented subjects 
61 
45 
10 
Relative Risk (95% CI)' 
0.67 (0.35 to 1.32) 
0.99 (0.47 to 2.12) 
0.11 (0.02 to 0.74) 
*Cox proportional hazards regression analysis adjusted for age, gender, diastolic and systolic blood 
pressure, stroke, diabetes mellitus. 
Of the 622 subjects excluded from the analysis because of missing values, 
approximately 40% reported use of blood pressure lowering drugs and llie overall 
incidence of dementia was 29.9/1000 person years. 
DISCUSSION 
In this population based prospective cohort study, we found a risk reduction of 
dementia in users of antihypertensive drugs. This risk reduction was most promi-
nent and significant for vascular dementia and more pronounced in males. Risk 
reduction for Alzheimer's disease was, alUlOugh not Significant, most prominent in 
those with concomitant vascular disease. 
Several issues of validity need to be discussed when interpreting these results, in 
particular potential information bias and confounding by indication. 
First, we should consider whether misclassification of exposure may have affected 
our results. A major concern in earlier, cross-sectional or retrospective, drug stud-
ies on dementia was the potential for bias due to underreporting of drug use among 
cases by proxy informants. Although our study only comprised subjects who were 
not demented at baseline, one might fear subtle impairment of memory in the 
pre-clinical phase of dementia and therefore less reliable answers and potentially 
different health related behavior. A spurious protective effect might then be the 
consequence of underreporting of antihypertensive drug use in cases. To assess 
this problem we performed separate analyses for a sample restricted to those not 
demented in the first year of follow-up and found similar risk estimates. 
Furthermore, in a study on the concordance of reported cardiovascular drug use 
at baseline and the actually filled prescriptions in the pharmacy an overall high cor-
respondence was found for participants of the Rotterdam Study (19). For the present 
study, we examined a subset of the analytical sample and found no major differ-
ences between demented and non-demented at follow-up with respect to reported 
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use and filled prescriptions in the local pharmacy. Although we have no information 
on compliance, iL seems unlikely that dHJerential misclassification of antihyperten-
sive drug use may explain the results. A second possibility of misc1assification of 
exposure may have occurred because patients were not asked how long they had 
been treated. As demented su~lects were older, the probability of detection of hyper-
tension over time may have been higher and therefore also the probabiliLy of treat-
ment may have been higher. If present, however, such a bias would have led us to 
underestimate ilie actual effect. 
Misclassification of hypertension may also have happened as a consequence of 
the disease, as it has been suggested that blood pressure drops in the pre-clinical 
phase of Alzheimer's disease (20). \Vhen such a pressure drop happened before 
baseline this might theoretically have led to discontinuation of antihypertensive 
treatment and therefore to an underestimation of long-standing b'eatrnent of hyper-
tension at baseline in subjects who became demented, resulting in a potential 
overestimation of the protective effect. However, iL is not common practice to stop 
antihypertensive b'eatment, and we consider it unlikely ti1at this kind of misc1assifi-
cation has affected our results. 
In a study on the effects of antihypertensives on dementia confounding by indica-
tion is an important issue as there is evidence that long-standing hypertension could 
lead to dementia (1-4). Although we tried to minimize this problem by adjusting for 
a number of putative confounders, we can not exclude the possibility that there may 
be some residual confounding. However, residual confounding by indication would 
tend to underestimate a truly protective eHect of antihypertensives in dementia. This 
could thus explain the lack of a statistically Significant effed in Alzheimer's disease 
but not ti1e observed lisk reduction in VD. An_ alternative explanation for finding no 
significant effect in Alzheimer's disease may be ti1e lack of power at the relative risk 
that we observed, in particular for the stratified analyses. However, given the 50 % 
risk reduction in the Syst-Ew' trial and given the number of ez..'-posed and unexposed 
and an expected 2.5% occurrence of disease we had over 80% power to detect a 
significant rIsk reduction. 
Given the existing evidence how should our study be valued? In contrast to the 
Sysl-Eur (21) trial and the Kungsholmen study (7) we did not find a significantly 
reduced risk of dementia. However, alUlOugh not significant, in the overall analyses 
we found a risk reduction of approximately 30%, which equals the reduction found 
in the Kungsholmen Study. An explanation for the lack of signHicance in our study is 
the higher mean age in the Kungsholmen Study leading to a higher exposure preva-
lence, a higher incidence of dementia and therefore a greater power. 
Although it is imolVn that treatment of hypertension reduces associated morbid-
ity, to our knowledge no prior study has shown a risk reduction of vascular demen-
tia. Moreover, our results do not indicate Ulat U1ere are harmful effects with respect 
to tile occurrence of the dementia subtypes. Our results underline the importance of 
adequate antihypertensive treatment. 
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In conclusion, our results are supportive of a protective role of the use of antihy-
pertensive medication in relation to the onset of dementia. Results were, however, 
based on a short-term follow-up and were only significant for vascular dementia. As 
future placebo controlled trials in subjects fulfilling established criteria for treatment 
are not likely to be executed because of eUlical complications, studies with longer 
follow-up, a larger sample of demented subjects and longitudinal exposure data are 
needed to fwiher explore this association. 
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.-STROGEN AND 
ALZHEIMER'S DISEASE 

Hormone replacement therapy 
and risk of Alzheimer's disease 
The Rotterdam Study 
ABSTRACT 
We report on the association between HRT use and the risk of Alzheimer's disease as 
observed in the Rotterdam Study. The study population comprised all women who were 
non-demented and had data on HRT exposure as provided during a baseline interview. 
Exposure to HRT use was defined either as ever use or as short-term (1-11 months) and 
long-term use (2 12 months). Dementia screening took place in 1990-93, 1993-1994 and 
1997-1999; in addition, the cohort was continuously monitored for incident cases of demen-
tia. Cox proportional hazards regression analyses were used to estimate the hazard func-
tion of Alzheimer's disease in relation to the use of HRT. Of the 3066 women in the study 
sample, 397 reported prior use of HRT. During a total of 17551 person-years offollow-up a 
total of 179 women developed Alzheimer's disease. We found no evidence of a risk reduc-
tion for Alzheimer's disease in HRT users with a relative risk of 0.83 (95% CI0.45-1.51). 
This observation was present adjusted for age, age at menopause, artificial menopause, 
education, systolic blood pressure and smoking. There was no evidence of a dose response 
effect of HRT. In conclusion, our results are not supportive of a protective effect of HRT on 
Alzheimer's disease. 
INTRODUCTION 
In recent years, it has been hypothesized t hat decreasing levels of circulating estro-
gen after menopause might increase the lisk of Alzheimer's disease and that substi-
tution may postpone or even prevent the onset ofllie disease. Indeed, neurobiological 
and behavioral studies suggest that estrogens improve brain function. Proposed bio-
logical mechanisms by which estrogen might attenuate neuronal injury are through 
direct stimulation of cholinergic neurons, development of gliacytes, anUoxldalive 
properties, and down-regulation of the amyloid-P-42 production and also UlfoUgh a 
decrease in excitotoxicily (1-7). 
Several epidemiologic studies examined lhe association between use of postmeno-
pausal hormone replacement therapy (HRT} and the risk of Alzheimer's disease (8, 
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9). Some of these studies showed a lower risk of Alzheimer's disease in former HRT 
users, yet selection and observation bias could usually not be excluded. Further-
more, in some studies confounding of the association of estrogen use and Alzheim-
er's disease by lifestyle and demographic characteristics might have been present. 
In ilie absence of results from primmy prevention trials there is a need for pro-
spective population based cohort studies, which are less vulnerable to bias. There-
fore, we studied the association between HRT use and incident Alzheimer's disease 
in the population based Rotterdam Study. 
METHODS 
Study population 
The Rotterdam Study is a prospective population-based cohort study of neurologi-
cal, cm'diovasculm', locomotor and ophthalmological diseases in tile elderly. After 
approval of the Medical Etilics Committee, all inhabitants of Ommoord, a suburb of 
Rotterdam in The Netherlands, aged 55 years or more and living in llie district for 
at least one year were Im1ted in 1990-1993 to participate in the study (10). In the 
Rotterdam Study, 4853 post-nlenopausal women participated. 
During a home interview, trained interviewers administered a questionnaire cov-
ering, among other topics, socio-economic background, medical histOly and medi-
cation use. During subsequent visits to the research center, subjects underwent 
additional interviewing and clinical exanlinations, including screening of dementia. 
Assessment of exposure to hormone replacement therapy 
During the baseline interview (1990-1993) questions on ever use of female hormones 
for menopausal complaints and duration of use were asked by trained interviewers. 
'Vomen who reported the use of female hormones for menopausal complaints were 
considered to be exposed and included in the study as ever user. 'Va men who 
reported the use of female hormones as contraceptive drug or for other reasons were 
excluded. 'Vomen reporting no prior use of female hormones were considered to be 
non-exposed and were defined as never users. 
Case ascertainment of dementia 
Both at baseline (1990-1993) and at the first (1993-1994) and second (1997-1999) 
re-examination, subjects were screened for dementia in a stepwise procedure. First 
pm'Ucipants were screened with a combined Mini Mental State Exanlination (MMSE) 
(II) and U,e Geriabic Mental State schedule (GMS-A, organic level) (12). Those sco-
ring 25 or below on tile MMSE or scoring one or more on the GMS were selected 
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for further diagnostic evaluation, compIising a CAMDEX diagnostic interview, which 
includes an informant interview (13). Finally, a neurologist, a neuropsychologist, 
eXaIl1ined subjects who were suspected of dementia and if possible a brain MRI was 
made. In addition to the dementia screening, the cohort is continuously monitored 
for interval cases of dementia (14). A clinical diagnosis of dementia and sub-diagno-
ses were made according to internationally accepted criteria (14, 15) by a panel that 
reviewed all existing information. In case of dementia, the date of onset was assumed 
to be midway the last date of the examination that the individual was known to be 
non-demented and tile date of examination at which the individual was diagnosed 
as demented. 
Measurement of potential confounders 
Data included in the interviews were medical histOlY, current medication, age at 
menopause defined as the cessation of menses for 1 year or more, type of menopause 
(natural or artificial), smoking habits. highest attained level of education. Height and 
weight were measured and a body mass index (BMI: kg/m2) calculated. Blood pres-
sure was measured twice with a random zero sphygmomanometer with the subject 
in sitting position, and averaged. Apolipoprotein E (APOE) genotyping was performed 
on coded DNA samples (16). 
Statistical analysis 
Of the 4221 non-demented women in this study, 4026 women had valid data on 
female hormone use. Of these, 2669 reported no prior use of female hornlOnes, 397 
reported a histOly of use of HRT, 854 reported use of female hormones as a contra-
ceptive drug and 106 women used ilie drug for different reasons. After exclusion of 
these latter 960 women the analytical sample comprised 3066 women. 
Analyses of covariance and chi-square statistics were used to compare baseline 
characteristics of ever HRT -lisers and never HRT-users. The strength of the associa-
tion between Alzheimer's disease and HRT use was studied as a hazard rate using 
Cox proportional hazards regreSSion analysis (17), with age as time axis and pre-
sented with 95% confidence intervals (95% el). End points were death, dementia or 
the end of the study period, whichever canle first. The multivariate analyses further 
included age at menopause, BMI, diastolic and systolic blood pressure, smoking, 
and type of menopause (natural/artificial). In these analyses, missing data on miss-
ing continuous covariates were imputed using the EM algorithm of SPSS 9.0. For 
missing data on categOlical variables we used missing indicators. 
To examine the effect of duration of HRT exposure, we compared the incidence of 
dementia in 3 sb·ata: non-use, 1-11 months of lise and 12 or more months of HRT 
use, in women reporting duration of hormone use. 
Because it has been suggested that there may be a pharmacogenetic interaction 
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between APOE genotype and HRT use (18, 19), a separate analysis was done to test 
for effect modHlcation by APOE genotype. To examine this, the study-population was 
divided into lbe following four groups: APOE4- (APOE2E2, APOE2E3 and APOE3E3) 
,vilbout HRT (reference), APOE4+ (APOE2E4, APOE3E4 or APOE4E4) ,vith and ,vilb-
out HRT and APOE4- ,vilb HRT. 
In order to examine the potential effect of the excluded subjects (reporting use 
for contraceptive or other reasons) on lisk estimates, a sensitivity analysis was per-
formed in which the excluded subjects were assumed to be eiUler exposed or unex-
posed. 
RESULTS 
Users of HRT were younger, had signlficantly more often an artificial menopause 
TABLE 1 
AgeMadjusted baseline characteristics of never vs. ever users of HRT. Values are 
means (SE) or proportions. 
Characteristics Never users of EVer llsers of P-value'" HRT (n=2669) HRT (n=397) 
Age 72.7 (0.18) 67.5 (0.38) P<0.001 
Body mass index 27.0 (0.08) 26.6 (0.21) P=0.14 
Age at menopause (yrs) 48.6 (0.01) 48.4 (0.15) P=0.46 
Systolic blood pressure (mmHg) 142.2 (0.43) 141.3 (1.11) P=0.72 
Diastolic blood pressure (mmHg) 73.7 (0.23) 73.5 (0.59) P=0.43 
Artificial menopause 20.1% 33.2% P<0.001 
Education P=0.08 
Primary education 33.6% 25.8% 
Primary vocational training 15.4% 17.8% 
Secondary education MAVO 18.2% 18.6% 
Secondary vocational training 9.9% 11.3% 
Secondary education HAVONWO 16.9% 20.6% 
College HBO 1.9% 2.3% 
University 3.9% 3.6% 
Olher 0.3% 
APOE genotype 
E2/4, E3/4 and E4/4 26.4% 29.5% P=0.22 
Smoking 
Never smoking 59.1% 48.3% P<0.001 
Former smoker 25.2% 33.2% 
Current smoking 15.7% 18.4% 
Missing values in percentage of total: age al menopause::: 3.4%; APOE=9.6%; blood pressure=5.2%; 
education=2.5%; smoking=1.4%; nalural menopause=O.5%; BMI=7.7%. 'Analysis of covariance 
adjusted for age or chi-square statistics when applicable. 
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and were significantly more often former and less often never smokers (Table 1). No 
significant age-acljusted differences were seen in BMI, age at menopause, blood pres-
sure, and dishibution of highest attained education and APOE genotype. Excluded 
subjects were younger (mean 62.6 years) than those included and had a lower inci-
dence of dementia, 
During 17751 person-years of follow-up (mean foHow-up 5,7 years), 179 women 
developed Alzheimer's disease. The age and education adjusted analysis showed no 
effect of HRT on Alzheimer's disease (Table 2), Additional adjustment for blood pres-
sure, smoking, 8MI, age at menopause and type of menopause did not markedly 
change iliese results. A subsequent analysis, among subjects with data on the dura-
tion of HRT use (88%) showed no association between duration of HRT use and risk 
of Alzheimer's disease. 
\Ve did not observe a clear interaction of an APOE4+ genotype with HRT use. 
Compared to never users with an APOE4- genotype, a protective effect of I-IRT, if any, 
seemed to be limited to APOE4- carriers. In the APOE4+ group the risk of Alzheimer's 
disease was significantly higher both in ever and in never users. Ever HRT use was 
not associated wit h a protective effect within the APOE4+ group. 
TABLE 2 
Use and duration of hormonal replacement therapy and the risk of Alzheimer's 
disease expressed as relative risk (95% confidence interval). 
HRT exposure Cases Relative risk" Relative risk t (95%CI) (95% CI) 
Never use 167 1,0 (reference) 1,0 (reference) 
Ever use 12 0,82 (0.45-1.48) 0.83 (0.46-1.52) 
Never use 167 1.0 (reference) 1.0 (reference) 
1-11 months 6 0.89 (0.36-2.19l:t 0.90 (0.37-2.21)tt 
~ 12 months 5 1.0 (0.31-3.17) 1.03 (0.32-3.30)tt 
* Cox proportional hazards regression analysis adjusted for baseline age and education. 
t Cox proportional hazards regression analysis adjusted for baseline age, education, body mass index, 
smoking, blood pressure, age at menopause and type of menopause. 
tt 52 women with missing duration excluded. 
TABLE 3 
Risk of Alzheimer's disease stratified by use of hormonal replacement therapy and 
APOE genotype. 
HRT exposure and APOE genotype 
Never HRT 
Ever HRT 
APOE4· 
1.0 (reference) 
0.43 (0.14-1.37) 
APOE4+ 
2.25 (1.60-3.18) 
3.21 (1.52-6.78) 
Cox proportional hazards regression analysis adjusted for age and education. APOE4· denotes the 
APOE2E2, APOE2E3 or APOE3E3 genotype; APOE4+ means APOE2E4, APOE3E4 or APOE4E4. 
Subjects of whom APOE genotype was unknown were excluded (n=300). 
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The sensitivity analyses in which we examined the effect of the exclusion of 
women reporting use of female hormones for other purposes then HRT yielded an 
RR of 0.73 (0.44-1.23) when all excluded subjects were considered to be ever users 
of HRT and an RR of 0.88 (0.49-1.23) when all were considered to be never users of 
HRT. 
DISCUSSION 
In lhis population-based study we found no evidence for a risk reduction of Alzheim-
er's disease in ever users of HRT. However, prior to interpreting the results, several 
methodological issues need to be addressed. 
The main limitation of our study was the low e),.'-p0sure prevalence. Overall expo-
sure to HRT was low in Ule age range where Alzheimer's disease incidence is highest 
(5.9% in subjects of over 75 years). The consequence of this low exposure prevalence 
is a lack of power. Therefore we could not evaluate with sutncient precision the role 
of duration, or effect modification by the various APOE genotypes. 
The Rotterdam Study is a population based cohort study Ulat by its prospective 
design reduces the potential for a number of biases, which may occur in case-control 
studies on HRT. Furthermore, it is representative of llie general population in terms 
of socioeconomic status, education and HRT use. 
Selection bias could be a problem. However, our study is population-based with 
a high response rate (78%) and very low loss to follow-up. Furthermore, additional 
sensitivity analyses on excluded subjects did not affect the risk estimate to a laJ-,ge 
extent. A number of studies have shown that estrogen users are healUlier than never 
users. As a consequence. their risk of Alzheimer's disease may be lower independent 
of the pharmacological effect of HRT. As we acijusted for a number of proxies for 
health-status and moreover as we found no effect of HRT we feel confident that such 
selection did not conlIibute to the observed risk estimates. Therefore. we think that 
our findings are not likely to be explained as a consequence of selection bias. 
A second potential hazard is that of information bias, as use of HRT was 
assessed by interview. Although all prevalent demented subjects were excluded 
there is a possibility of diflerential misclassification of exposure, as the agreement 
between self-reported HRT use and actual use may decrease with age and increas-
ing age is associated WiUl a higher risk of Alzheimer's disease. If such differential 
underreporting would be present this may lead to bias sugg;estive of a protective 
effect. However, a study on the agreement between interview information and physi-
cian records on histOlY of menopausal estrogen USe was not suggestive [or such 
differenlial misclassificalion (20). The reported /i'equcncy of HRT use (13.0%) was 
comparable to that of another follow-up study from Ule NetheriaJlds in which 12% 
of the women between 45 aJld 60 llsed HRT (21). In studies on HRT and Alzheimer's 
disease, timing of HRT intake may also be impOliant. In our study. we were not 
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informed about the exact age at intake. In the past, however, HRT was usually 
started during menopause and there is no reason to assume differences with respect 
to this timing of HRT use between subjects who developed Alzheimer's disease and 
those who did not. Moreover, we adjusted for time of onset of menopause. Another 
source of misclassification may be the varying contents of HRT. According to data 
from the Dutch Institute of Medical Statistics the most frequenUy prescribed HRT 
in the study period were unopposed estrogens in a dose of 0.0625 mg daily (22). 
Besides conjugated equine estrogens, also estradiol was prescribed. Progestins were 
added in 0.6% of prescriptions in 1970, gradually increasing to 11% ofprescliptions 
in 1986. As it is unknown if and how these progestins influence Ule Alzheimer's 
disease process, it is unclear how this could have affected our results. 
Finally, we dealt with the issue of confounding, by acUusting for known risk fac-
tors for Alzheimer's disease. \Ve measured the status of these risk factors at baseline. 
and applied them on HRT use before baseline. As most potential confounders are 
(relatively) stable, we do not expect these changes of covariates to have a large impact 
on our results. 
How do our results compare to existing Hndings? Although studies have shmvn ben-
eficial effects of estrogen on cognition and memOlY, evidence from epidemiological 
studies in Alzheimer's disease is limited and inconsistent. Of the published studies 
on late onset Alzheimer's disease, two-third suggested a decreased risk whereas the 
remaining studies showed no effect. Of the former studies only two were prospec-
tive cohort studies, both claiming a protective effect (l8, 23). A "meta-analysis" of 
10 observational studies, including the latter 2 studies, suggested a 29% decreased 
risk of developing dementia among estrogen users, but the Hndings of the studies 
are heterogeneous. This 29% reduction is different from our risk estimate of 0.83, 
but probably also not comparable. As our lisk estimate was far from significant. our 
results are more compatible with no effect of HRT on Alzheimer's disease. 
Existing evidence vvith regard to differences in HRT effect over villious APOE 
genotypes Is SCilllty and not in line with our findings (l8, 19). However, Ulese strati-
fied analyses lacked sufficient power. In conclusion, our results are not supportive of 
a protective effect of HRT on the development of Alzheimer's disease. \Vhether or not 
HRT is preventive will probably not be definitely elucidated until the ongoing primmy 
prevention trials m'e published. However, the results of two recently published sec-
ondruy prevention trials in which the efficacy of estrogen did not differ ii'om placebo, 
are also not velY promising (24, 25). 
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Chapter 6 
RYCHOTROPIC DRUGS 
AND COGNITIVE FUNCTION 

Antidepressants and anticholinergic 
drugs, but not benzodiazepines, 
are associated with cognitive impairment 
ABSTRACT 
We describe a sludy on Ihe relationship belween Ihe use of psycholropic drugs and cog-
nitive function under everyday circumslances. In a population-based sludy of 1077 non-
demenled elderly subjecls, dala on Ihe use of benzodiazepines, antidepressanls, and drugs 
with anticholinergic properties were oblained during a slruclured inlerview. Cognitive func-
tion was assessed by a series of neuropsychological lesls aimed 10 measure multiple 
cognitive domains, including global cognitive function (MMSE), memory function, menial 
processing speed and overall cognitive function. The results from linear regression analyses 
suggesled Ihal users of selective serolonin re-uplake inhibilors performed worse on memory 
lasks (-1.14 SO; 95% CI -2.08 10 -0.19), and overall cognitive function (-0.87 SO; 95% CI 
-1.5410 -0.19) Ihan non-users of investigaled psycholropic drugs. Users of anticholinergic 
drugs and more in particular of tricyclic antidepressants performed worse on mental process-
ing speed (-0.54 SO; 95% CI-1.0 10 -0.09), on memory lasks (-0.57 SO; 95% CI-1. 11/0 
-0.02) and on overall cognitive function (-0.55 SO; 95% CI -0.95 10 -0.16), as compared 10 
non-users. Benzodiazepine users did nol differ significantly from non-users with respecllo 
any of Ihe cognitive scores. All resulls were adjusled for age, sex, educational level, CES-O 
(depression) score, concomilanl use of olher psycholropic drugs, as well as timing and valid-
ily of cognitive lesls. In conclusion, in Ihis sludy users of anticholinergic drugs and antide-
pressanls performed significantly worse on lesls measuring memory performance, menial 
processing speed and overall cognitive performance, whereas Ihis was nol found for benzo-
diazepine users. 
INTRODUCTION 
Benzodiazepines, selective serotonin re-uptake inhibitors (S5Rls), and tricyclic anti-
depressants (TeAs), are commonly associated with an increased risk of accidents in 
tile elderly (1-5), Several factors have been proposed a.s important in the etiology of 
Ulcse potential drug-induced effects, such as dose and duration of administration, 
binding affinity and molecular structure (6, 7), As for the treahnent of Jnsonmia, 
there has been a trend towards the use of short -acting benzodiazepines and lower 
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doses. An example of this is the relatively new class of halogenated-5-alyl- (H5A) 
benzodiazepines (including triazolobenzodiazepines) (7). The use and development of 
these short-acting benzodiazepines has led to questions regarding safety, 19cusing 
on impairment of memOlY functions and speed of mental processing (8-16). 
Mainly because of a more beneficial safety profile, antidepressive therapy has 
shifted from the use of TeAs to an increased use of SSRls. TCAs have been associ-
ated with impairment of short-term memoty and psychomotor speed (17, 18), which 
has been attributed to a-receptor blockade, to antlhistaminic properties as well as to 
their anticholinergic properties. SSRIs are supposed to exerl these effects lo a lesser 
extent and sometimes even improve cognitive dysfunction (18). Anticholinergic drugs 
form a less homogenous group and are prescribed for various indications, like COPD. 
cardiac problems and depression. As a relative acetylcholine deficit is, for example, 
seen in Alzheimer's disease (19), anticholinergic drugs are expected to impair bolh 
memOlY and psychomotor performance. 
In large database studies, investigating drug related accidents, moderate atten-
tion has been paid to potential confounders such as underlying depression, cogni-
live impairment or co-morbidity. On a population level little elTort has been put into 
unraveling potential mechanisms of the use of psychob'opic drugs and the increased 
risk of accidents. \Ve hypothesized that an impaIrment of cognitive function and 
speed of mental processing may underlie Ulis increased risk in users of psychotropic 
drugs. Although these drug effects have extensively been studied in healthy individu-
als in an experimental selting, much less is known of their impact under everyday 
therapeutic conditions. The aim of the present study was to determine whether the 
use of psychotropic drugs is associated with allerations in memmy performance, 
speed of mental processing, and overall cognitive functioning in a non-demented 
elderly population under evelyday circumstances and to study to what extent these 
associations are influenced by potential confounders. 
\Ve eXalllined these associations in the population-based Rotterdam SCall. Study 
in which data on drug use were collected without knowledge of ilie current study 
hypothesis and independently of neuropsychological iesis (20). 
METHODS 
Study population 
The Rotterdam SCall. Study is a population-based study of causes and consequences 
of age-relat.ed brain changes. Details concerning this study have been described else-
where (20). The study was approved by the local ethics conllnittee. Subjects were 
sex all.d age matched and eligible when they were aged between 60 and 90 years, 
not demented or blind, alld as the Rotterdam Scan Study included cerebral MRI 
assessment, subjects did not have a MRI conb·aindication. Examinations took place 
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in 1995/96 and included a structured interview on medical history including drug 
use assessmenl and cognitive lesting. Of 1717 eligible subjects, 1077 (62.5%) partici· 
pated, and gave \vritten informed consenl. Participants were younger, with a mean 
age difference of 3.8 years (p<O.OOI), more often had a university degree (5% dif· 
ference, p=0.05), and had higher baseline MMSE·scores (age and gender acljusled 
mean difference 0.4 points, p<O.OOl) than non participants. 
Drug use assessment 
Participants were asked to bring and report all currently used medication to the 
interview. At the reseal'ch center, all drugs were classified according to their corre-
sponding Analomical·Therapeulical·Chemical·code (ATC·code) (21). All drugs coded 
as N05BA (anxiolylics), N05CD (hypnotics), N06AA (TCAs), and N06AB (SSRls) or 
as drugs with anticholinergic properties were studied. Benzodiazepines were fur-
thermore classified into H5A-benzodiazepines and non-H5A-benzodiazepines accord-
ing to the presence of a halogenated 5-a1'yl group in the molecule. The prescribed 
H5A-benzodiazepines were lorazepam, llurazepam, flunitrazepam, ionlletazepam, 
midazolam, and loprazolam. Non-H5A-benzodiazepines prescribed were diazepam, 
chlordiazepoxide, oxazepam, temazepam, nitrazepam and bromazepam. Eighty sub-
jects received drugs with anticholinergic properties. Drugs prescribed in this group 
were mainly digoxine (41.S%), ipratropium (SO%) and TeAs (imipramin, clomipramin, 
amlLtyptilin) (11.3%). The oniy SSRI prescribed was paroxellne. PartiCipants and 
investigators had no knowledge of the research hypothesis when they recorded and 
classified the medication. 
Measurement of cognitive function 
To assess speed of mental processing, memOlY function and global cognitive function 
several neuropsychological tests were performed in each partiCipant as described 
previously (20). To evaluate speed of mental processing four tests were used: an 
abbreviated Stroop test consisting of three subtasks (22), the Paper-and-Pencil 
Memory Scanning Task consisllng of three subtasks (23, 24), the Letler·Digil Sub· 
stitution Task, and a verbal fluency test in which as many animals as possible 
had to be named within Sixty seconds. Memory performance was assessed by using 
a validated verbal word learning task (25). As a measure of global cognitive func-
tion we used the Mini Mental State Examination (MMSE) (26). Trained investigators 
administered the tests. \Ve obtained compound scores for speed of mental proces-
sing, memOlY function and overall cognilive function by transforming raw test data 
into Z-scores. The compound score for speed of mental processing was calculated 
as the mean Z-scores of the l-Ietter sub-task of the Paper-and-Pencil MemOlY Scan-
ning Task, the naming sub-task of the Stroop test and the Letter-Digit Substitution 
task. The compound score for memory function was calculated as the mean Z-scores 
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for the immediate and delayed recall subtasks of the word-learning test. An overall 
compound for cognitive function was calculated as ti1e weighted mean of the two 
other compounds (20). During lesling, the reliability of the lesl resuils was coded. 
Codes for invalid test results comprised codes for lack of motivation, presence of 
cognitive or physical handicap, or deviation from the instructions. For 99% of a11 
participants scores could be calculated of whom 90.5% had valid test-results for all 
neuropsychological tests. 
Potential confounders 
Data on potentially confounding factors including sex, age, level of education and 
mood disturbances according to the Center of Epidemiological Studies on Depres-
sion (CES-D) (27), were collected at the interview. Finally, we took into account the 
time of testing (morning or afternoon) and reliability of llie neuropsychological test 
result. 
Statistical Analyses 
Demographic characteristics and depression vaIiables were compared over vmious 
age groups llsing aIlalysis of vruiance or chi-squm·e statistics when appropriate. 
ComparIsons between benzodiazepine users and non-benzodiazepine users were 
made for benzodiazepine users in general. for benzodiazepines classified as hypnot-
ics or anx101ytlcs and classified as benzodiazepines with or without a halogen mol-
ecule on position 5 of the aryl ring. In these two latter analyses subjects using both 
classes were excluded. Similar comparisons were made for users of anticholinergic 
drugs in general, TCAs, and SSRIs. 
Subsequently, we performed multiple linear regression analysis to ob~ain the 
adjusted mean. difference in cognitive function conditional on psychotropic drug user 
status. In this analysis we adjusted for age, sex, educaUonallevel, CES-D score, con-
comitant use of other psychotropic drugs. as well as timing and validity of cognitive 
tests. 
RESULTS 
Basic characteristics of all 1077 participants according to three age strata moe 
given in table 1. \Vith increasing age, level of education and average MMSE score 
decreased and CES-D score increased. The use of psychotropic drugs, in particular 
llie non-H5A-henzodiazepines, the hypnolic henzodiazepines and anticholinergic 
drugs increased WiUl advancing age (table 1). 
The relations between drug user-status and neuropsychological-test outcome are 
given in Table 2. There were no significant differences between aI1Y of the drug expo-
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TABLE 1 
Characteristics and drug use of the Rotterdam Scan Study Participants by age 
category. 
AGE (YEARS) 
Characteristics p·value* (N=1077) 60·69 70-79 80-89 
(N=465 (N=416 (N=196) 
Age (SO) 65.2 (2.6) 74.7 (2.8) 83.7 (2.7) 
Female 239 (51.4%) 211 (50.8%) 104 (52.7%) Ns 
Only primary education 140 (30.1%) 140 (33.7%) 96 (49.0%) p<0.001 
Mean MMSE (range) 27.8 (21-30) 27.4 (19-30) 26.8 (19-30) p<0.001 
Mean CES-O (SO) 5.3 (5.9) 6.2(6.1) 6.5 (7.0) p=0.021 
Test-time after 13.00 hr 253 (54.4%) 257 (61.8%) 108 (55.1%) Ns 
Benzodiazepines t 
non-H5A 22 (4.7%) 30 (7.2%) 24 (12.2%) p=0.002 
H5A 5 (1.1%) 9 (2.2%) 7 (3.6) Ns 
Benzodiazepines tt 
Anxiolytics 16 (3.4%) 20 (4.8%) 8 (4.1%) Ns 
Hypnotics 10 (2.2%) 19 (4.6%) 23 (11.7%) p<0.001 
Anticholinergic drugs 22 (4.7%) 25 (6.0%) 29 (14.8%) P<0.001 
Antidepressants 
SSRI 1 (0.2%) 2 (0.5%) Ns 
TCA 4 (0.9%) 3 (0.7%) 2 (1.0%) Ns 
"Tested with chi-square statistics or analysis of variance. NS=non-significant. t four subjects using both 
types excluded. tt five subjects using both types excluded 
sure groups in global cognitive function as measured wilh the MMSE. The use of 
benzodiazepines had no significant relation lo any of ti1e cognitive measures. Users 
of anticholinergic drugs (11=80) in general, and in particular users of TeAs (n=9) 
performed significantly worse on measures for speed of mental processing and over-
all cognitive function as compared to non-users. In addition, TeA users performed 
significantly worse on measures of memory function. SSRI users (n=3) performed 
significantly worse on measures of memOlY function, as well as on overall cognitive 
funclion. 
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TABLE 2 
The relation between drug use and neuropsychological-test outcome. 
Difference in test result compared to non users (95% confidence intervai)* 
Test (compound score) Mini Mental State Mental processing Memory performance Overall cognitive 
Examination score speed (Z-score) (Z-score) performance (Z-score) 
All benzodiazepine users (n=1 01) 0.06 (-0.54 to 0.42) -0.08 (-0.24 to 0.08) 0.14 (-0.06 to 0.33) 0.04 (-0.10 to 0.17) 
Benzodiazepines 
Non-H5A (n=76)' 0.10 (-0.59 to 0.40) -0.10 (-0.28 to 0.07) 0.09 (-0.11 to 0.30) -0.05 (-0.15 to 0.14) 
H5A (n=21) 0.35 (-1.14to 1.86) 0.28 (-0.23 to 0.80) 0.52 (-0.10 to 1.14) 0.40 (-0.04 to 0.85) 
Benzodiazepines 
Anxiolytics (n=44)' -0.20 (-0.87 to 0.47) -0.15 (-0.37 to 0.08) 0.01 (-0.28 to 0.28) -0.08 (-0.2810 0.13) 
Hypnotics (n=52) 0.03 (-0.58 to 0.63) -0.05 (-0.26 to 0.15) 0.23 (-0.02100.48) 0.09 (-0.09 to 0.27) 
Anticholinergic drugs (n=80) 0.20 (-0.28 to 0.68) -0.17 (-0.33 10 -0.04) -0.15 (-0.33 to 0.05) -0.16 (-0.30 10 -0.01) 
Tricyc!ic anti·depressants (n=9) -0.37 (-1.80 to 1.06) -0.54 (-1.0 to -0.09) -0.57 (-1.11 to -0.02) -0.55 (-0.95 to -0.16) 
Selective Serotonin Reuptake 
Inhibitors (n=3) -0.40 (-2.85 to 2.05) -0.60 (-1.39 to 0.18) -1.14 (-2.08 to -0.19) -0.87 (-1.54 to -0.19) 
"Regression coefficients and 95% C! controlling for age, gender, educational level, CES-D score, co-medication, timing of the tests and test-status. 
r Concomitant users excluded. 
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DISCUSSION 
In this population-based study. we found that the use of TCAs as well as of SSRIs 
was associated with an impaired function on multiple cognitive domains. These asso-
ciations were independent of the subjects' depression score. \Ve found that the use of 
benzodiazepines was not associated with impaired performance on any of the stud-
ied cognitive domains. This lack of association was found for the sub-classifications 
of anxiolytics and hypnotics. and did not depend on the presence of a halogen group 
in the molecule, 
Major threats to the validity of any study consist of selection bias. information 
bias and confounding. Although in our study, as in any population based study, 
health status was an important determinant of participation, this was probably inde-
pendent of preferenlial prescribing of pharmacotherapeutic subtypes of psychot.l'o-
pic drugs. Because the Dutch health insurance system provides the large majority 
of drugs without ex-tra payment by patients, bias by preferenlial prescribing of drug-
subt.ypes is unlikely. Because participants were asked to bring along their actual 
medication instead of merely repOiting the used drugs, differential reporting of 
the use of drugs was excluded, Moreover, because no one was aware of t.he study 
hypothesis at. the time of data coHecUon, it is unlikely that over- or underreporling 
would be seleclive among drug-user groups. hereby limiting the extent of informa-
tion bias that. could have occurred. Misclassificatlon of drug-use may have affected 
our results as no information was gathered on dose- and duration at the interview. 
Subjects on chronic treat.ment may have adapt.ed betier t.o pharmacological effects 
on performance than subjects who recently st.art.ed. If so this may have led to an 
underestimation of t.he observed effects. 
The indication for a speCific drug presctiption is a potential confounder in t.his 
study. As cognitive impairment, depression and sleeping problems often coincide, 
preferential prescribing of antidepressants and benzodiazepines to subjects with 
an impaired cognitive function, or vice versa, to depressive subjects could have 
occurred, To limit this bias we excluded subjects with dementia and adjusted the 
analyses for the score on the CES-D. 
\Ve found no relation between the use of benzodiazepines and cognitive function. 
Although it is possible that the used compound scores for cognitive function were 
not. sensitive enough to reflect subtle differences in speed or memOlY tasks, we con-
sider tilis unlikely as also in tile separate neuropsychological tests no association 
was found between cognitive performance and t.he use of benzodiazepines (data not 
shown). 
To our IUlowledge, this is one of t.he first population-based st.udies to report and 
quantify the association bet.ween psychotropic drug use and memOlY performance, 
speed of mental processing and overall cognitive functioning. Although the cross-
sectional nature and small numbers of t.his study necessitate confirmation in laJ.'ger 
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longitudinal studies. we found evidence that the use of antidepressants (SSRls and 
TeAs) may contribute to cognitive impairment. In contrast, this was not found for 
users of benzodiazepines. 
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ENERAL DISCUSSION 

General discussion 
I\. Ithough dementia was early recognized as a distinct syndrome (l), for a long 
rlUme it was thought to be an inevitable consequence of aging. The fact that age is 
indeed by far the most important known risk indicator for dementia may have con-
tributed to the fact that research in this area has been relatively neglected. However, 
in recent years some light has been shed on the prevalence and incidence of demen-
tia and its subtypes (2). Also a number of risk factors for dementia (3-8) have been 
identified. However, because of a naturally occurring order in scientific research in 
which Identification of potenllally beneficial agents usually follows the Idenllficallon 
and evaluation of potential!isk factors, evidence on tile efficacy and effectiveness of 
these agents Is still limited. 
The studies described in this thesis were LIiggered by the perception that demen-
tia and in particular Alzheimer's disease will be an increasingly important health 
problem in the coming decades and moreover, by the awareness that preventive 
agents and beneficial treatment modalities were largely absent. 
The population-based Rotterdam Study, a single center prospective foHow-up 
study of 7983 subjects. aged 55 years 01' over (9), that started in 1990 pr0\1ded, 
and still provides, a unique opportunity to gain more lrnowledge on the epidemiol-
ogy of dementia and also on the role of certain potentially beneficial pharmacological 
agents. 
In this thesis, several of these agents have been studied. The rationale for investi-
gating these agents is that inflammatory processes (lO, 11), vascular (12-14), neuro-
protective (15) and oxidative factors (16-18) and hormonal deficiencies (19-21) may 
playa role in the pathogenesis of dementia. All agents that we studied are drugs 
and therefore modifiable risk factors. This is important as this may create the pos-
sibility of modulating disease progreSSion, postpone the onset of dementia or even 
prevent dementia. In addition, our research may provide new clues and ideas for 
future research. 
After a brief description of the main fIndings, we will discuss some methodological 
problems, earlier discussed in chapter 2, which are typical for pharmacoepidemio-
logical studies in dementia. In addition, we briefly discuss health care aspects and 
the clinical relevance of our findings. Finally, several potential dimensions of future 
research will be addressed. 
MAIN FINDINGS 
The main results on pharmacological agents and !ish:: of dementia are extenSively 
described In the earlier chapters of this thesis. In blief, we found a consistent inverse 
association between the long-term use of non-steroidal anti-inflammatOlY drugs 
(NSAID) and Alzheimer's disease. This finding is in line with existing evidence from 
immuno-histochemical, biochemical, molecular studies and observational studies 
indicating that inllammatOlY processes may be Imporiant In the pathophysiology of 
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Alzheimer's disease. 
Following from the observation that hypertension may also conbibute to the 
development of cognitive Impairment and dementia (14, 22, 23), we eXaIuined the 
role of antihypertensive drugs. \Ve found evidence for a beneficial effect of antihy-
pertensive agents in Ule prevention of dementia, in particular in the prevention of 
vascular dementia but also in subjects with Alzheimer's disease in Ule presence of 
vascular disease. 
In contrast to the results of a number of observational studies but in alignment 
vnth evidence from recent secondary prevention b-ials (24, 25), we found no evidence 
of a substantial beneficial effect of Hormone Replacement Therapy in Alzheimer's 
disease. 
Next to these studies on dementia, we found anti-depressants and aIlticholiner-
gic drugs, but not benzodiazepines, to be associated with impairment on multiple 
cognitive domains, in the cohort of the Rotterdam Scan Study of which the partici-
pants were free of dementia at the time of measurement. 
Triggered by contradictOly studies regarding the association between use of 
NSAID and the occurrence of Alzheimer's disease based on cross-sectional NSAID 
exposure and for a better understaIlding of the validity of these studies, we inves-
tigated the degree of measurement error induced by the use of interview data on 
NSAID in estimating chronic use. \Ve showed that this type of information is an 
invalid measure for estimating chronic use in a population based cohort and more-
over iliat Ulese data should not be used in studies on Alzheimer's disease. 
METHODOLOGICAL CONSIDERATIONS 
Validity 
A number of biases have been described that apply to epidemiological studies in 
general (26). There are, however, certain types of bias that are particularly impOl-tant 
for the interpretation of studies on drug exposure and Alzheimer's disease (27) and 
other types of dementia. Roughly they can be categorized as selection bias related 
to survival and to inclusion into the study; information bias by misclassification of 
exposure; aIld confounding by factors related to wheUler or not someone receives a 
medication (confounding by indication, severity or co-morbidity). 
Selection bias 
Selecllon bias may occur when the use of a drug leads to a difference In survival 
between cases and non-cases. For example, a drug may slow progression of a fatal 
disease Ulat is dHTerenUally distributed between cases and controls. Or, inappropri-
ate drug intake as a consequence of cognitive problems in the pre-clinical phase of 
dementia could lead to severe adverse efJecls and a lower survival. In both instances 
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in a study based on prevalent cases tilis may lead to the conclusion Ulat the drug 
protects against dementia. Selection bias may also occur if cases and controls are 
drawn from different source populations (28, 29). Biased selection into a study popu-
lation in studies of dementia may also occur when persons taldng drugs against car-
dio- or cerebrovascular disease are in- or excluded from a diagnosis of Alzheimer's 
disease a priori. 
lriformation bias 
A major concern is the potential for misclassification of exposure to drugs. Ade-
quate exposure assessment includes: type of drug compound, daily dose, duration 
and tinling of use, and route of administration. These are all elements involved in 
studying dose-response effects of medications and Ulerefore a potential source of 
misclassification. 
Alzheimer's disease and to a certain e.~ient also other types of dementia, are prob-
ably preceded by a long sub-clinical period, and it is velY difficult to get reliable 
estimates of the exact time of onset. DHlerent drugs may exhibit their beneficial 
properties at different times in the disease process. For example, antihypertensives 
may be protective in a velY early phase or even before disease onset. \Vhen initiated 
in a late pre-clinical phase, however, these drugs may even be hazardous (30). In 
case of anti-inflamrnatOlY drugs there has to be inflanlIllation in order to suppress 
it, whereas once given at a stage in which there are too many end stage lesions the 
effeel may be minimal or even absent. An important potential source ofmisclassifica-
tion is a difference bet ween cases and controls, regarding the collected information 
from proxy informants. Furthermore, ever/never drug use reported in a baseline 
interview is often used as an approximation of chronic use. As chronic use gener-
ally increases with age and age is the most important risk ractor for dementia, mis-
classification by such approximation may be dUJerential and can not be adjusted for. 
An additional source of exposure misclassification may be differences in compliance 
between dementia cases and non-cases in the pre-clinical stage. 
Corifounding by indication, severity or co-morbidity or other forms of difrerential 
prescribing are particularly important in studies of persons with compromised cogni-
tive runction. It is possible that drugs are differentially prescribed, depending on the 
patients' cognitive status. For example, cognitively intact patients may more assert-
ively demand drugs with a putative beneficial effect against cognitive impairment. 
This may lead to a differential prescription of these drugs and to an overestimation of 
its protective effect. Or, doctors may be reluctant to prescribe drugs with a high fre-
quency of adverse reactions to cognitively impaired patients, An approach to reduce 
this problem in incidence studies on dementia with longitudinal exposure data is to 
use the method of lagging (31, 32). It is probable that drug usage patterns several 
years before clinical onset are less likely to be affected by the early symptoms of 
dementia. 
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Bias in prevalence studies 
Cross-sectional studies use prevalent cases and this may lead to biased estimates. 
Validity may be compromised by selective survival, by an unclear exposure-disease 
sequence and by the fact that information is obtained ii<om pro:>.:y informants. 
Bias in incidence studies 
Because of the absence of the so-caned "prevalent-case bias", studies relying on inci-
dent cases of dementia are thought to be more valid with respect to strength and 
direction of the association. However, a problem typically m<jsing in incidence stud-
ies, is the competing risk for death or dementia. This may be an alternative explana-
tion for Ule fInding that some drugs m<e inversely associated with onset of dementia. 
Users of certain drugs may have more co-morbidity and consequently a higher mor-
tality rate than subjects who do not use these drugs. Users m'e then less frequently 
able to reach the endpoint of dementia because they die and appem' to be protected 
by the drug. This may in pmticulm' be a problem in studies on drugs used in dis-
eases with a high mOIiality rate. 
Precision 
Insufficient power is a potential problem that may arise in epidemiological studies 
on dementia, but is often not addressed. As most population-based epidemiological 
studies are multi-purpose and not speCifically designed to study drug effects in 
Alzheimer's disease, sample size is often a limiting factor for studying drugs with 
a low exposure prevalence. This is in pm'Ucular a problem when dose-response is 
under investigation, as inability to show dose-response effects limits the possibility 
to strengthen the likelihood of an association. Although power may be a real problem, 
an alternative explmlation may be type of m1alysJs that is used. Most frequently, the 
relationship between drug exposure and dementia is modeled using a small number 
of exposure categories, This method, however, has some shortcomings (33, 34). First, 
the probably smooth dose response relation is approximated with an unrealistic step 
function with sudden Jumps. Second, no use is made of the within-category infonna-
lion, Third, results can be sensitive to the choice of the categOlY cut-points. Taking a 
larger number of categorIes makes the estimates very unstable, Therefore, it may be 
better to use an alternative type of analytical method, such as spline regression (33, 
34). This allows a smooth continuous estimate of the duration response relationship, 
while no within-categOlY information is lost. 
CLINICAL RELEVANCE AND HEALTH CARE ASPECTS 
For all drugs studied in observational studies, it is currently unknown to what extent 
they really prevent or delay onset of dementia. Clinical and public health implica-
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lions are therefore unclear and can only be discussed in very general terms. How 
could "society" benefit from these potenliai Ulerapies? Costs of dementia depend on 
the perspeclive from which they are considered. Viewed from society, bOUl direct 
and indirect costs are important. However, from the perspective ofinsurance compa-
nies and most pricing authorities, indirect costs are not or only marginally taken 
into account and usually not reimbursed. In contrast, from the viewpoint of policy 
makers indirect costs are of major Importance, as these costs outweigh short-term 
direct costs. Next to these macro-economic costs (financial costs) also from the 
perspeclive of caregivers, "costs" are important. In a recent trial. the effect of metri-
fronate (a cholinesterase inhibitor) treatment on the psychological burden of care-
givers was examined. The results suggested that beneficial drug therapy for palients 
could also have benefits for their caregivers (35). Brookmeyer et al. vIsualized the 
enormous potential impact of efficacious ilierapies that would delay Alzheimer's dis-
ease onset. They calculated Ulat an average delay of Alzheimer's disease for one year, 
comparable with a 10% risk reduction, could in the USA lead to annual savings of 
$10 billion after a pedod of 10 years. An average risk reduction of 50% would lead 
to a decrease of an estimated 4 million demented subjects after a period of 50 years 
(36). Effective treatment and effective prevention would therefore have an enormous 
potentJal to reduce both direct and indirect costs associated Witil dementia. 
Although trials for primal}' prevention are cumbersome, more intensive efforts by 
pharmaceutical companies might show wheUler some of these drugs could contrib-
ute to the prevention or treatment of Alzheimer's disease. Currently, such primaly 
prevention studies appear to orJginate from outside tile pharmaceutical industry. 
It is neverUleless. too easy to blame llie pharmaceutical induslt}' as it is doubtful 
whellier fuey are provided with tile incentives needed to invest in primal}' preven-
lion. An additional problem follows from the growing awareness lliat dementtng ill-
nesses and cardiovascular disease may. at least in part. have a common eliology. 
This is important, as ethics COIllluittees may not easily approve adequately sized 
placebo-controlled primmy prevention hials with existing drugs of proven efficacy. 
If for instance aIltihypertensives. besides lowering blood pressure. would decrease 
the Iisk of dementia it would be uneUlical to include a placebo-controlled aI"m in 
patients WiUl hypertension. Finally. Ulese committees will be reluctant to approve 
trials in healthy subjects usIng drugs with a high likelihood of adverse reactions. 
RECOMMENDATIONS FOR FUTURE RESEARCH 
Several areas of future research can be identified: 
e Development oj phannaco"epidemiological methods and analytical techniques 
Most observational studies of dnlgs in dementia, but also in other diseases, make 
use of cross-sectional drug exposure data or a histOl}' of drug use. As earlier men-
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tioned, these type of data oversimplify exposure patterns and are analyzed accord-
ingly. In order to more validly assess these associations the use of more reliable 
e},.'P0sure data from pharmacy databases or from automated medication dispensing 
systems in combination with the use of more sophisticated analytical techniques 
should be encouraged. 
o Uniformity of diagnosis and development oj diagnostic tools 
In current dementia research, incidence rates tend to vary over djfferent populations. 
These differences are small in an absolute sense but large in a relative sense (2). 
Age specific differences in prevalence and incidence over various popUlations seem 
to reflect methodological rather than real differences (2). There is a tendency to use 
DSM IJI-R criteria and uniform additional criteria for sub-diagnoses of Alzheimer's 
disease (37) and vascular dementia (38). However, because of changing specificity 
and sensitivity application of these criteria to different populations may lead to differ-
ent estimates of prevalence and incidence of dementia. Estimations of future abso-
lute prevalence of dementia in the population are sensitive to assumptions about 
age-specific incidence rates and are therefore rather uncertain. The prevalence of 
Alzheimer's disease is expected to quadruple over the next 50 years in the USA 
and probably also in other western countries. Because of the expected high preva-
lence relatively large amounts of money will have to be allocated. Inappropriate 
allocation of these resources as a consequence of uncertainties in the estimated 
prevalence of dementia therefore carries a potential of important medical and social 
consequences. Therefore, there is a need to further optimize comparability of stud-
ies and to increase the standardization of screening and diagnostic tools. 
o Future contributions oj observational studies 
Currently available therapy for Alzheimer's disease is mainly based on cholinergic 
augmentation. However, this type of drugs targets only one of several dysfunctional 
neurobiological systems. Cholinergic therapy improves cognition and reduces behav-
ioral symptoms only slightly and in only 15 to 40% of patients ,vith Alzheimer's 
disease (39, 40). There has been much debate as to the clinical relevance of cur-
renlly available strategies (41, 42) as the ideal drug would improve memory and 
cognitive deficits and would simultaneously halt disease progression. Basic research 
has suggested new eXCiting therapeutic possibillties. Examples of these are anti-
inflammaiOl}" anti-amyloid and neuroprotectivc drugs addreSSing other aspects of 
the underlying neuropathology in Alzheimer's disease. As also shown in this thesis, 
these strategies may prove useful in slOWing progression in an early phase. 
Although in the end randomized trials are needed to really address the different 
hypotheses, observational studies may conb-ibute by further exploration of the 
timing and mechanism of potential drug effects, by establishing the best outcome 
measure to study the effects of the interventions, by determining U1e optimal dose 
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level and the development of (genetic) techniques in order to be able to identify high-
risk subjects (43). A highly important contribution of observational studies may 
come from areas in which it is no longer ethical to do placebo-controlled b*ials. A 
typical example is Ule potential effect of antihypertensive treatment on dementia. An 
important limitation of obsenrational studies is Ulat they only permit tile exploration 
of the potential effects of existing drugs. This is important as currently available 
drugs only target a small minority of all receptors. 
To develop meaningful strategies that reduce incidence or address progression of 
dementia, a further contribution of observational studies will be needed. This contri-
bution in particular wiB have to come from studies in the post-marketing phase of 
new chemical entities. These studies, that will probably focus on effectiveness, are 
needed because the effects of drugs in large unselected populations under evelyday 
cirCUlllstances are usually different from the effects that were expected on the basis 
of research in small selected trial populations, in which subjects are often followed 
for only a relatively short period of time. In the last few years, unforeseen safety 
issues, often detected by regulatOlY authorities, have led to a relatively large number 
of new drugs that had to be \vithdrawIl from the market. These extremely costly 
affairs have already led to the recognition, by some, that in order to be optimally pre-
pared there is a necessity of industly-initJated post marketing studies Umt address 
tilese issues. In the near future also pricing and regulatOlY authOlities will more 
frequenUy be demanding these studies on effectiveness In order to get tile drug reim-
bursed, respectively re-reglstered after 5 years. 
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Chapter 8 
UMMARY / SAMENVATTING 

8.1 
Summary 
The incidence of dementia rises exponentially after age 55. Several factors have been proposed as lisk factor for this poly-etiological disease, although only few 
are really established. On the basis of these proposed risk factors several types of 
drugs have been proposed as being potentially efficacious in dementia. 
The fITst part of this Ulesis focuses on what is known from observational studies 
on protective drug effects and discusses aspects of validity and precision. In Ule 
second part of this thesis the association of non-steroidal anti-inflamrnalOIY drugs 
(NSAID). aspirin, estrogen and antihypertensive use with dementia is exanlined and 
descIibed. In actdilion, the association between cognitive function and the use of 
psychotropic medication in non-demented subjects is described. 
In Chapter 2 we review the existing epidemiologic studies on the effects of currently 
used drugs on AD. which have not specifically been designed for the prevention or 
treatment of Alzheimer's disease. The focus is on the potential methodological pit-
falls related to validity and precision of the various studies. 
NSAID and to a lesser extent hormone replacement therapy (HRT) are the drugs 
which have most frequently been studied in relation to Alzheimer's disease. A pro-
tective effect was most consistently demonstrated for the long-term use of HRT. 
However, only two-third of all published studies have been positive and secondary 
prevention trials are inconsistent. If proven efficacious a further growth of its use 
seems likely. Although optimistic reviews, mainly based on studies in prevalent 
Alzheimer's disease, have been published on the potentially protective role of NSAID 
in Alzheimer's disease, not all prospective studies support this. Even when these 
drugs appear to be protective, large-scale preventive use of these drugs in their cur-
rent form is unlikely given their toxicity. However, these studies may boost the devel-
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opment of safer NSAID. 
Studies on antihypertensive therapy and Alzheimer's disease are scanty but 
promising. As these drugs are of proven efficacy in cerebro- and cardiovascular 
disease, placebo controlled pIimmy prevention trials are uneUlical and additional 
observational studies are needed to quantity their effect. 
Free radical scavengers comprise a variety of substances. The most promising, 
are Ginkgo biloba, selegiline and vitamin C/E. Evidence is promising but too lim-
ited and too diverse to draw conclusions. However, given the good safety profile of 
a nUll1ber of these agents, if proven efficacious, a further increase in their use is 
likely. 
Epidemiological studies on glucocorticoids, oiller anti-inflammatOlY drugs, H2-
antagonists, and benzodiazepines are inconsistent and insufficient to judge illeir 
potential contribution. As glucocorticoids are toxic mld benzodiazepines addictive 
during long-term use, it is unlikely that these drugs will be of major value in the 
prhl1my prevention of Alzheimer's disease, even when effective. 
In conclusion, we are only just in the beginning of malting valid and useful assess-
ments of protective drug effects in Alzheimer's disease. Currently available studies 
m'e often vulnerable to a number of obvious and less obvious biases. Given this 
fact, for no single agent preventive use is currently Justified. For the future, placebo-
controlled trials are needed but Uley may prove to be difficult. In the meantime, 
there are a number of niches that will remain in which observational studies will be 
able to conb-lbute. However, in order to further untangle these often difficult issues 
more uniform and morc valid approaches are needed. 
In chapter 3.1 a study on the validity of cross-sectional interview data as a mea-
sure of chronic use of non-steroidal anti-inflammatory drugs (NSAID) is described. 
\Ve explored the effects of exposure misclassification on the association between 
reporled and chronic use of NSAID and Alzheimer's disease. In this retrospective 
cohort study within the population-based Rotterdam Study, participants who were 
interviewed after Janumy 1 sl 1992, who were registered vnth one of the pharmacies 
that provided data to the Rotterdam Study and who pl-ovided baseline interview 
data on drug use (n=4402) were Included In the study. Sensitivity. specificity. nega-
tive and positive predictive value of interview data as a measure of NSAID exposure 
compared to pharmacy data were used as outcome measures. In conclusion, cross-
sectional assessment of NSAID exposure is not a valid method for the assessment of 
chronic use of NSAID in the elderly. The validity of cross-sectional interview NSAID 
exposure data varies highly with age, sex and mental status. In our study the mis-
classification resulted in a bias towards the null regarding the association between 
chronic use of NSAlD and Alzheimer's disease. However, cross-sectional exposure 
assessment of NSAID at baseline in a cohort study among elderly may yield risk esti-
mates for Alzheimer's disease that can be biased in any direction since the anlOunt 
of nlisclassification depends on age, gender and cognitive function at baseline. In 
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order to prevent this we recommend the use of longitudinal pharmacy data for drug 
exposure assessment in analytical epidemiologic cohort studies. 
In chapter 3.2 we present a study on the association between NSAID use over a 
ten year period and the risk for incident Alzheimer's disease using a nested case-
control design in Ule popUlation based Rotterdam Study. This study was performed 
as recent studies suggested that the use of non-steroidal anti-inflammatory drugs 
(NSAID) might reduce the risk of Alzheimer's disease. The study was performed in 
306 su~lects; 74 Alzheimer patients clJagnosed according to NINCDS-ARDRA criteria 
and 232 age and sex matched controls. NSAlD use was abstracted from general 
practitioners medical records and expressed as cumulative prescription days. The 
relative risk for Alzheimer's disease associated with long-term use (~ 2 months) was 
0.95 (95% CI: 0.46-1.99) as compared to non-users, after controlling for potential 
confounders. In a separate examination, subjects who had more than 6 months of 
prescription days had a non-significant reduced relative risk for Alzheimer'S disease; 
0.74 (95% CI: 0.20-2.72). In an age-stralified analysis the effect tn long-term users 
was evident in those aged 85 and under; 0.53 (95% CI: 0.15-1.77). All risk estimates 
were lower when llie last two years of eA--posure were excluded from the mlalyses. Our 
point estimates in subjects younger thml 85 years and in subjects using NSAID for 
6 monllis or more are consistent with the hypothesis that long-term use of NSAID 
reduces the risk of Alzheimer's disease. However, overall there was no Significant 
association behveen NSAID use and tile risk for incident Alzheimer's disease. 
In chapter 3.3 we examined the association behveen NSAID mld Alzheimer's disease 
in more detail using a larger sample of demented su~lecls and more detailed and 
more reliable exposure data. A large number of observatfonal studies on the associa-
tion between NSAID and Alzheimer's disease have been published, but the results 
have been inconsistent. Almost all previous studies have obtained information on 
exposure to NSAID using methods vulnerable to mjsclassification, To examine the 
association between NSAID and aspirin use mld the long-term risk of incident 
Alzheimer's disease and vaseulm' dementia we conducted a prospective cohort study 
using data from the population-based Rotterdam Study, The study population com-
prised all subjects (n=6989) who were non-demented at baseline and had complete 
data on drug use during the study period provided by tile 7 phm'macies serving this 
community. Dementia screening took place in 1990-93,1993-1994 and 1997-1999, 
In addition, the cohort was continuously monitored for Incident cases of dementia. 
Proportional hazards regression mlalysis was used to estimate the risk of Alzheim-
er's disease in relation to the use of NSAID. NSAID use was defined as fOUf mutu-
ally exclusive time vatytng exposure categories: no exposure, less than 1 month 
(incidental). 1-23 months (intermediate) mld 24 months or more (long-term), AdJust-
ments were made for age, gender, education and use of aspirin. H2-mltagonlsts, 
mltihypertensives and anti-diabetic drugs, During 47498 person-years of follow-up, 
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394 subjects developed dementia, of whom 294 had Alzheimer's disease, 55 vascu-
lar demenlia and 45 other types of dementia. Average follow-up was 6.8 years. Com-
pared to non-use the relative risk of Alzheimer's disease was 0.95 (95% CI 0.70-1.29) 
in incidental users, 0.83 (95% CI 0.62-1.11) in intermediate users and 0.21 (95% CI 
0.05-0.83) for those subjects that used NSAlD for 2 years or more. The use and dura-
tion of NSAlD use were not associated with the risk of vascular demenlia. This study 
suggests that prolonged NSAID use may reduce the risk of Alzheimer's disease. 
There is increasing evidence that hypertension may contribute to the development 
of dementia. In chapter 4 we investigated Ule relation of antihypertensive drug use 
and the risk of dementia in Ule cohort of the population based Rotterdam Study. 
The study cohort included 7046 elderly, free of dementia at baseline. Dementia was 
diagnosed in a stepwise procedure. Participants were first screened. Screen positives 
were further tested. Those suspected of dementia underwent a diagnostic work-up. 
Dementia and its subtypes were diagnosed according to internationally accepted cri-
teria. A Cox proportional hazards model was used to estimate relative risks. After 
a mean follow-up of 2.2 years, subjects tal<ing antihyperlensive medication at base-
line (n=2015) had a reduced incidence of dementia (adjusted relative risk, 0.76; 
95% conHdence interval 0.52-1.12). A significant risk reduction was confined to vas-
cular dementia (adjusted relative risk, 0.30; 95% conHdence interval 0.] 1-0.99). For 
Alzheimer's disease the risk estimate was 0.87, but nol statistically significant. In 
conclusion our results suggest Ulat the risk ofvaseular dementia may be decreased 
by antihypertensive treatnlent. In order to investigate such a relation in Alzheimer's 
disease, larger observational studies with longer follow-up are needed. 
Approximately fifteen studies on the association behveen hormonal/estrogen replace-
ment therapy (HRT) and Alzheimer's disease (Alzheimer's disease) have been pub-
lished, but the results have been inconsistent. Most previous studies, however, were 
either not population based or not prospeclive, leaving room for uncertainty because 
of potential bias inherent to the type of study. In chapter 5 we report on the associa-
tion behveen HRT use and the risk of Alzheimer's disease as observed in the Rot-
terdam Study. The study population comprised all women who were non-demented 
and had data on HRT eX'P0sure as provided dUling a baseline interview. Exposure 
to HRT use was dellned eiUlcr as ever use or as short-term (1-11 months) and long-
term use (? 12 months). Dementia screening took place in 1990-93, 1993- 1994 and 
1997 -1999; in addition, the cohort was continuously monitored for incident cases of 
dementia. Cox proportional hazards regreSSion mlalyses were used to estimate the 
hazard Ittnction of Alzheimer's disease in relation to the lise of HRT, or the 3066 
women in the study sample, 397 reported prior use of HRT. During a total of 17551 
person-years of follow-up a total of 179 \vomen developed Alzheimer's disease. \Ve 
found no evidence of an important risk reduclion for Alzheimer's disease in HRT 
users; relative risk 0.83 (95% CI 0.45-1.51). This observation was present adjusted 
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for age, age at menopause, artificial menopause, education, systoHc blood pressure 
and smoking. There was no evidence of a dose response effect of HRT. In concluSion, 
our results are not ~upporlive of a protective effect of HRT on risk of Alzheimer's 
disease. 
In chapter 6 we describe a study on the relationship belween the use ofpsycholropic 
drugs and cognitive funclion under evelyday circumstances. In a population-based 
study of 1077 non-demented elderly subjects, data on the use of benzodiazepines, 
antidepressants, and drugs with anticholinergic properties were obtained during a 
structured interview. Cognitive function was assessed by a series of neuropsycho-
logical tests aimed to measure mulUple cognitive domains, including global cognitive 
function (MMSE), memOlY function, mental processing speed and overall cognitive 
function. The results Ii'DIn linear regression analyses suggested that users of selec-
tive serotonin re-uptalce inhibitors performed worse on memory tasks (-1.14 SD; 
95% C[ -2.0S (0 -0.19), and overall cognitive function (-0.S7 SD; 95% C[ -1.54 to 
-0.19) than non-users of investigated psychotropic drugs. Users of anticholinergic 
drugs and more in particular oftricyclic antidepressants performed worse on mental 
processing speed (-0.54 SD; 95% C[ -1.0 (0 -0.09), on memOlY (asks (-0.57 SD; 
95% C[ -1.11 to -0.02) and on overall cognitive function (-0.55 SD; 95% C[ -0.95 (0 
-0.16), as compared to non-users. Benzodiazepine users did not differ signHlcantly 
from non-users with respect to any of the cognitive scores. All results were adjusted 
for age, sex, educational level, CES-D (depression) score, concomitanl use of other 
psychotropic drugs, as well as timing and validity of cognitive tests. In conclusion, 
in this study users of anticholinergic drugs and antidepressants performed signHi-
canUy worse on tests measuring memOlY performance, mental processing speed and 
overall cognitive performance, whereas this was not found for bcnzodiazepine users. 
Finally, chapter 7 briefly reflects our main findings. Our studies on NSAID and anti-
hypertensives are suggestive of a beneficial effect whereas tile study on HRT is not. 
However, these results should be confirmed in other studies, preferably in primary 
prevention trials. Subsequently, we discllss some methodological problems lypical 
lor pharrnacoepidemiological studies in dementia. In addition, we briefly discuss 
health care aspects and clinical relevance of our findings. Lastly, several potential 
dimensions and proposals for future research are addressed, such as tile further 
development of pharmacoepidemiologicai methods and analytical techniques, the 
promotion and stimulation of uniformity in diagnosis and development of diagnostic 
tools and lastly what the future contributions of observational studies should be. 
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8.2 
Samenvatting 
D e incidenUe van dementie stijgt exponenuee1 l1a het 55e jaar. Diverse facioren ziJn geopperd als mogelljkc risicofador voor deze aandoening. hoewel het van 
slechts enkele vastslaat clat ze dat oak daadwcrkeli.lk zijn. Op basis van deze voorge-
slelde risicofacloren is met betrekking tot een aanlal geneesmiddelen verondersteld 
clat. ze cffectief zijn bij de behandeling of preventie van dementle. 
Het cerste deel van dU proefschrift rieht zich op hetgeen bekend is uit observatio-
nele studies omtrent de beschermende effecten van geneesmiddelen blJ de ziekte van 
Alzheimer en behandelt aspecten van validileit en predsie. In het tweede gedeelte 
van bet proefschrift word! hel verband beschreven LUssen ctcmcnlie en het gebruik 
van respectievelijk non-steroidal antHriflammatonJ drugs (NSAID), aspirine, oestroge-
nen en anUhypertensiva, zoals werd bestudeerd in het Erasmus Rotterdanl Gezond-
heid en Ouderen (ERGO) onderzoek. Daarnaast wordt het verband beschreven 
tussen het gebruil{ van psychotrope medicatie en de cognitieve functie van nid 
demente ouderen. 
In hoofdstuk 2 bespreken wJj de bestaande epidemiologische studies naar de effec-
ten van geneesmiddelen in relatie tot het ontstaan van de ziekte van Alzheimer. Bet 
hoofdstuk concentreert zich met name op de methodologische valkuilen in de diverse 
studies met betTelddng lot validiteit en precisie. 
NSAID en in mindere mate hormonale substituUe therapie vormen de medi~a­
menteuze behandelwijzen die hel meest uHgebreid zijn bestudeerd in relatie tot de 
ziekte van Alzheimer. Een beschermend effect lijkt het meest consistent aanwezig 
bJj langdurJg gebruik van honnonale substitutie Ulerapie. Echter, slechts tweederde 
van aile observationele studies was suggesUef voor een beschermend effect. In de 
ERGO-populaUe vanden wiJ geen aanwJjzingen voor een beschermend effect. Ook 
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secundaire preventie b-ials bliJken !o! op heden geen dUideliJk beschermend effect 
aan te tonen. Wanneer hormonale subs!Hutie therapie effectief zou blijken te zijn, is 
eeo verdere groei van het gebruik eehter waarsehijnlijk, Hoewel opUmistische epide-
miologisehe overziehlsarlikelen z1Jn gepublieeerd over de mogelijk beschermende rol 
van NSAlD by de ziekte van Alzheimer ziJo deze gegevens voornamelijk gebaseerd op 
dwarsdoorsnede onderzoek en worden de resultalen niet in aIle prospeeUeve studies 
bevestigd, Alhoewel deze geneesmiddelen echt lijken te besehermen tegen de ziekle 
van Alzheimer, is groo!sehalig gebruik in de huiclige vorm onwaarschijnliJk, gegeven 
he! hoge risieo op bijwerkingeo bij chroniseh gebruik, Anderzijds zou de on!wikke-
ling van nieuwe NSAlD met cen gunsUger balans werkzaamheid/sehadelijkheid hier 
vel'andeling in kunneo brengen, 
Studies naar de effeetivHeH van anUhypertensieve !herapie in relatie tot de ziek!e 
van Alzheimer zijn schaars maar veelbelovend, Omdal deze geneesmiddelen effeetief 
ziJn bij cerebro- en cardiovasculaire ziekten, ziJn placebo geeontroleenie primaire 
preventie trials onethisch en zijn additionele observationele studies noodzakeliJk om 
he! effed !e kwantificeren, 
Het begrip "vrije rad1calen vangers" Ol1lvat een varieteit aan substanties, De meest 
veelbelovende zijn Ginkgo bUoba, selegiline en vitallline elK De resultaten van stu-
dies naar de toepassing van deze potenHele geneesmiddelen bij demenHe zijn nag 
onvoldoende en !e divers am een goed ool'deel te kunnen vormen, Gegeven het aan-
vaardbare veiligheidsprofiel van een aanta1 van deze middelen is een verdere groei 
van het gebruik bij bewezen effecliviteit zeer waarschijnlijk. 
Epidemio}ogische studies naar de effecien op dementie van glueocorUcoiden, 
andere anti-inOamma!oire middelen, H2-antagonlsten en benzodiazepinen zijn te 
inconsistent en/of te schaars om hun potenW~le rol te kunnen beoordelen. Gegeven 
het feit da! glucocorticoiden toxisch en benzodiazepinen gewennend zijn bij langdu-
rig gebruik is het onwaarschiJnlijk da! deze geneesmiddelen van gro!e be!ekenis 
zullen zijn Vaal' de preventie van de ziekte van Alzheimer, zeUs wanneer ze werkzaam 
zijn. 
Concluderend Imn worden gesteld da! slechts onlangs een begin is gemaald met 
de uihroeIing van valide en bruikbare studies naar de beschermende effecten van 
geneesmiddelen bij de ziek!e van Alzheimer en andere vormen van dementie. De nu 
beschikbare studies ziJn vaak gevoelig voor een aantal duideliJke en lninder duide-
liJke biases {vertekeningen}. Gegeven dit felt is er op clit moment geen rechhraardi-
ging voor het chronisch gebruik van een van de bovengenoemde geneesmiddelen 
biJ de preventie van dementie, tenzij overige indicaUcs {bijvoorbeeld antlhyperten-
siva bij patienten die tevens hypertensie hebben} he! gebruik van deze geneesmid-
de1en noodzaakt. Eel's! zuBen de effeden in placebo gecontroleerde studies moe ten 
worden bevestigd, ook al zuBen deze soms moeiliJk zijn ult te voeren. To! die Ujd 
zijn er een aantal onderzoeksterreinen waaraan observaHonele studies een biJdrage 
kunnen leveren. 
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In hoofdstuk 3.1 wordt een studie beschreven naal' de validiteit van interviewge-
gevens uit dwarsdoorsnede onderzoek als maat voor chronisch gebruik van NSAID. 
\Vij onderzochten de effecten van misclassUicatie van exposiUe met betl'ekking lot 
het verband lussen de ziekte van Alzheimer en gerapporteerd en chronisch gebruik 
van NSAID. In deze cohort studie binnen het ERGO-onderzoek werden deelnemers 
ge'includeerd wanneer ziJ waren ge'interviewd na januari 1991. gereglstreerd waren 
biJ een van de deelnemcnde apotheken en interviewgegevcns hadden met betrekl<ing 
lol het geneesmiddelgebruik {n=4402}. Om de concordantie tussen inlerview- en 
apolheekgegevens te meten gebruikten wij als uitkoll1stmaten de sensitiviteit, speci-
ficiteit en de positief- en negatief-voorspellende waarde. Concluderend kan gesteld 
worden clat huiclig gebruik ten tiJde van een interview geen goede maal is vaal' chro-
nisch gebruik van NSAID biJ oudcren. De uitkomslmalen van de interviewgegevens 
varii:~ren sterk mel leeftijd, geslacht en cognitieve functie. In onze stu die resulteerde 
deze misclassificatie in een risicoschatting met een vertekening in de richting van 
geen beschermend effed van NSAID op de ziekte van Alzheimer. Het probleem is 
echter dat een exposltiemeting op basis van dergeli.lke gegevens uit dwarsdoorsnede 
onderzoek rislcoschattlngen kan geven, die zowel tal een overschatting als tot een 
onderschatting van het effect kunnen leiden. Dil omdal de mate van misclassificatie 
alliangt van Jeeftijd, geslacht en cognitieve fundie. Om dit te voorkomen raden wiJ 
aan in analytische epidemiologische cohort studies zoveel mogeliJk gebruik te maken 
van longitudinale apoUleekgegevens voor het vaststellen van geneesmiddelcAlJositie. 
In hoofdstuk 3.2 presenteren we een studie naar het verband tussen het gebruik 
van NSAID gedurende een peri ode van 10 .Iaar en het risico op de ziekte van 
Alzheimer. Hierbij maakten wij gebruik van een pat lent -contrale onderzoek genest 
in het ERGO-onderzoek. De stuelie went uHgevoerd omdat recente studies sU!tt:{e-
reerden dat gebruik van deze geneesmlddelen lllogeliJk het risico op de ziekte van 
Alzheimer zou verminderen. De sludle werd uitgevoerd bij 306 personen waarvan biJ 
74 patienten de diagnose was gesleld "olgens N1NCDS-ADRDA crileria, en bij 232 01' 
leefti.ld- en geslachl gematchte cont.roles. Het geneesmlddelgebrulk werd vastgesteld 
aan de hand van huisarlsgegevens. Hel relaUeve lisico op de ziekte van Alzheimer biJ 
langdllrlg gebruik 12.2 maanden} was 0.95 {95%-betrouwbaarheidsinterval [95%BI}: 
0.46-1.99) vergeleken met niet -gebruikers na correctie vaal' mogeliJke confounders. 
Personen met een gebruik van meer dan 6 maallden hadden een risico van 0.74 
(95%81:0.20-2.72). In een - op leeftijd gestratificeerde - analyse was het effect bij 
de langdurig gebruikers meer uitgesproken bij personen tot 85 .Iaar. ABe risicoschat-
tingen waren lager wanneer de laatste twee .Iaar van expositie werden uHgesloten. De 
risicoschattingen bij mensen .longer dan 85 Jaar en biJ lallgdllrlg geexponeercien zi.ln 
consistent met de hypothese dat lallgdurig gebruik van NSAID beschermt tegen de 
ziekte van Alzheimer. Er was echter geen sprake Vfill ecn Significant beschennend 
verband tussen hel gebruik van NSAID en de ziekte van Alzheimer. De lage aantal-
len en de matige rcglslratie van geneesmiddelgebruik in de huisarlsgegevens hebben 
135 
Hoq[dstufc 8.2 
hier waarschijnlijk in belangrijke mate aan bijgedragen. 
In hoofdstuk 3.3 onderzochten we het verband tussen NSAID en de ziekte van 
Alzheimer in meer detail, met grotere aantallen en met betrollwbaarder expositiege-
gevens. Genoemde associatie is in een groot aantal observaUonele studics onder-
zocht. echter met tegenstrijdige resuitaten. Bijna aile eerdere studies maalden 
gebruik van informatiebronnen voor vaststelling van expositie die gevoelig zijn voor 
misclassificatie. Om de relaUe tussen het gebruik van NSAID en aspirine en de ziekte 
van Alzheimer en vasculaire demenUe te onderzoeken verrichUen wij een prospec-
tieve cohort studie waarbij gebruik werd gemaakt van de gegevens van het ERGO-
onderzoek. De studiepopulaUe omvatte 6989 mensen die bij aanvang van de studle 
niet dement waren en complete geneesmiddelexposiUegegevens hadden gedurende 
de follow-up volgens de 7 apotheken in Ommoord. Screening van demenUe vond 
plaats in 1990-93, 1993-94 en in 1997-99. Daarnaast werd het cohort continu 
gevolgd om tussentijdse gevallen van dementie op te sporen. Gebruik van NSAID 
werd gedefinieerd als vier wederzijds uitsluitende exposiUe-calegoriccn: geen bloot-
stelling. mindel' dan een maand (incidenteel), 1-23 maanden (intermediair) en 24 
maanden of meer (Iangdurig). Analyses werden gecorrlgeerd voor leeftijd, geslacht, 
hoogst behaalde oplelding. gebrulk van aspirine, H2-antagonisten. antihypertensiva 
en antidiabetica. Gedurende 47498 persoonsjaren onhvikkelde 394 mensen clemen-
tie waarvan 294 de ziekte van Alzheimer hadden. 55 vasculaire demenUe en 45 
een ander type dementie. De gemiddelde foHow-up was 6.8 jaar. Vergeleken met 
niet gebruikers hadden incidentele gebruikers een relatief risico van 0.95{95%BI: 
0.70-1.29), iniennediare gebruikers 0.83 (95%BI: 0.62-1.11) en diegencn die NSAlD 
gedurende 2 jaar of langer gebruikten een re1atief risico van 0.21 (95%BI: 0.05-0.83). 
Voor vasculaire dementie werd geen risicovermindering waargenomen. Deze studie 
sllggereert dat langdurlg gebruik van NSAID de kans op de ziekte van Alzheimer 
verkleint. 
Er zUn steeds meer aamvijzingen dat hypertensie bijdraagt aan de onhvikkeling van 
demenUe. In hoofdstuk 4 onderzochten we het verband tussen het gebruik van 
anUhypertensiva en het risico op del11entie in het ERGO onderzoek. De cohortstudie 
omvatte 7046 niet-demente ouderen. Del11enUe werd gediagnosUcecrd in eell staps-
gewijze procedure. Deelnel11ers werden eerst gescreend waarna de screen-positieven 
verder werden onderzocht en getest. Dementie en subtypes van del11entie werden 
gediagnosticeerd volgens internalionaal aanvaarde criteria. Na een follow-up van 
gemiddeld 2.2 jaar bleken personen die bij aanvang van de studie antihypertensiva 
gebruikten (n=2015) een lager dsJco op dementie te hebben dan niet behandelden, 
corresponderend met een relatief risico van 0.76 (95%BI: 0.52-1.12). Een signifi-
cant verJaagd risico van 0.30 (95%81: 0.11-0.99) werd aileen gezien voor vasculaire 
dementie. Het reiaUeve dsico op de ziekte van Alzheimer was met 0.87 niet signifi-
cant verlaagd. Onze resultaten su~~ereren dat het risico op vasculaire demenUe ver-
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laagd wordi door het gebruik van antihypertensiva. Om een dergelUk verband bij de 
ziekte van Alzheimer te kunnen onderzoeken zijn grotere en langere observationele 
studies noodzakelijk. 
Tot op heden ziJn ongeveer 15 studies gepubliceerd wamin het verband lussen oes-
trogeen substUutie therapie en de ziekte van Alzheimer wordt beschreven, maar de 
resultaten van deze studies zijn niel eenduidig. Op de meeste van deze studies is wei 
iels aan te merken, of weI omdat ze niet population-based zijn, of wei niet prospectief 
zijn uttgevoerd zodat vertekening mogeliJk is. In hoofdstuk 5 beschrijven wij het 
verband tussen het gebruik van oestrogeen substUutie en het risico op de ziekte van 
Alzheimer, :wals dat werd gevonden binnen het ERGO onderzoek. De studiepopulatie 
omvatte aIle vrouwen die bij hel begin van de sludie niel dement waren en van wie 
gegevens bekend waren met beu'ekking tot oesb'ogeen substitutie, zoals verkregen 
middels een interview bij aanvang van de studle. Bloolstelling aan oesb'ogenen werd 
gedefinieerd als ooit ofals kortdurend (I-II maanden) en langdurend (12 maanden 
of meer). Screening van dementie yond plaats in 1990-93, 1993-94 en in 1997-99. 
Daarnaast wen! het cohort continu gevolgd am tussentijdse gevallen van dementie 
op te sporen. Van de 3066 vrouwen in de studiepopulatie rapporteerden er 397 
gebruik van oestrogeen substitutJe. Gedurende 17551 persoonsJaren onhvikkelden 
179 vrouwen de ziekte van Alzheimer. \Vij vanden geen aanwijzingen voor een 
belangrijke risico reductie. Het relatieve risico op de zielde van Alzheimer biJ gebrui-
kers was 0.83 (95%BI: 0.45-1.51). Deze lisicoschatting was aanwezig na correctJe 
voor leeftiJd, leeftijd waarop de menopauze inlrad, hoogste opleiding, systolische 
bloeddruk en roken. Er waren geen aanwiJzingen voor een dosiseffect re1atie. De 
belan~riJkste conclusie is dat oesu'ogeen substitutIe na de menopauze niet lijkt te 
beschermen tegen de ziekte van Alzheimer. 
In hoofdstuk 6 beschrijven wij een studie naar de relatie tussen het gebruik van psy-
chob'ope gcneesmiddelen en cognitieve functic onder alledaagse omstandigheden. In 
een populatie-onderzoek biJ 1077 niet demente personen werden biJ aanvan~ mid-
dels cen gestructureerd interview gegevens verzameld met betreldctng tot het gebruik 
van benzodiazepinen, anlidepressiva en geneesmiddelen met anticholinerge efiecten. 
De cognitieve functie werd bepaald met behulp van een aantaI neuropsychologische 
tests gericht op een aantal domeinen van de cognitie, waaronder algemene cognitieve 
funcUe (MMSE), geheugenfunctie, mentale venverklngssnelheid en globale cogniUeve 
funclie. De resultaten van de Iineaire regressie analyses toonden dat gebruikers 
van selectieve serotonine heropname remmel'S slechter presteren op hel gebied van 
geheugen (-1,14 SO; 95%Bl: -2.08 tot -0.19) en globale cognitieve funclle (-0.87 SO; 
95%81: -1.54 tal -0.19) dan niet gebruikers van genoemde psychou'ope geneesmid-
delen. Gebruikers van anticholinerge geneesmiddelen - in het bijzonder van u'icy-
clische antidepressiva - scoren slechier op verwerkingssnelheid (-0.54 SD; 95%BI: 
-1.0 tot -0.09), geheugen (-0.57 SO; 95%81: -1.11 tol -0.02) en globale cognilieve 
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funclle (-0.55 SD; 95%Bl: -0.95 tot -0.16). Gebrulkers van benzodiazepines hadden 
scores die vergeli.lkbaar waren met die van personen die geen psychotrope genees-
middelen gebruiklen. Deze resuHaten werden gecorrigeerd voor Icc[Ujd, geslacht. 
hoogste opleiding, CES-D (depressle) score, gelijkllJdlg gebrllik van andere psycho-
trope geneesmiddelen alsmede de timing en validiteit van de tests. 
In hoofdstuk 7 ten slolte worden onze voornaamste bevindingen beschreven. 
Onze studies naar NSAID en anlihypertensiva suggereren een beschermend effed 
tegen het opu-eden van dementie, tenviJl geen significant beschenllend effect werd 
waargenomen voor oestrogeen substitulie. Deze resultaten zuBen echter bevestigd 
moeten worden door andere studies, bij voorkeur door middel van prospectie[ geran-
domiseerd onderzoek. In dit hoofdstuk wordt tevens een aantal methodologische 
problemen besproken die zich vaal( voordoen bij fru'macoepidemiologische studies 
op het gebied van dementie. Daarnaast bespreken 'vij kart de consequenUes voor de 
gezondheldszorg en de klinische relevanUe van onze bevindingen. Ten slolte worden 
enkele voorstellen voor loekomstig onderzoek gedaan, zoals een verdere ontwild(eling 
van farmacoepidemiologische methoden en analyse technieken en de bevordering 
van eenvormigheid in hel stellen van de diagnose dementie. Voorts wordt besproken 
welke de toekomstige bijdragen van observationele studies zouden moeten zljn. 
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